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Abstract
The targeted stimulation of collateral blood vessel growth in ischaemic tissue, therapeutic
angiogenesis, holds great promise as a treatment for chronic vascular disease. It may however, prove
equally useful as an adjunct in reconstructive surgery where planned tissue transfers are for the most
part limited by native vascularity. The controlled induction of angiogenesis may overcome some of
these limitations. Recent work has suggested that therapeutic angiogenesis may be achieved using
gene therapy techniques based on the cytokine vascular endothelial growth factor (VEGF). This
project will investigate the hypothesis that such techniques may be used to induce angiogenesis in an
experimental model of flap ischaemia and improve flap survival.
All members of the VEGF family of cytokines stimulate angiogenesis. This work was based on
VEGF beta (VEGFB). Two delivery strategies were investigated: intra-arterial administration of
'raw' plasmid DNA encoding the gene for VEGFB and subcutaneous injection of cultured cells
genetically modified to produce the VEGFB cytokine.
The rat epigastric island flap is designed to undergo partial ischaemic necrosis to a predictable extent.
In this series mean flap survival was 85% (95% C.I. 82, 89) at one week. Flap vascularity was further
characterised histologically and angiographically at two time points: immediately following elevation
and at one week when demarcation of the non-viable tissue had occurred. A pattern of physiological
angiogenesis occurring within the ischaemic flaps was apparent from the analysis of these results.
Optimal conditions for gene transfer and expression were first investigated in vitro using the green
fluorescent protein (GFP) reporter system and cultured endothelial cells. Use of the transfection agent
DOTAP significantly improved the number of cells expressing GFP at all observations. The
substitution of a mammalian expression plasmid containing the VEGFB gene (pEF-BOS-VEGFB) for
the reporter plasmid resulted in positive expression of VEGFB by the endothelial cells as detected by
immunostaining. Successful transfer of the VEGFB gene to the endothelial cells with exogenous
protein production had therefore been achieved. Replication of these conditions in vivo using the rat
epigastric island flap model however, failed to produce any evidence of either gene transfer to the
arterial wall within the flap pedicle or stimulated angiogenesis within the flap itself.
Further experiments were conducted using Chinese hamster ovary cells (CHO) genetically modified to
produce VEGFB. In a pilot study, the injection of CHO-VEGFB cells (mean dose 5.9 x 105 cells/cm2)
into the axial portion of the experimental flap resulted in a significant increase in mean flap survival to
95% (95% C.I. 89, 100) (p<0.05). A larger, randomised controlled trial designed to test these results
however, found no evidence of stimulated angiogenesis when experimental and control groups were
compared for flap survival, average microvascular density and angiographic branch point count.
Subsequent optimisation of an immunohistochemical protocol for the detection of cellular VEGFB
production in culture found fewer than expected CHO-VEGFB cells staining positive. Expression of
VEGFB may have declined in the interval between the two studies as the cell population aged.
It is likely that these systems failed as a result of their inability to deliver sufficient active cytokine to
the tissues of the flap. In addition, evidence is emerging that therapeutic angiogenesis may best be
performed using a combination of agents where additional cytokines are employed in conjunction
with a primary angiogenic agent to promote both the stability and function of immature endothelial
cells. The optimisation of delivery strategies for the transfer of genetic material to experimental flaps
coupled with a greater understanding of the most effective agent, or combination of agents, needed to
produce new vessels which are both functional and permanent are essential requirements for the
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Chapter 1 - Introduction
1.1 Growing new blood vessels
The targeted stimulation of new blood vessel growth represents an exciting prospect
for all clinicians required to deal with consequences of ischaemic disease. The
feasibility of such a strategy has now been demonstrated with the results of extensive
laboratory studies culminating in the first clinical application of this technology
reported by Isner in 1996 (Isner et al. 1996). The process has been termed
therapeutic angiogenesis and can be defined as the 'clinical use of growth factors to
enhance or promote the development of collateral blood vessels in ischaemic tissue'
(Henry DT 1998). In Isners paper, gene therapy techniques were used to deliver the
angiogenic cytokine, vascular endothelial growth factor (VEGF) to the popliteal
artery of a patient with critical lower limb ischaemia. Angiographic and flow data
confirmed an increase in collateral vessels and a rise in both resting and maximum
arterial flows compared to the preintervention state.
Although the majority of angiogenic gene therapy research has been performed by
groups whose primary interest lies in the management of chronic vascular disease,
the technique may find equal application in any situation where the augmentation of
local vascularity is desirable. Such situations are commonly encountered within
reconstructive surgery where the transfer of tissue from one location to another is
both made possible by the extent of the native vascularity, and at the same time,
limited by it. In this respect, the ability to selectively enhance blood supply by the
use of angiogenic agents would find many applications.
1.2 Implications for reconstructive surgery
Techniques in reconstructive surgery have been developed based on a knowledge of
the anatomical and physiological properties of living tissue and in particular the
recognition of patterns of blood supply. The quality and distribution of this blood
supply may however, prove to be a limiting factor in some situations. With
therapeutic angiogenesis comes the potential to enhance native blood supply either to
increase the chances of success with any given surgical option or to increase the
overall number of options available to choose from. An unfavourable set of
circumstances may therefore be changed into more favourable ones. In addition,
angiogenesis is known to play a key role in normal wound healing and in the
vascularisation of grafted tissue elements (Duprez et al. 1991;Singer & Clark 1999).
Therapeutic angiogenesis therefore, may also be of benefit when physiological
wound healing is impaired.
A further consideration in any tissue transfer is the morbidity associated with the
donor site. The concept of flap prefabrication is an attempt to address this problem
by importing a vascular pedicle into a potentially desirable donor site as a
preliminary stage before definitive flap transfer (Erol 1976). The success of the
technique relies on communications developing between the pedicle and the vascular
channels in the surrounding tissue. Early work has suggested that the use of
angiogenic growth factors in conjunction with this technique can increase both the
reliability and size of tissue transfer that may safely be undertaken (Bayati, Russell,
& Roth 1998).
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More innovations will surely follow as the technique of therapeutic angiogenesis
undergoes increasing refinement and more novel applications are identified.
One clear application however, is the use of this technique to extend the vascular
territory of a given flap and therefore increase the size of tissue transfer that may be
reliably undertaken on a given vascular pedicle. Many agents have previously been
evaluated for their ability to improve flap survival as will be seen.
1.3 The principles of tissue transfer
The replacement of missing tissue and the restoration of function are the founding
principles of reconstructive surgery. To achieve these goals techniques have been
developed to permit the movement of tissue from an area of relative surplus to an
area of need. To survive however, all living tissues are reliant on an adequate system
for oxygen and nutrient delivery and waste product removal in keeping with their
metabolic demands. These services are normally provided by an appropriate blood
supply.
1.3.1 Non vascularised tissue transfer
Tissue may be moved in two principal ways. For the simplest of transfers, tissue is
relocated as a graft. For the graft to survive it must acquire a blood supply from its
new surroundings before irreversible ischaemic injury has occurred. A tolerance of
ischaemia is therefore a requirement for tissue to be moved by this technique and
limits what can be achieved. Similarly the recipient site must be of sufficient
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vascularity to provide a foundation from which revascularisation of the graft can
proceed. Thus, a balance exists which may be tipped in one direction or the other
dependant on factors relating to the nature of the graft but also, and probably more
importantly, the vascularity of the recipient site (Wang HJ et al. 1997). The most
successful grafts are those in which the tissue to be moved is known to be relatively
tolerant of ischaemia, has a relatively large surface area to volume ratio and where
the recipient bed is vascular.
As the tissue required for transfer becomes less tolerant of ischaemia and as the
recipient bed becomes less likely to provide an adequate source of blood vessels to
which vascular connections can be made, then the likelihood of a successful tissue
transfer proportionately decreases. In these circumstances, an alternative approach is
needed.
1.3.2 Vascularised tissue transfer
1.3.2.1 Flaps
A composite of tissue designed for transfer with its circulation intact, or only
temporarily interrupted, is termed aflap. A flap therefore, contains within its
substance a functioning network of blood vessels that ensure its survival independent
of the vascularity of the recipient site into which it is placed. The blood enters and
exits the flap through a vascular pedicle. The maximum dimension to which a flap
can be raised with the expectation of complete survival is therefore, limited by the
extent to which blood flow can be maintained to all areas of the flap by the vessels of
the pedicle. Knowledge of the local vascular anatomy makes such a prediction
possible.
1.3.2.2 The concept ofthe angiosome
The blood vessels in the skin and superficial fascia form a continuous plexus over the
entire body surface however, demonstrable vascular territories do exist (Taylor &
Palmer 1987). Such territories are termed angiosomes. Using a variety of techniques
including ink injection, cadaveric dissection and radiographic analysis Taylor and
colleagues have provided an angiosomal map to encompass the entire body (Taylor
& Palmer 1987). Angiosomal territories are not however, mutually exclusive and
considerable overlap between these territories often exists in life where blood flow
characteristics are a reflection of changing pressure gradients (McGregor 1992).
With careful planning however, a block of tissue comprising a given angiosome may
be surgically elevated and moved around an axis defined by the position of the
feeding vessels, to a new location with the expectation that the circulation will be
adequate to ensure complete survival of the flap in its new location. The size and
shape of tissue that can be moved in this way is defined in the most part, by the
anatomy of the underlying angiosome (Taylor & Palmer 1987).
1.3.2.3 Skin flapfailure
Despite careful planning however, flaps still fail. Kerrigan has reviewed the
pathophysiological processes implicated in this failure and draws a distinction
between extrinsic and intrinsic factors (Kerrigan 1983). Extrinsic factors include the
existence of unfavourable patient comorbidities and adverse local conditions. The
author makes the point that in the majority of cases, these factors may be addressed,
at least in part, by careful preoperative preparation and postoperative management.
In contrast to the variety of extrinsic factors recognised only a single intrinsic factor
was identified, namely an inadequate nutrient blood flow. Following a series of
experiments using an animal model of skin flap failure Kerrigan draws the simple
conclusion that skin flaps fail because of arterial insufficiency (Kerrigan 1983). A
more complex explanation is not required.
1.4 The search for techniques to enhance flap survival
The recognition that flap survival was intimately linked to the extent and quality of
the nutrient blood supply encouraged attempts at augmenting this blood supply with
the hope of extending the described territories and improving flap reliability. Both
surgical and pharmacological techniques have been explored with mixed results.
1.4.1 The delay phenomenon
It has long been known that the surgical interruption of a portion of the blood supply
of a flap at a preliminary stage before transfer can lead to improved flap survival
(Myers & Cherry 1969). The changes within the flap that accompany this procedure
are collectively known as the delay phenomenon and debate continues as to the exact
mechanism by which the final effect is achieved (Dhar & Taylor 1999). Early work
by Braithwaite led him to conclude that the non-lethal ischaemia induced by a delay
procedure conditioned the tissues of the flap to survive with reduced blood flow
(Braithwaite 1951). Other authors studying the histological changes in flap
vascularity associated with delay have reported increases in both the number and
diameter of vessels within the first two weeks following the procedure (Arranz
Lopez et al. 1995;Jonsson et al. 1988). Callegari et al. (1992) studied changes in the
choke vessels located between perforator angiosomes in a series of skin flaps raised
in dogs and noted maximal dilation to occur in these vessels.
It would seem therefore, that vasodilation is an important factor in the success of the
delay phenomenon and in particular dilation of the choke vessels located at the
boundary between neighbouring angiosomes. Although angiogenesis clearly takes
place its contribution to increased blood flow at the time of flap transfer is not
certain. Where there is no doubt however, is in the overall effectiveness of the
technique in improving flap survival, as demonstrated by many authors (Guba, Jr.
1979;Morrissey, Jr. & Hallock 2000;Pang et al. 1986).
Although effective, there are obvious drawbacks with the use of surgical delay as a
technique to improve flap survival. Firstly, there is the requirement for an additional
surgical procedure with the attendant risks and potential for complications.
Secondly, it is of limited use when reconstruction is required urgently making any
delay unacceptable. This has fuelled attempts to identify alternative, non-surgical
techniques capable of achieving the same effect.
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1.4.2 Improving blood flow pharmacologically
The association between the delay phenomenon and vasodilation led to an intensive
search for a pharmacological agent that would achieve the same results. Numerous
agents have been trialled employing a variety of modes of action. These include
sympatholytic drugs (Goshen, Wexler, & Peled 1985), direct vasodilators (Finseth
1979), calcium channel blockers (Pal, Khazanchi, & Moudgil 1991) and
prostaglandins (Okamoto, Nakajima, & Yoneda 1993). In general however, the early
successes have proved difficult to reproduce (Kerrigan & Daniel 1982). Another
approach to mimic the success of the delay phenomenon aimed to improve the flow
mechanics of blood either by increasing erythrocyte deformability and flexibility
(Takayanagi & Ogawa 1980) or by lowering blood viscosity (Earle, Fratianne, &
Nunez 1974). Yet further work has centred on drugs such as dimethyl sulphoxide
that offer a degree of protection against ischaemic injury (Grossman et al. 1983).
Pang and colleagues offer a detailed review of the successes and failures that have
been reported in using these drugs to improve the survival of ischaemic flaps (Pang,
Forrest, & Morris 1989). In their closing remarks they conclude that the evidence to
support their use is in general weak and often conflicting with inconsistencies in
experimental design making the interpretation of results difficult. Consequent to this
they have found little place in clinical practice.
1.4.3 A potential role for angiogenic cytokines
Advances in the field of genetic engineering have made possible the large-scale
preparation of a wide variety of purified human growth factors including those with a
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central role in the control of angiogenesis. The use of such growth factors to
improve the survival of ischaemic flaps by the induction of angiogenesis became the
focus of much research. Khouri et al. were amongst the first to report a significant
improvement in flap survival following instillation of 1 pg recombinant human basic
fibroblast growth factor (bFGF) suspended in 2 mg collagen beneath ischaemic
dorsal skin flaps raised in rats (Khouri et al. 1991). Im et al. achieved similar
success using bovine bFGF (Im et al. 1992) while Ishiguro et al. examined the
potential benefit of repeated doses of bFGF and found no additional flap survival
advantage over a single dose administered at the time of elevation (Ishiguro et al.
1994). In a model of flap ischaemia in mice however, Uhl et al. reported no
improvement in flap survival following subdermal injection of human bFGF unless
administered 18 days before flap elevation (Uhl et al. 1994). Norrby compared the
angiogenic response of bFGF and VEGF using the mesenteric window angiogenesis
assay and found VEGF to be the most rapidly active agent (Norrby 1996). A further
advantage of VEGF over bFGF is its specificity of action as will be seen later
(Ferrara & Davis-Smyth 1997).
In 1996 Padubidri and Browne investigated the action of recombinant human VEGF
administered intra-arterially to the pedicle of an ischaemic rat epigastric island flap
and reported a significant average increase in flap survival of 21 % compared with
controls (Padubidri A & Browne E 1996). The improved flap survival was
associated with increased capillary density observed histologically and the authors
therefore concluded that the observed survival advantage was due to angiogenesis
induced by VEGF.
Although few in number these reports suggest that angiogenic cytokines can be
effective in improving the survival of ischaemic flaps. Many such cytokines exist
however, together participating in the complex and closely regulated process of
angiogenesis. To harness this mechanism for therapeutic ends first requires an
understanding of the physiological process.
1.5 The control of angiogenesis
Angiogenesis is the fundamental process by which new blood vessels are formed
from existing vascular channels and should be distinguished from vasculogenesis,
which describes the formation of blood vessels from angioblasts, a process that
occurs in the developing embryo but rarely in adult life (Risau 1997). Normal
development, reproduction and wound healing all depend on effective angiogenesis
for completion. Regulation is tightly controlled with long periods of inactivity
punctuated by periods of intense cellular proliferation in response to an appropriate
stimulus.
Capillary blood vessels consist of a single layer of endothelial cells and a basal
lamina. The endothelial cells are curved to form a tube just large enough to allow the
passage of red blood cells in single file. In cross section the walls of the tube may be
formed by a single cell or as many as three cells. Capillaries may be classified as
continuous orfenestrated (Figure 1.1). Fenestrated capillaries contain circular pores
ranging in diameter from 80 - 100 nm spanned by a diaphragm with a central
thickening. Pericytes may be found in relation to either subtype and when present
are enclosed by a further basal lamina that is continuous with that of the
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endothelium. The exact role of the pericyte is not clear however, it is thought to
represent a relatively unspecialised cell capable of differentiating into other cell types
(Ross & Reith 1985). These two cell types carry all of the genetic information to









Figure 1.1 - Schematic diagram demonstrating the structure of continuous and
fenestrated capillaries. Both may have associated pericytes. Taken from Ross and
Reith 1985.
The principal steps involved in the process of angiogenesis can be summarised as:
release of angiogenic cytokines, endothelial cell binding, activation and proliferation,
directional migration within a remodelled extracellular matrix followed by tube
formation and stabilisation with the arrival of pericytes. These steps are shown





Figure 1.2 - Schematic diagram illustrating the process of angiogenesis. Adapted
from the Angiogenesis Foundation 2001 (www.angio.org).
Specific angiogenic molecules can initiate this process whilst specific inhibitory
molecules can stop it (Hanahan & Folkman 1996). These molecules with opposing
functions appear to act continuously to maintain a dynamic balance resulting in a
great stability of the endothelial cell population where cell turnover is measured in
thousands of days (Iruela-Arispe & Dvorak 1997). The same endothelial cells
however, can undergo bursts of mitotic activity when the need arises. Similarities
can be seen between this system and that which operates in the control of coagulation
although the protein interactions in the latter are better understood (Folkman & Shing
1992).
Many factors have been demonstrated to initiate angiogenesis both in health and in
disease (Kuwano et al. 2001). Folkman and Shing have tabulated some of the more
important ones (Table 1.1) (Folkman & Shing 1992). These polypeptides differ
greatly in their biochemical and biological properties. The VEGF family for
example, are highly specific mitogens for endothelial cells whereas by contrast, the
FGF's are pleiotropic, that is, they stimulate the growth of several cell types
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including endothelial cells, smooth muscle cells and fibroblasts as well as acting as a
differentiating factor for nerves (Togari et al. 1985).
Table 1.1 - Angiogenic polypetides and their related biological activities. Adapted
from Folkman and Shing 1992.

















Increases vascular permeability, highly
specific endothelial cell mitogen
Stimulate migration of edothelial cells and
tube formation, embryonic activity
Stimulates endothelial cell DNA synthesis
and chemotaxis, proliferation not reported
Transformation of normal cells, binds to
EGF receptor
Enhances extracellular matrix production,
chemotactic for monocytes
Stimulates endothelial cells to secrete
prostacyclin, has unique RNA activity
essential for angiogenesis
Induction of bFGF in endothelial cells and
enhances its secretion, chemotactic for
monocytes, activates macrophages
Knowledge of the precise biological properties of these cytokines and the
mechanisms by which they interact to control angiogenesis remains incomplete
however, most authors agree on the pivotal role played by the VEGF family of
polypeptides (Ferrara & Davis-Smyth 1997). These proteins have been the subject of
intense research and consequently VEGF is one of the best characterised of all
angiogenic growth factors (Ferrara 1999). This work has highlighted a number of
important properties of relevance to the use of VEGF as an agent for therapeutic
angiogenesis.
1.6 The biology of vascular endothelial growth factor
1.6.1 The VEGF family
VEGF was the first of what is now recognised to be a family of angiogenic
polypetides to be described (Lobb et al. 1985) and is often referred to as VEGF-A* to
distinguish it from the other family members (VEGF-B, VEGF-C, VEGF-D and
placenta growth factor). VEGF-A is a 45 KDa glycoprotein that binds to the
VEGFR-1 (Fit-1), VEGFR-2 (Flk-1, KDR) and neuropilin-1 receptors of vascular
endothelial cells and illicits a profound angiogenic response seen in a wide variety of
in vivo models (Leung et al. 1989). It is however, mostly devoid of any mitogenic
activity for other cell types (Ferrara & Henzel 1989). Production is by a variety of
cells including macrophages, T-cells, smooth muscle cells and keratinocytes
(Klagsbrun & D'Amore 1996).
As well as acting as a stimulant for endothelial cell division and migration, VEGF is
also known to increase vascular permeability and was initially known as vascular
permeability factor (VPF) (Senger et al. 1983). The conversion of continuous
capillaries to the fenestrated phenotype under the influence of VEGF leading to
protein extravasation is thought to be the primary mechanism by which permeability
is increased (Roberts & Palade 1997). Dvorak et al. believe that the increase in
microvascular permeability to proteins is a crucial step in angiogenesis allowing the
formation of an extravascular fibrin 'gel' into which new vessels sprout (Dvorak et
al. 1995b). Other authors dispute this (Elicciri et al. 1999).
*
VEGF will be used synonomously with VEGF-A in this work.
The gene encoding for VEGF has been assigned to the locus p21.3 on chromosome 6
spanning approximately 14 kb and comprising eight coding regions (exons)
interrupted by seven non-coding regions (introns). Alternative splicing of the
resultant mRNA leads to the generation of four different species of VEGF in man
(VEGF121, VEGF 165, VEGF 189, VEGF206). The shorter of the four isoforms
(VEGF121 and VEGF165) are freely diffusible proteins whilst VEGF189 and VEGF
206 are almost completely sequestered in the extracellular matrix (Park, Keller, &
Ferrara 1993). VEGF165 is the most biologically active (Ferrara 2001).
Although VEGF expression can be induced by a variety of hormones, growth factors
and cytokines one of the most important regulators of expression is hypoxia. Low
oxygen tension has been demonstrated to increase VEGF mRNA expression
experimentally by as much as ten fold in vitro (Plate & Warnke 1997). Secreted
VEGF exerts its effect via high affinity receptors located on the surface of
endothelial cells which when bound activate nitric oxide synthase leading to cellular
proliferation (Morbidelli et al. 1996). Binding sites for VEGF are thought to be
restricted to these cells explaining the high target cell specificity of the active
protein. VEGF has been shown to provide a potent stimulus to angiogenesis both in
vitro and in vivo (Connolly et al. 1989;Shweiki et al. 1993).
Two other properties of VEGF are noteworthy with respect to its use in therapeutic
angiogenesis. Firstly, maximal stimulation of endothelial cells has been
demonstrated to occur at very low concentrations, in the region of 22pM solutions
(approx. 1 -4 ng/ml) (Ferrara N et al. 1991). Very little cytokine is therefore
required to achieve biological activity. Secondly, VEGF is known to exert a dose
dependant vasodilatory effect by relaxing vascular smooth muscle (Ku et al. 1993)
and therefore will tend to increase blood flow to the local tissues.
All members of the VEGF family are structurally related and all stimulate
angiogenesis (Ferrara & Davis-Smyth 1997). Patterns of activity and tissue
distribution however vary between species. This work is based on VEGF-B.
1.6.2 Vascular endothelial growth factor B
VEGF-B is a relatively recent addition to the VEGF family (Olofsson et al. 1996).
The gene has been mapped in humans to the ql3 locus of chromosome 11 and is
approximately 4Kb in length comprising 7 coding exons. Alternative splicing yields
two polypeptide forms, VEGF-B 167 and VEGF-B 186 with molecular masses 42 kDa
and 60 kDa respectively with the 167 homologue being the most biologically
prevelent (up to 90 % mRNA transcripts in adult mice) (Olofsson et al. 1999).
Although a full characterisation of the protein has yet to be performed, some aspects
of its biological behaviour are known. A close structural similarity with VEGF-A
(approximately 44 % identical), with which it is often coexpressed, exists and a wide
tissue distribution has been recorded although it is most abundant in heart and
skeletal muscle as well as pancreas. The myocyte appears to be the principal cell of
production and the secreted VEGF-B protein remains, in the most part, bound to cells
or to the extracellular matrix (Olofsson et al. 1996). Like VEGF-A, VEGF-B is a
powerful endothelial cell mitogen and its ability to promote angiogenesis in vivo has
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been well documented (Silvestre et al. 2003). Unlike VEGF-A however, it would
appear not to be significantly regulated by local tissue oxygen tension (Enholm et al.
1997).
VEGF-B appears to be secreted by the majority of human tumours and may be of
particular importance in the angiogenesis associated with ovarian cell tumours
(Sowter et al. 1997). Although the exact role of VEGF-B in the regulation of
angiogenesis remains unclear, it is known that VEGF-B exerts its effect by binding
to the VEGFR-1 and neuropilin-1 receptors of endothelial cells and therefore it is
likely that the cellular signals resulting from the binding of both VEGF-A and
VEGF-B, at least in part, overlap (Olofsson et al. 1999).
Based on this overlap we believed that VEGF-B may show similar therapeutic
activity to that reported for VEGF-A in the exogenous induction of angiogenesis
(Takeshita et al. 1994c). In addition, novel techniques have recently been described
for delivery of the angiogen to the target tissue in the genetic form rather than the
active cytokine itself (Takeshita et al. 1997). One major advantage of this approach
is the relative stability and improved handling properties of DNA in comparison to
the purified polypeptide. The techniques that permit the movement of genetic
material from one location to another and achieve its expression in this new location
have their foundation in the field of genetic engineering. The development of such
techniques has occurred only in the very recent past.
1.7 The principles of gene manipulation
The first genetically engineered drug, human insulin, was marketed in 1982. Since
this time the techniques used to sequence, copy, amplify and achieve expression of a
given genetic sequence have undergone continual refinement. A core feature of
these techniques is the ability to isolate stretches of DNA from their host organism
and propagate them in the same or a different host. A technique known as cloning
(Old & Primrose 1995a). In order for a cloned segment ofDNA to achieve
propagation in its new location with subsequent cell division it must contain an
origin ofDNA replication, or replicon. Constructions ofDNA that act as replicons
for the purposes of gene manipulation are known as cloning vehicles. Many such
constructs are now available permitting the efficient transfer of genetic material into
a host cell, facilitating expression of the target gene and ending with the production
of a desired protein (Bendig 1988). The original cloning vehicle however, was the
bacterial plasmid (Itakura el al. 1977).
1.7.1 Basic plasmid biology
Bacterial plasmids exist in the main as circular, double stranded, extrachromosomal,
DNA molecules and are widely distributed amongst prokaryotes. They vary in size
from less than 1 x 106 to greater than 200 x 106 daltons and the information they
encode is generally expendable in terms of the survival of the organism as a whole.
Phenotypes they confer on their host include attributes such as antibiotic resistance
as well as antibiotic and enterotoxin production amongst others. They exist in the
cytoplasm as single or multiple copies and may be transferred directly from one
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organism to another following cellular contact (conjugative plasmids) (Brock &
MadiganMT 1994).
For researchers interested in the transfer and expression of genetic material, plasmids
possess a number of important and potentially useful characteristics. One of the
most important of these is they all contain an origin of replication, allowing
replication to proceed independent of nuclear DNA (i.e. integration into the host
genome is not required for propagation of the plasmid DNA). In this way plasmids
exhibit stable inheritance in an extrachromosomal state (Hartl 1994). In addition,
well established methods exist for the isolation and reintroduction of intact plasmid
DNA from and to cells in culture, providing a powerful means by which genetic
material may be moved from one location to another (Sherratt 1979).
These properties have made bacterial plasmids the starting point for much that has
been achieved in the field of gene manipulation (Old & Primrose 1995b).
1.7.2 Plasmids as cloning vehicles
If bacterial plasmids are to be employed as transport vehicles for DNA, then a
number of technical difficulties must be overcome. Old and Primrose (1995a)
summarise these as:
1) Purification and cutting open of the plasmid (vector) DNA
2) Insertion of passenger DNA into the vector molecule to create an artificial
recombinant
3) Joining the ends of the new DNA molecule
4) Transformation* of the artificial recombinant into a suitable host cell.
5) Amplification of the whole system by expansion of the host cell population.
The stages involved are illustrated in Fig. 1.3.
Initially the majority of successful transformations were carried out in Escherichia
coli however, since then other species of bacteria (Ehrlich 1977), yeasts (Hinnen,
Hicks, & Fink 1978), plants (Fraley et al. 1983) and also animal cells (Schaffner
1980) have all been successfully transfected using plasmids.
*
The term 'transformation' as used here denotes the transfer of cloned DNA into a host ceii (by the
process of transfectiori) and should be distinguished from growth transformation meaning the sudden
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Figure 1.3 - Schematic diagram illustrating the principles of cloning using bacterial
plasmids. A fragment of DNA from any organism is joined to a cleaved plasmid.
The recombinant plasmid is then used to transform a bacterial cell, and, thereafter,
the foreign DNA is present in all progeny bacteria. Taken from Genetics by Daniel
L. Hartl 1993.
The first experiments were conducted using naturally occurring plasmids, for
example Chang and Cohen successfully used the pSClOl plasmid of Salmonella
panama to achieve expression of Staphlococcus aureus genes in E coli. (Chang &
Cohen 1974). Since this time many other naturally occurring plasmids have been
similarly used however, with increased understanding of the genetics involved, it
became possible to design and construct plasmids in vitro for the sole purpose of
cloning (Denhardt et al. 1988).
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Useful features were included in the design, such as antibiotic resistance (to allow
selection), multiple unique restriction enzyme cleavage sites (permitting insertion of
DNA at chosen locations) while maintaining a low molecular weight making the
final construct less prone to shear damage. The plasmid pBR322 was one of the first
to be constructed in this way and has since proved a highly successful cloning
vehicle (Balbas et al. 1988). The first genetically engineered human protein,
somatostatin, was produced from E coli. using pBR322 as the cloning vector (Itakura
etal. 1977).
1.7.3 Plasmids as expression vectors
The primary aim in cloning experiments is to achieve the successful transfer of a
target gene from one location to another, the final quantity of gene product that
results from the transfer is of less significance (Ehrlich 1977). If instead however,
protein production is the goal, optimal conditions for expression of the new genetic
material become important (Friehs & Reardon 1993).
To achieve expression of cloned DNA using a plasmid vector a gene promoter
sequence must be incorporated into the plasmid upstream from the coding region.
The 'power' of this promoter sequence is one of the most significant factors in
determining the level of expression of the target gene and therefore the magnitude of
protein production (Kobayashi, Kurusu, & Yukawa 1991). Promoter efficiency
varies considerably and the choice of promoter is therefore, an important
consideration when selecting or constructing a plasmid for protein production
(Jensen & Hammer 1998). Similarly, the promoter must be appropriate for the
chosen host cell, for example, if the target is the bacterium E. coli then one of the
promoters known to be effective in E. coli should be selected (Harley & Reynolds
1987).
Plasmids that have been optimised for protein production are referred to as
expression vectors. The plasmid expression vector selected for use in this project is
known as pEF-BOS and will be described in detail later.
1.7.4 Techniques to improve the efficiency of DNA transfer
Most of the early genetic engineering experiments were performed using Escherichia
coli as the host organism (Chang & Cohen 1974). This came about because initially,
plasmids and bacteriophages* suitable for use as vectors were only known to exist in
Escherichia coli. To begin with the efficiency with which transformation ofE. coli
could be achieved was disappointingly low however, the results of subsequent
experiments resulted in the identification of several important factors, which if
present, could result in a significant improvement in the level of success attained.
Such factors included the presence of calcium and other metal ions in the transfection
mixture and a low initial temperature with a subsequent heat-shock (Hanahan 1983).
An alternative method, which is effective in the transformation of bacterial cells and
can also be used in the transfection of mammalian cells, is that of electroporation.
This technique is based on the observation that cell plasma membranes can be
*
Bacteriophages are viruses that infect bacteria.
induced to fuse when subjected to a brief electric current (Zimmermann & Vienken
1982). Further work led to the discovery that cells exposed to an electric impulse
will also take up exogenous DNA from solution, possibly through holes momentarily
created in the cell membrane. A proportion of these cells may then become stably
transformed (Dower, Miller, & Ragsdale 1988). Transformation efficiencies with
Escherichia coli using this technique have been found to equal those using the
calcium chloride technique however, electroporation has the added advantage of
achieving successful transfection in a wide variety of plant and animal cells and has
achieved success with some cell types that had proved resistant to other approaches
(Chu, Hayakawa, & Berg 1987).
The transfection of mammalian cells can also be effected by the use of small
unilamellar (single bilayer) vesicles prepared from cationic lipids known as
liposomes. This technique depends on the observation that DNA in solution
spontaneously and efficiently, complexes with these vesicles which in turn bind to
the cell membrane of animal cells (Feigner et al. 1987b). It has been suggested that
liposomes achieve their effect by fusing with the plasma membrane of the target cell
wall creating a temporary gap through which the exogenous DNA can pass (Pagano
& Weinstein 1978). The use of liposomes to achieve enhanced transfection
efficiency in this way is termed lipofection and the cationic lipid is referred to as a
transfection agent.
Numerous transfection agents have been described however, the basic mode of
action is the same.
1.8 Techniques in therapeutic angiogenesis
Any given technique for therapeutic angiogenesis essentially consists of two main
components: an active angiogenic agent, or combination of agents, and a delivery
strategy. The most effective agent and the optimal method of delivery however, have
yet to be clearly defined.
1.8.1 The choice of angiogen
Although a number of agents are known to play a role in the stimulation of
angiogenesis in vivo, only a relative few of these have to date undergone evaluation
for their ability to stimulate angiogenesis exogenously. In addition to VEGF, acidic
fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and platelet
derived growth factor (PDGF) have provided the focus for much of the published
work. A comparative analysis of the relative effectiveness of each of these agents
has yet to be performed however, all have been used successfully to stimulate
angiogenesis in vivo (Machens et al. 2002;Pu et al. 1993b;Rinsch et al. 2001a). The
majority of therapeutic angiogenesis experiments have so far employed VEGF as the
active agent (Henry 1999). The popularity of VEGF reflects a favourable biological
profile namely endothelial cell specificity, a local vasodilatory effect and enhanced
activity in ischaemic tissue due to an upregulation of VEGFR-1 receptors (Brogi et
al. 1996). In addition, some evidence exists to suggest that VEGF is a more potent
stimulator of angiogenesis than bFGF under similar circumstances (Lee, Peters, &
Mooney 2003).
Initial work was invariably conducted using the VEGF-A165 homologue however,
recognition and characterisation of other members of the VEGF family has resulted
in encouraging work using these species also (Rissanen et al. 2003). At the time of
this study, no reports existed on the use of VEGF-B167 for therapeutic angiogenesis.
1.8.2 Delivery strategies
Many different ways of delivering angiogenic agents have been investigated. At
present there is no consensus as to the superiority of any one technique relative to the
others and thus, at the present time at least, all would appear to be equally valid.
1.8.2.1 Purified cytokine
Purified polypeptide administered intraarterially or subcutaneously has been shown
to stimulate angiogenesis in a number of experimental models. Ishiguro et al.
injected 20 pg bFGF beneath caudal ischaemic skin flaps in rats and reported an
average increase in flap survival of 13 % at seven days (Ishiguro et al. 1994). As
previously noted Padubidri and Browne recorded similar success using 5 pg VEGF
administered intraarterially to rat epigastric island flaps (Padubidri A & Browne E
1996). The disadvantage of this approach is the complexity of the purification
processes resulting in an expensive final product that also has a relatively short half-
life. These limitations have resulted in increased interest in the alternative approach
of gene therapy.
1.8.2.2 Unmodified 'naked'DNA
Genetically engineered expression plasmids have also been used successfully to
induce angiogenesis in ischaemic flaps. Taub et al. report their experience with a
plasmid encoding the gene for VEGF-A. Significant improvements in flap survival
were noted when this agent was administered intraarterially at a dose of 7 jug to a
series of rat epigastric island flaps (Taub PJ et al. 1998). Although having the
advantage of being easier to work with than purified cytokine, plasmids when used
alone have the disadvantage of relatively low rates of gene transfer. In Taubs series
the transfection agent lipofectamine was used in conjunction with the plasmid to
improve transfection efficiency. An alternative approach is to increase the dose of
plasmid DNA used as reported by Takeshita et al. who recorded evidence of
stimulated angiogenesis when 400 pg plasmid DNA was administered in a rat model
of lower limb ischaemia (Takeshita et al. 1997).
1.8.2.4 Viral vectors
Viral vectors have been developed to enhance the efficiency of gene transfer. The
genome of recombinant viral vectors is modified to carry a copy of the angiogenic
gene and all such vectors are rendered 'replication deficient' in their host cell (Safi,
Jr. et al. 1997). The adeno virus has been used most commonly in this respect for in
vivo transfections (Poliakova et al. 1999). Although highly effective in transferring
their genetic material to a target cell the generation and use of live viruses is
technically demanding and not without hazard. Nevertheless these vectors have been
used in phase I clinical trials without complication (Rosengart et al. 1999).
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1.8.2.5 Genetically modified cells
A further technique that has been trialled with reported success is the use of cultured
cells genetically modified to secrete angiogenic protein as vectors for therapeutic
angiogenesis. Machens et al. performed ex vivo transfection of syngeneic rat
fibroblasts to produce cells expressing the platelet derived growth factor gene.
Reintroduction of these cells beneath rat epigastric island flaps one week prior to flap
elevation resulted in a significant survival advantage (84 ± 9 % v 57 ± 7 %; p <
0.01). The authors also comment on an increase in capillary numbers throughout the
thickness of the flap when compared to controls.
1.9 Aims
My aim in this project was to determine whether I could use gene therapy techniques
based on the angiogenic cytokine VEGF-B, to stimulate angiogenesis in the rat
epigastric island flap model of tissue ischaemia and in so doing, influence flap
survival. Two delivery strategies would be investigated. Firstly, a bacterial
expression plasmid encoding the gene for VEGF-B and secondly, cultured cells
genetically modified to secrete VEGF-B.
Chapter 2 - Validation of the experimental model
2.1 Introduction
2.1.1 The model
To evaluate the proposed techniques for the induction of angiogenesis in vivo, an
animal model of tissue ischaemia was required. A review of the literature identified
the laboratory rat as being commonly used (Pang, Forrest, & Morris 1989).
Advantages of the rat over other laboratory animals included local availability, ease
of handling, disease resistance and low cost both in terms of acquisition and
maintenance (Dunn & Mancoll 1992). Having decided to use a rat model we
identified our requirements for an experimental ischaemic flap as being:
1) Suitable for the collection of data related to changes in vascularity
2) Of sufficient size to allow the planned experimental work
3) Founded on reliable anatomy
4) Technically easy to raise
The rat epigastric island flap, as first described by Finseth and Cutting, appeared to
satisfy these requirements (Finseth F & Cutting C 1978). This flap incorporates the
two major ventral angiosomes of the rat integument and comprises the panniculus
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carnosus muscle layer and all soft tissue superficial to it. In their paper they observe
that:
If an island flap of the complete abdominal wall skin of a rat is based on both
sets of neurovascular bundles (arising from each groin), it remains entirely
viable and heals without necrosis. If the neurovascular bundle in one groin is
divided, the corresponding half of the abdominal wall skin that it serves
becomes dependent on the opposite half of the abdominal wall skin for its
vascular supply. Conceptually, therefore, a random pattern flap is now attached
to an axial pattern flap. It is this arrangement in our experimental model that
produces a consistent, reproducible pattern of surviving flap area across the
midline which interfaces with an area of skin flap necrosis. The area of
surviving flap across the midline is, in essence, the bioassay for the nutritional
cutaneous blood supply.
(Finseth & Cutting, 1978)
2.1.2 Anatomical considerations
The vascular anatomy of the ventral skin and panniculus of the rat, providing the
basis for this flap, is well described (Petry & Wortham 1984). The femoral artery
and vein emerge from beneath the inguinal ligament and pass directly into the hind
limb, deep to the extensor compartment of the hip. In the cleft between this
compartment and the muscles of the abdominal wall, the femoral artery gives origin
to the superficial inferior epigastric artery (SIEA).
From this point the SIEA turns superiorly and enters a more superficial plane
although remaining deep to the panniculus carnosus. Here it divides into a medial
and larger lateral, branch. The former remains on the ventral surface of the animal
travelling cephalad and ending by collateralising with the terminal branches of the
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internal mammary vessels descending from their origin in the chest. The latter
extending laterally to collateralise with vessels descending from the lateral chest wall
in the region of the mid lateral line (Petry & Wortham 1984). Both branches give
supply to the full thickness of the overlying integument (skin, superficial fascia and
panniculus carnosus) via a combination of musculocutaneous and direct cutaneous
vessels, with the former thought to predominate (Dunn & Mancoll 1992).
Several perforating vessels arising from the deep epigastric system pass through the
muscles of the abdominal wall and reinforce this network. The venous drainage
follows a similar pattern with the emergence of the superficial inferior epigastric vein
in the groin of the animal, draining into the femoral vein at a point just medial to the
origin of the artery. This anatomy is constant and not prone to significant anatomical
variation.
2.1.3 Flap design
In the original description, Finseth and Cutting highlighted the difference between
the ventral and dorsal rat skin. On the ventral surface the skin is relatively thin and
supple when compared to the coarse, and more adherent, dorsal skin. They identified
the transition as occurring between 4 and 5 cm from the midline in animals weighing
between 350g and 400g. Flap dimensions of 9x9cm were therefore recommended.
Petry and Wortham pointed out the variability in survival patterns of these flaps
dependent on whether the lateral branch of the SIEA was included in the flap, or not
(Petry & Wortham 1984). Padubidri and Browne therefore preferred to base flaps
solely on the medial branch of the SIEA and proposed 8 x 8 cm as the dimensions
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most likely to facilitate retention of this branch whilst allowing for the successful
identification and interruption of the lateral branch (Fig 2.1) (Padubidri & Browne E
Jr 1997).
Figure 2.1 - Epigastric island flap design taken from Padubidri & Brown, 1997.
In my preliminary work with this model I found that for rats weighing 350 - 450 g,
flaps raised with dimensions 8x8 cm invariably included the lateral branch of the
SIEA. Since I did not want to risk damage to the main vascular pedicle by
attempting to interrupt the lateral branch within the flap itself, I decided to base my
work on a flap design that comprised an 8x8 cm skin island incorporating both
medial and lateral branches of the SIEA.
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2.1.4 Autocanabalism
A flap designed in this way is, in the main, insensate and the tendency for the animal
to devour its own tissue (autocanabalism) is well reported (Brindle, McCarthy, &
Bell 1999). It is surprising therefore that neither Finseth and Cutting nor Padubidri
and Browne make any reference to the problem. My own experience with this model
was that unprotected, I could expect to lose between a third and a half of flaps as a
result of autocanabalism (Fig. 2.2). Various strategies have been proposed to combat
this problem. The most obvious manoeuvre is to shield the flap from the animals
teeth either directly by means of a protective vest, or indirectly, by use of a collar
(Bayramicli, Yilmaz, & Numanoglu 1998b). Alternatively the animals teeth
themselves may be shortened as advocated by Komorowska-Timek et al.
(Komorowska-Timek et al. 1999). I preferred the use of a protective collar since it
avoided direct pressure on the flap and did not interfere with flap observation.
Suitable collars were made from unexposed x-ray film (Fig. 2.3). The design was
such that the rats' ability to feed and drink was in not impeded.
Figure 2.2 - Autocannabalism as seen here, was a common occurrence in
unprotected flaps.





Methods of data collection were chosen for their ability to provide objective
evidence on the extent to which flap vascularity had been influenced by therapeutic
interventions. The techniques chosen were: (1) measurement of the area of the
surviving portion of the flap after demarcation of the ischaemic portion, and an
assessment of the surviving flap vascularity using (2) microangiography and (3)
histological analysis. Only the first two systems will be considered here since the
histological evaluation of experimental skin flaps forms the basis of the next chapter.
2.1.5.2 Measurement offlap areas
A number of important factors must be considered when selecting a technique for the
measurement of skin flap areas. In particular, Bayramicli et at. highl ighted the
tendency for the flap to undergo contraction during the period of demarcation. In a
series of 15 epigastric island flaps, they reported the mean final flap area to have
reduced to 54% of the starting area when measured at one week (Bayramicli, Yilmaz,
& Numanoglu 1998a). Therefore, measurements of surviving area expressed as a
percentage of initial area will be misleading (Akyurek et al. 1999). A more
representative value was obtained by Chow et al. by expressing flap survival as a
percentage of the final flap area, once demarcation had taken place (Chow, Chen, &
Gu 1993).
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The method by which the area will be measured must also be considered. Published
techniques include template based methods(Finseth F & Cutting C 1978;Roberts,
Cohen, & Cook 1996), the use of area grids(Taub PJ et al. 1998), or rely on the
capture of digital images with subsequent analysis performed by computer
software(Nichter et al. 1984;Padubidri & Browne E Jr 1997).
The convexity of the rodent abdomen suggested to us that the use of digital images
taken directly from the animal would introduce error as the three dimensional surface
is compressed into a two dimensional image. This error would be most marked
where the surface of the flap was at its most convex, i.e. the edges of the flap where
the abdomen joins the flank, exactly the position where necrosis is expected. We
therefore preferred the template technique proposed by Roberts (Roberts, Cohen, &
Cook 1996). In addition, since the viable portion of the flap is known to undergo
less contraction than the necrotic area, we elected to construct each template from the
surviving area of the whole flap, thus giving us a figure for percentage flap survival
rather than percentage flap necrosis (Bayramicli, Yilmaz, & Numanoglu 1998a). We
also anticipated that the majority of the flap would survive and therefore the error
incurred in the construction of the template would be less significant than for the
smaller necrotic area. To minimise this error further, we elected to use multiple
templates with the final analysis based on mean values for each series.
2.1.5.3 Microangiography
Accurate imaging of the vascular architecture of experimental flaps is made possible
by the technique of microangiography where barium sulphate and lead oxide are the
most commonly used contrast agents (Quinodoz et al. 2002;Rees & Taylor 1986).
The experimental flap may be infused directly with contrast agent through the
feeding artery, or alternatively, a central artery may be cannulated and the entire
arterial system imaged including that of the flap. Both methods achieve acceptable
results (Nishikawa, Manek, & Green 1991;Padubidri et al. 1997). The use of
mammography film is preferred in preference to standard X-ray film when
performing the angiogram since it provides for improved vascular definition and is a
further refinement in the technique (Quinodoz et al. 2002).
Various techniques have been proposed to extract objective data relating to flap
vascularity from such angiograms. In their work investigating an anatomical basis
for the delay effect, Cederna et al. performed angiograms of abdominal cutaneous
island flaps in a series of thirty rabbits and counted the number of vessels, over
0.5mm, crossing the midline (Cederna et al. 1997). Takeshita et al., also working
with rabbits, preferred the use of an angiographic score calculated from vessel
intersections with a standard grid (Takeshita et al. 1994c). Since I was most
interested in detecting differences in overall numbers of blood vessels, I considered
the technique of counting the number of vascular branch points in a given area to be
most suited to my work (Cheng, Chan, & Wu 2001). All such techniques however,
rely on consistent filling of the vascular network during angiography, ifmeaningful
comparisons are to be made.
With particular reference to the rat epigastric island flap, angiographic data reported
in previous studies often takes the form of a subjective assessment of vascularity if
reported at all (Akita et al. 2002). Similarly, a search of the literature found no
reference to the angiographic appearance of normal abdominal rat skin.
2.1.6 Aims
The aim of these experiments was to evaluate the rat epigastric island flap as a model
of ischaemic flap necrosis and to characterise the physiological changes in
vascularity that occur within the flap over an experimental period of one week by
means of microangiography.
2.2 Materials and Methods
2.2.1 Animals
Sixteen male Sprague-Dawley rats, weighing between 355 and 455g were used in
this project. Animals were supplied from, and housed at, the animal house facility of
the University of New South Wales based at Prince Henry Hospital, Little Bay, New
South Wales, Australia. The 'Australian code of practice for the care and use of
animals for scientific purposes' was closely followed for all experiments. The
procedures were undertaken in an operating theatre equipped for the task and all
instruments and disposables were used sterile. The Animal Care and Ethics




Two experimental groups were created comprising eight rats each. The first group
would provide data on the native vascularity of the flap whilst data from the second
group would provide information on the extent and consistency of flap necrosis and
any accompanying changes in flap vascularity resulting from normal physiological
processes. Identical epigastric island flaps were planned and raised in all animals.
2.2.2.1 Group 1 (n=8)
In this group angiography was performed prior to flap elevation. The animals were
killed while under anaesthesia using 1ml intracardiac Lethabarb (Arnolds Pty Ltd,
Baronia, Victoria, Australia). The flaps were then excised and subjected to data
collection as described below.
2.2.2.2 Group 2 (n=8)
These animals were allowed to recover from anaesthesia following surgery and
observed for one week to permit demarcation to occur between the viable and non¬
viable areas of the flap. Before reversal of anaesthesia they were fitted with plastic
collars to prevent autocanabalism
All rats underwent elevation of the experimental flap in the same manner.
2.2.3 Surgical procedure
General anaesthesia was achieved using 2.7ml/kg of a solution comprising hypnorm
(0.315 mg/ml fentanyl and 10 mg/ml fluanisone, Janssen-Cilag) 1 part; midazolam 5
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mg/ml (Roche Products Ltd) 1 part and water for injection 2 parts, administered
intraperitoneally. Halothane 2-3% with oxygen (2 1/min) was given via facemask if
backup anaesthesia became necessary. The abdomen was shaved and the outline of
the proposed 8 x 8 cm flap marked on the skin. The operative field was then painted
with aqueous iodine solution and protected with a perforated sterile drape. All
operations were performed under loupe magnification (x3.5).
All flaps were raised on the left superficial inferior epigastric artery and vein. The
dissection began cephalad and moved caudally. The distal ends of the right and left
SIEA's were first identified leaving the flap and coagulated with bipolar diathermy
and divided. The multiple musculocutaneous perforating vessels encountered
entering the deep surface of the flap were similarly dealt with as the flap was
separated from the abdominal muscles. The right superficial inferior epigastric
neurovascular bundle was then identified, ligated and divided. The dissection
finished with the completion of the skin incisions in the left groin and identification
of the flap pedicle. No attempt was made to skeletalise the vascular pedicle and the
associated nerve was left intact. On completion, each flap was islanded entirely on a
single neurovascular bundle in the left groin with all other soft tissue connections
having been divided. The flap was then returned to its bed and secured with a
continuous 4/0 prolene suture (Ethicon) across the base to avoid damage to the
pedicle and skin clips (Autosuture) to the remaining edges (Fig 2.4).
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Figure 2.4 - The surgical procedure. (A) The outline of the proposed flap is marked
on the abdominal skin. (B) and (C) Intra-operative views of atypical epigastric
island flap. The left superficial inferior epigastric vascular pedicle is seen
highlighted by a blue background. (D) An example of the experimental flap on
completion of surgery. The transverse lines mark the positions where histological
sections will be taken (see Chapter 3).
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Analgesia (Buprenorphine (Reckitt & Colman) 0.05 mg/kg) and fluid (5ml normal
saline) were given at a site away from the flap on the animals back. Anaesthesia was
then reversed using subcutaneous naloxone (F.H. Faulding) at a dose of 500 pg/kg.
2.2.4 Immediate postoperative management
Animals were recovered in cleaned rat cages containing fresh bedding (wood
shavings) and drinking water. Once fully recovered they were provided with food
pellets and transferred to the postoperative rat room adjacent to the operating theatre.
Each was housed individually and all animals were reviewed at the end of the days
operating and examined for postoperative complications and signs of distress.
2.2.5 Daily postoperative management
All animals were reviewed daily and assessed in terms of their appearance,
behaviour, appetite and water intake. The wound was examined for evidence of
infection, dehiscence, demarcation and autocannibalism. All data were recorded on
postoperative observation charts (Fig. 2.5).
2.2.6 Data collection
The animals were killed humanely on day seven postoperatively in a carbon dioxide
euthanasia chamber. The skin clips were removed and the outline of the flap was
traced onto clear exposed x-ray film to produce accurate templates (Fig 2.6). Three
tracings were taken of each flap. A further tracing was made and put to one side
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Figure 2.6 -Examples of (A) a typical epigastric island flap at one week showing
partial necrosis of the random pattern component and (B) a template drawn from the
flap at the time of data collection for use in the calculation of percentage flap
survival.
Figure 2.7 - Cannulation of the superficial inferior epigastric artery. In (A) the left
groin has been opened and the SIEA identified and prepared prior to (B) cannulation
and infusion with barium solution. Two 7/0 prolene ligatures have been used to
secure the cannula in place.
66
Microangiography was then performed. Initial experience with the model confirmed
direct cannulation of the SIEA in the groin as the optimal route for infusion of
contrast medium into the flaps. This technique proved more reliable and provided
for more control than central cannulation of the arterial system via the carotid artery
in the neck and was therefore adopted in all experiments.
The left groin was opened outside the flap margin and the SIEA identified at its
origin from the femoral artery. Using an operating microscope, the SIEA was
separated from the accompanying vein and dissected to expose the vessel wall over a
length of approximately 1 cm. Lignocaine 1% was applied as necessary to abolish
vasospasm.
A suitable point to perform a proximal arteriotomy was identified and the adventitia
at this point excised. A transverse arteriotomy was then performed. The vessel
opening was gently dilated to allow cannulation with a 24 gauge intravenous catheter
(Terumo Medical), which was advanced and secured in place using two 7/0 prolene
ligatures. The cannula was flushed with 0.5ml saline to ensure freedom of flow and
the absence of leaks. The flap was then infused with 0.2ml of barium sulphate
contrast medium (Liquid C) (Fig 2.7). A single 7/0 prolene ligature placed distal to
the tip of the catheter prevented escape of contrast material following removal of the
cannula.
The experimental flap was then excised taking a margin of surrounding tissue and
washed in clean water. To restore the in vivo dimensions, each flap was then pinned
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out on the previously prepared plastic template drawn from the flap whilst in-situ on
the abdominal wall. A length of fuse wire was secured to the template, passing
across the flap at the point of demarcation between viable and non-viable skin,
allowing visualisation of this zone radiologically (Fig 2.8). The specimen was
transferred to 10% formalin solution prior to transfer.
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Figure 2.8 - (A) Pinning to a plastic template prior to imaging restored the in vivo
dimensions of each flap. A wire marker indicates the line of demarcation. The
resulting angiogram is shown in (B). This specimen is unusual in that a number of
vascular markings are seen within the necrotic skin.
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2.2.7 Radiology
All angiograms were exposed using the Giotto Mammography Unit housed at The St
George Hospital, Kogarah. I am grateful for the help ofAshif, senior radiographer in
the department of radiology who operated the machine in all cases. Kodak Min R
2000 film was loaded into a Kodak Min-R2 cassette with C-1N window and min-R
screen. Following a series of trial settings the optimal exposure was achieved with




Flap templates were drawn from exposed x-ray film in all cases. Prior experiments
had confirmed that this material was of an acceptably uniform weight -area ratio to
be used for this purpose (Appendix 1). Percentage flap survival was calculated for
each animal using flap template weights according to the formula:
Percentage flap survival = weight of surviving-flap template
weight of total-flap template
All weights were recorded from a single analytical balance accurate to two decimal
places. Results were expressed as percentage survival of the whole flap with respect
to the final flap area at the time of angiography.
2.2.8.2 Angiographic evaluation
Highest branch point counts per square centimetre (HBPC/cm ) were obtained from
microangiograms in the following way: Each angiogram was placed flat on a
standard photographic light box and viewed with a photographic loupe (x4
magnification, Nikon). A screen made from black card containing a central aperture
cut to one square centimetre was used to define the area to be analysed. The three
areas judged to be of highest vascularity for each hemiflap (random pattern and axial
pattern) were identified and the number of clear, vessel branch points per square
centimetre counted for each hemiflap in each of the three separate locations. The
highest of these values gave the final result for each hemiflap for a given animal.
The calculation of mean values for an experimental group (mean HBPC/cm )
allowed statistical comparisons to be made.
2.3 Statistics
Confidence intervals are presented at the 5% and 95% levels. Differences in the
angiographic scores between the two groups were analysed using the Mann-Whitney
U test, p<0.05 was considered to represent statistical significance.
2.4 Results
2.4.1 General
There were no intra-operative complications in either group. All animals in
experimental group 2 recovered from anaesthesia without event and remained well
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during the study period. There were no incidences of autocannabalism or of flap
infection however, one rat required replacement of the plastic collar on the first
postoperative day and a further rat required resuturing of a minor dehiscence of the
left lateral aspect of the flap on day 2. Both of these procedures were performed
under general anaesthesia (Halothane 3 % with 2 1/min oxygen). All animals
survived to seven days.
Mean operating time was 55 minutes. The earliest recorded evidence of demarcation
between the viable area of the flap and the ischaemic area, detected as a
discolouration of the involved skin, was on day two of the follow up period. This
was noted in five of the eight flaps in group 2. In all flaps, the zone of demarcation
was clearly visible by the third postoperative day.
2.4.2 Flap survival
The flap survival data for each animal in group 2 are given in Table 2.1. The mean
flap survival for this group was 85.0 % (C.I. 81.4, 88.6) at one week. The mean area
of the flaps had decreased to 78.8 % (C.I. 75.6, 82.1) of the starting area by the
seventh postoperative day.
Table 2.1 - Survival of rat islanded epigastric flaps expressed as a percentage of
final flap area at seven days.
Animal
reference
Animal weight (g) Wl(g) W2 (g) Flap survival (%>)
PI 420 1.25 1.05 84
P2 450 1.22 1.01 83
P3 415 1.29 1.19 92
P4 455 1.23 1.01 82
P5 430 1.42 1.29 91
P6 420 1.31 1.11 85
P7 440 1.27 1.06 83





Wl=Mean weight of 3 templates taken of the whole flap
W2=Mean weight of 3 templates taken of the surviving flap
2.4.3 Microangiography
Typical angiograms for both groups are given in Fig. 2.9 & 2.10. The gross vascular
patterns were markedly different. In the flaps subjected to angiography immediately
after elevation (group 1), the vascular markings appeared much finer and very little
contrast medium was seen to cross the midline. Where this did occur it was most
commonly noted very proximal in the flap (3 of 5 flaps) (Fig. 2.9). In angiograms
performed on flaps at one week vascular markings were more substantial than in the
immediate harvest group consistent with dilation of the feeding vessels and in all
cases contrast medium was seen to travel freely across the midline. In addition, an
area containing increased vascular markings was consistently seen adjacent to the
zone of demarcation indicated by the wire marker and to a lesser extent around the
perimeter of the viable flap (Fig 2.10).
The highest branch point counts (HBPC) for each experimental group were collated
and mean values calculated. The mean of the highest branch point counts for the
axial pattern hemiflaps in group 1 (n=8) was 11.1 branch points/cm (C.I. 9.1, 13.2),
whilst in group 2 (n=8) it had risen to 16.9 branch points/cm2 (C.I. 13.8, 19.9) and
this difference was statistically significant (p<0.01) (Figure 2.11). Imaging of the
random pattern hemiflap was uniformly poor in group 1 flaps as noted above and not
suitable for further analysis. In group 2, the mean HBPC for the random pattern
hemiflaps was 16.1 branch points/cm2 (C.I. 13.1, 19.2). No significant difference
existed between mean HBPC recorded from the axial and random pattern hemiflaps
in group 2 animals (p=0.56) i.e. the vascularity, by this measure, was the same on
either side of the mid-line.
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Figure 2.9 - (A) Typical angiogram obtained from group 1 flaps performed
immediately following elevation. On the occasions where contrast medium was
observed crossing the midline this invariably occurred proximally as seen in (B).
Figure 2.10 - Typical angiograms obtained from group 2 flaps performed at one
week. These angiograms consistently exhibited increased vascular markings within
the zone of demarcation indicated by the wire marker and in all cases contrast
medium was seen to cross the midline.
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Group 1 (immediate) Group 2 (one week)
time of angiogram
Figure 2.11 - Boxplot of highest angiographic branch point count recorded from the
axial pattern flaps of group 1 (immediate flap angiography) and group 2
(angiography at 1 week) animals. The difference between the means was statistically
significant (p<0.01).
2.5 Discussion
We were encouraged by these results. The 95 % confidence interval for our flap
survival data was narrow (7.2 %), suggesting the extent of flap survival, and
therefore necrosis, was likely to be reproducible and predictable. The techniques
employed to raise the flap, monitor the animals and retrieve data appeared efficient
and effective and well tolerated by the rats.
Comparisons with other reported experimental series of the rat epigastric island flaps
are made difficult by the variability both in the size of flaps used, and in the way in
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which the results are reported. In their original series of 10, 9x9cm flaps, Finseth
and Cutting measured only the area of the flap that survived across the midline. To
do this they used single paper templates weighed against an area-weight standard.
By this method they reported the area of surviving flap across the midline to be 10.4
± 6.2 cm at seven days. The same figure when calculated for my series was 17.7 ±
2.0 cm (Appendix 2). To perform this calculation however, requires an assumption
that flap contraction is uniform, which we know not to be the case (Bayramicli,
Yilmaz, & Numanoglu 1998a) and an increased contraction of the necrotic right
hemiflap is the most likely explanation for the observed differences in flap survival
between the two series. Of note also is the higher variability around the mean seen in
the Finseth and Cutting series compared to the present one.
Other reported series providing data on the survival of rat epigastric island flaps
where both the medial and lateral branches of the SIEA have been retained, are given
in Table 1.3. My results are in broad agreement with these findings.
Table 2.2 - Published series of rat epigastric island flap survival.
Reference Skin paddle dimensions Flap survival
Sasaki et al. 1980 8x8 cm 76.7 %
Roberts et al. 1995 anatomical landmarks, 7 cm width 81.2%
Bayramicli et al. 1998 anatomical landmarks used 75.4 %
The extent to which our flaps underwent contraction (final area reduced to on
average, 78.8 % of starting area at one week) was however, significantly less than
that reported by Bayramicli (flap area reduced to 54.12 % of starting area)
(Bayramicli, Yilmaz, & Numanoglu 1998a). The reasons for this discordance are not
apparent.
The striking difference between the angiographic appearance of the native abdominal
rat skin and the that of the flap at one week, is in keeping with Taylor's angiosome
model of the vascular territories of the body, each being separated by a series of
choke vessels from its neighbour (Taylor & Palmer 1987). The presence of these
choke vessels along the ventral mid line of our flap is evidenced by the lack of
contrast medium crossing the midline and gaining access to the right hemiflap in
group 1. When contrast was seen to have passed in to the right side, it was most
frequent proximally, probably reflecting a higher luminal pressure generated by the
syringe at more proximal branches of the main artery and overcoming the resistance
of the choke vessels.
The opening of choke vessels to permit the passage of blood from one angiosome to
another under the influence of an ischaemic insult formed part of Taylor's original
model and has subsequently been confirmed by others (Cederna et al. 1997;Taylor &
Palmer 1987). This phenomenon is well demonstrated in the present series.
Fewer reports however, objectively describe the angiographic changes that
accompany these events, and none have done so for a rat model as far as I am aware.
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Cederna et al. found an increase in overall vessel numbers in delayed rabbit
epigastric island flaps, but noted this did not reach statistical significance until day
21 following the delay procedure (Cederna et al. 1997). Our results in the rat show a
significant difference by day seven. Comparisons are difficult since the flap design
and choice of animal model are different however, one explanation for these
differences may be the more severely ischaemic conditions present in our model
(designed to produce tissue necrosis), a condition absent from the rabbit model.
In considering these results however, I recognise the limitations inherent within the
angiographic data. The increased numbers of vessels imaged in group 2 flaps cannot
be considered a definitive reflection of angiogenesis since the same number of
vessels may have been present in group 1 flaps where, in the 'resting' state their
small calibre placed them beyond the imaging resolution of the angiographic
technique. The differences in angiographic appearances may therefore be accounted
for to some degree by changes in flow characteristics rather than new vessel
formation. The area where the angiographic appearances are most likely to represent
true angiogenesis is within the zone of demarcation where high densities of fine
vessels are consistently observed in group 2 angiograms, appearances which are not
seen elsewhere within the body of the flap. Thus although angiography is a useful
guide to the gross vascular changes occurring within the flaps, definitive evidence of
angiogenesis requires a more sensitive method of data collection.
2.6 Conclusions
1. The rat epigastric island flap, as first described by Finseth and Cutting and
later modified by Padubidri and Brown, provides a reliable and reproducible model
of tissue ischaemia.
2. The techniques employed to raise the experimental flap, monitor the animal
in the postoperative period and collect relevant data, proved successful.
3. Analysis of microangiograms performed on day 0 confirmed the existence of
a vascular watershed in the mid line. This watershed was not apparent on day 7.
This change in the dynamics of blood flow was accompanied by a significant
increase in the number of vessel branch points identified angiographically on both
sides of the flap. This finding is consistent with, but not conclusive evidence of,
angiogenesis occurring within the flap.
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Chapter 3 - The assessment of average microvascular
density in rat epigastric skin
3.1 Introduction
3.1.1 Overview
To detect evidence of induced angiogenesis in my experimental flaps I needed a
reliable method to accurately quantify changes in their vascularity. The development
of a quantitative technique to achieve this was therefore, central to my experimental
work. Although some published work exists describing techniques that have been
employed in other models of ischaemia, reports using the epigastric island flap model
have tended to comment on an observed change in vascularity without objective
measurement (Ishiguro et al. 1994;Padubidri A & Browne E 1996). Similarly, no
published data was available regarding the native vascularity of abdominal rat skin.
One suitable method to achieve an objective analysis of vascularity is the assessment
of microvascular density (MVD) (Gowdak et al. 2000;Walter et al. 1996).
Microvessel quantification in this way was first described by researchers interested in
tumour angiogenesis and has led to the development of internationally recognised
guidelines for its use in the histological assessment of solid tumours (Vermeulen et
al. 2002;Weidner et al. 1991).
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To obtain a measure of microvascular density, counts of microvessels are performed
on paraffin embedded tissue or frozen sections and the results expressed either per
unit area or by the use of a grading system (Pazouki et al. 1997;Saclarides et al.
1994). Microvascular density may be reported either in terms of the highest value
for the sample examined, highest microvascular density (h-MVD), most commonly
used in the evaluation of malignant tumours, or as an average figure more
representative of the section as a whole, average microvascular density (a-MVD)
(Bosari et al. 1992;Chandrachud el al. 1997). In the case of the former, the tissue
section to be analysed is first examined under low magnification (x40) to identify
areas of maximal vascularity, often referred to as vascular hotspots, and vessel
counts are then performed in these areas using a higher magnification (e.g. x200).
The highest of these counts provides the final result (Weidner et al. 1991). In the
assessment of a-MVD, the slide may first be orientated under low magnification
before converting to high power and performing a series of microvessel counts at
random positions throughout the specimen. The number of such counts performed
varies between authors but typically 8-10 counts will be undertaken and the final
result expressed as the sample mean (Chandrachud et al. 1997).
The practicalities of this technique most frequently involve the manual counting of
blood vessels under a microscope. An eyepiece graticule is commonly used to place
a grid over the section under review, allowing the counts to be performed in a
systematic manner across the area of interest (Obermair et al. 1997). An alternative
technique is to use an eyepiece containing a series of points instead of a grid, and
count the number of stained vessels that coincide with these points (Chandrachud et
al. 1997). This is known as Chalkley point overlap morphometric analysis, and
provides a relative area estimate rather than a true vessel count (Vermeulen et al.
2002). Vascular area measured in this way has been shown to correlate well with
microvascular density expressed in terms of vessel numbers (Pendleton et al. 1998).
In an attempt to automate the counting process, computer programs have been
developed to perform the same task using digitally captured images (Rendell et al.
1998). This technique is best suited to the analysis of intersection points, as is the
case when performing Chalkley counts, or in analysing images of intact
microvascular networks, as can be provided by fluorescent labelled 'whole mount'
tissue preparations (Fox et al. 1995). In the latter case, the number of intersections
that occur between the vascular network and a superimposed grid are counted
(Rieder, Roman, & Greene 1997). This technique also correlates well with manual
counting (Rieder, O'Drobinak, & Greene 1995).
To be successful however, any technique designed to quantify the vascularity of a
tissue sample is heavily reliant on the ability of the process to accurately identify the
vessels to be counted. The use of an appropriate histological stain is helpful in this
respect. Furthermore, Schor et al. studied the relationship between methodology and
outcome in the assessment of microvascular density for a series of solid tumours and
in normal breast tissue. They identified the chosen staining protocol as the single
factor most likely to introduce variability in the results (Schor et al. 1998).
Immunohistochemical staining is the most commonly used technique for the
identification of blood vessels prior to counting (Weidner 1995). In this technique,
specific antibodies are raised against known vessel-wall antigens. The resulting
antibody-antigen complexes are then identified by an appropriate detection system
allowing a positive result to be recorded. Such detection systems may incorporate a
fluorescent marker for example, or induce a local colour change. Heyderman
describes the technique in more detail as:
An immunological method which may be used for the demonstration ofvarious
substances in tissue sections and utilises labelled or unlabelled antibodies and the
very stable enzyme, horseradish peroxidase. The most widely used substrate,
diaminobenzidine, polymerises in the presence of peroxidase and hydrogen
peroxide to form an insoluble brown polymer which is deposited at the site of
antigen-antibody reaction.
Heyderman (1979)
There are several methods by which this technology may be employed however, only
the indirect method is of relevance here (Heyderman 1979). This technique involves
two antibodies, the primary antibody directed against the target antigen and a
secondary antibody, conjugated with horseradish peroxidase, directed against the
primary antibody. The peroxidase acts on 3,3'-diaminobenzidine (DAB) substrate to







Antigen 'A' located on cell
wall
Figure 3.1 - Schematic diagram illustrating the principles of the immunoperoxidase
stain technique where rabbit and goat antibodies are given as examples (HRPO:
horse radish peroxidase, DAB: 3,3'-diaminobenzidine).
Many antigens may be targeted in this way, with vast arrays of complementary
primary antibodies now available commercially (www.dako.co.uk). Target antigens
useful in the identification of small blood vessels are usually located on the wall of
endothelial cells, for example CD31, CD34, av(33 integrin, and von Willebrand factor
have all been used successfully whilst many others are also recognised (Khan et al.
2002;Lindmark etal. 1996;Pazouki et al. 1997).
A further important factor in the planning of any immunohistochemical protocol is a
consideration of the effects fixation may have on the antigen-antibody reaction
(Montero 2003). In our experiments the tissue will be fixed using standard solutions
of 10% formaldehyde in phosphate buffered saline. The binding of formaldehyde to
the tissues, in addition to preservation, may also result in a degree of 'masking' of
antigen localisation sites, most likely as a result of cross-linking between elements of
the antigen macromolecule (Ezaki 1996).
Formalin fixed tissue is therefore, often pre-treated before proceeding to
immunohistochemical staining in an attempt to reverse this process (Cattoretti et al.
1993). Enzymatic or non-enzymatic techniques may be used. Both techniques aim
to destroy the acquired cross-linkages so exposing the antigen binding site and
permitting antibody localisation (Ezaki 1996). The use of proteolytic enzymes such
as trypsin and protease constitute the former whereas in the non-enzymatic
technique, referred to as antigen retrieval, heat may be used to achieve a similar
effect, as first reported by Shi et al. in 1991 (Shi, Key, & Kalra 1991).
Ezaki et al., in their review of these techniques, make a number of important points
(Ezaki 1996). Firstly, the time with which the tissue is exposed to the fixative should
be kept to a minimum to increase the likelihood of successful unmasking, secondly,
increasing attempts at antigen retrieval by increasing the temperature and/or
prolonging the time of heat exposure, are likely to result in a variable degree of
unwanted, non-specific background staining. In addition, false positives may be
observed making the interpretation of results difficult. In summary he concluded
'each antigen requires a "tailor-made" tissue preparation for optimal preservation of
its antigenicity and precise localization.' My experiences in the use of this technique
with my own tissue preparations concur entirely.
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A further important consideration in the proposed use of immunohistochemical
staining techniques for these experiments was that our specimens would be of animal
and not human origin. Although not their intended use, anti-human antibodies have
been successfully used for the identification of vascular endothelium in animal tissue
(Ray et al. 2000). Two important factors however, must be considered in this
situation. Firstly, the primary antibody is raised against a human antigen, and
although a degree of cross-reactivity with the animal counterpart is common, this
will vary dependant both on the target antigen chosen and the animal species in
question. Species specific antibodies, which are increasingly now available, are
therefore recommended (Azimzadeh et al. 1998). At the time this work was
conducted however, no species specific endothelial stain for rats was available to us.
Secondly, from our own experience of the technique, a degree of cross-reactivity
may be encountered between the primary and / or the secondary antibody and other,
non specific antigens in the field resulting in a misleading level of background
staining making interpretation difficult. This problem may be eased to a degree by
the use of an affinity isolated secondary antibody, designed to be more specific to the
binding site of the primary antibody and therefore reducing the incidence of
background staining (Martinez-Hernandez et al. 1975).
Ifappropriate consideration be given to these technical aspects then the staining of
animal preparations using antibodies raised against human antigens is likely to be
successful and of significant value in the completion ofmicrovascular counts for
research purposes (Chichester et al. 2001).
In relation to our experimental model of tissue ischaemia, an important feature in the
planning of a suitable technique for the assessment of MVD was that it should be
comparable between animals. In this respect the counts should be performed in
specific and well-defined locations. Similarly, we wished to analyse the vascularity
of the flap in a generalised manner, to reduce the influence of any localised changes,
and therefore we chose to measure average-MVD as offering the most useful
assessment in this respect.
3.1.2 Aims
The aim of this study was to evaluate the use of immunohistochemical staining in
formalin fixed, paraffin embedded rat tissue, as an aid to the assessment of
microvascular density and apply this technology to an analysis of rat skin in the
epigastric island flap model of tissue ischaemia.
3.2 Materials and Methods
Immunohistochemical preparations were performed with the help and advice of Ms
P. Marr, Department of Anatomical Pathology, The St George Hospital, Sydney,
Australia, to whom I am very grateful.
3.2.1 Antibodies
All antibodies were from Dako (Botany, NSW, Australia). The following panel of
primary antibodies were evaluated, chosen on the basis of their successful use in
microvascular analysis in humans: monoclonal mouse anti-human von Willebrand
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factor (product code: M 0616), polyclonal rabbit anti-human von Willebrand factor
(product code: A 0082) and monoclonal mouse anti-human CD31 (product ref: M
0823) (Lindmark et al. 1996). Biotinylated rabbit anti-mouse (product code: E 0354)
and goat anti-rabbit (product code: E 0432) secondary antibodies were used
accordingly.
3.2.2 Reagents
Bacterial protease type XXIV, 3,3'-diaminobenzidine (DAB) and TRIS buffer was
from Sigma-Aldrich (Castle Hill, NSW, Australia). Streptavidin peroxidase label
(product ref: 493000) was from Immunon (NSW). Xylene and ethanol were from
Ajax Cehmicals, NSW, Australia. Imidazol was from Fluka (Australia). Skimmed
milk powder was bought locally. Bovine serum albumin was from Life
Technologies (New York, USA). Slides and cover slips were from Menzel Glaser
(Germany). Harris' haematoxylin, deionised water, slide racks, glasswear,
humidifier box and an oven were all available in the imunohistochemical laboratory
at The St George Hospital. The microscope and eyepiece screen used was by
Olympus.
3.2.3 Solutions
TRIS buffered saline: Dissolve 6 g TRIS (Sigma-Aldrich) in 1000 ml
normal saline and adjust to pH 7.6 using 10M HC1.







Add 20 ml hydrogen peroxide (30% w/v) to 180ml
methanol (100%). Store at 4°C for a maximum of 2
days. Final solution 3% w/v hydrogen peroxide.
Measure 200 ml TRIS buffer (pH 7.6) into a flask
and add 6 g skimmed milk powder. Stir until
dissolved. The solution will last for 5 days. Final
solution 30 mg/ml (3% w/v).
Add 0.5 g bovine serum albumin to 50 ml TRIS
buffer (pH 7.6). Final solution 0.1 mg/ml.
Measure 50 ml TRIS buffer (pH 7.6) into a flask and
add 25 mg protease and mix well. This solution
should be used at 37°C and may be warmed in a
microwave. Final solution 0.5 mg/ml.
Measure 50ml TRIS buffer (pH 7.6, room
temperature) into a flask and add 0.03 g of 3,3'-
diaminobenzadine. To this add 1ml of a 0.1M
solution of imidazole and 15 pi 30% hydrogen
peroxide solution. Stir gently.
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3.2.4 Tissues
Formalin fixed, paraffin embedded tissue sections from rats in experimental groups 1
and 2 (8 animals in each group) were used in these experiments (see Chapter 2).
Details of the methodology used in the preparation of the histological blocks are
given in Appendix 3. Sections were inked to allow orientation such that black ink
denoted the medial extent of the section whilst blue ink was lateral. Full width
sections of each flap were taken at two positions and divided as shown in Fig. 3.2,
providing four blocks for analysis from each flap. Serial sections (5 pm, microtome)
were cut from the blocks and lifted onto standard glass microscopy slides.
Optimization of the process was performed on tissue from a single group 1 flap.
Formalin fixed epigastric
island flap
Transverse sections taken at:
(i) three quaters point (position 1)











































Blocks numbered 1 to 4 and
marked with unique animal
identifier
Figure 3.2 - Schematic diagram illustrating the technique devised for the preparation
of histological sections from predetermined positions in rat epigastric island flaps.
Transverse sections were taken at points three quarters of the way and halfway along




Before immunostaining, the paraffin sections were dewaxed in xylene and processed
to ethanol. Two techniques of antigen retrieval were evaluated. After washing in
phosphate-buffered saline for 5 minutes, sections were submitted to either (i)
microwave (750W) heating in 0.21% citric acid monohydrate for 10 minutes or (ii)
treatment with 0.5 mg/ml protease type XXIV solution for 5 minutes at 37°C.
3.2.5.2 Immunostaining
Tissue sections were stained with each of the three trial antibodies (monoclonal
mouse anti-human CD31, monoclonal mouse anti-human von Willebrand factor and
polyclonal rabbit anti-human von Willebrand factor) in the following manner, based
on standard procedure in our laboratory.
To block endogenous peroxidase activity, slides were treated with methanolic
hydrogen peroxide (3% w/w hydrogen peroxide) for 10 minutes. Slides were rinsed
in water and washed with PBS before transferring to non-specific binding block (3%
skimmed milk in TRIS buffer) for a further 5 minutes. Following a further water
rinse, tissue sections were localised with a PAP pen and an even coat of primary
antibody applied at the highest concentration recommended by the manufacturer.
Two primary antibody incubation times were evaluated. Slides were incubated at
room temperature for either (i) 60 minutes or (ii) overnight. All specimens were
given two further washes in PBS, 5 minutes each, incubated with the appropriate
secondary antibody for 30 minutes at the manufacturers recommended dilution and
washed again in two changes of PBS. Staining was visualised using a streptavidin
peroxidase label at a dilution of 1/150 applied evenly for 30 minutes followed by 2
washes with PBS and application of DAB reagent for 5 minutes. The slides were
washed thoroughly in water and counterstained with Harris' Haematoxylin for 10
seconds, before dehydrating with absolute alcohol, clearing with xylene and
transferring to an automated cover slip machine.
3.2.6 Quantification of a-MVD
Vessels were quantified by manual counting under light microscopy. A computer-
assisted technique was evaluated but found to be unhelpful. An eyepiece
incorporating a grid was fitted to the microscope to define the area to be counted. A
countable vessel was defined as a cluster of positively staining endothelial cells of
any size, with or without an identifiable lumen, clearly separated from neighbouring
vessels defined similarly. Two regions of each flap were assessed, (i) the area
adjacent to the zone of demarcation separating viable and non-viable tissue and (ii)
the whole breadth of the flap. Each region was further subdivided into a superficial
and deep plane separated by the panniculus carnosus muscle layer. Counts were
performed for each of these regions and at both levels in the flap relative to the
panniculus.
The assessment of a-MVD was performed as follows: Specimens were orientated
under low magnification (x40). The panniculus carnosus was identified running
through the specimen. The zone of demarcation was identified if present in the
specimen under review and the first series of counts performed at this point.
Magnification was increased to x400 and four sequential counts performed in the
area bounded by the full grid square (0.0625 mm2 at x400 magnification). For the
first count the grid was positioned to abut the zone of demarcation. The subsequent
three counts were performed in adjacent positions to count 1 moving towards the
viable flap such that on completion, four consecutive grid areas had been assessed
within the zone of demarcation. Results were recorded.
A series of 8 non-consecutive counts were then performed, using the same technique,
at random positions across the full width of each section (also at x400
magnification). Both counts were performed at two levels within each specimen,
namely above and below the panniculus carnosus muscle layer.
3.3 Statistics
Results for a-MVD are expressed as mean values with 95% confidence intervals for
each region counted namely, position 1 and position 2 of both the axial pattern and
random extension of each flap above and below the panniculus carnosus. Results for
the zone of demarcation in group 2 flaps (one week post elevation) are presented
similarly. Comparisons were performed using the Mann-Whitney U test and p<0.05
was taken to represent statistical significance.
3.4 Results
3.4.1 Optimization of endothelial staining technique
Protease digestion appeared to be superior to antigen retrieval by heating, as a pre-
treatment. Polyclonal rabbit anti-human von Willebrand factor was the best
performing primary antibody with a higher density of staining observed than either
of the monoclonal antibodies tested. There appeared to be no advantage to
incubation with the primary antibody over night when compared to the standard
incubation time of 60 minutes.
Our most successful protocol for the staining of formalin fixed, rat endothelium in
epigastric island flaps can therefore be summarised as: protease pre-treatment,
endogenous peroxidase block, non-specific binding block, polyclonal rabbit anti-
human von Willebrand factor primary antibody (1 hr incubation), affinity isolated
biotin labelled goat anti-rabbit secondary antibody (30 minute incubation), standard
streptavidin detection system (Fig. 3.3).
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Figure 3.3 - Immunoperoxidase preparations of sections taken from rat epigastric
island flaps (Polyclonal rabbit anti-vWF primary antibody, biotinylated goat anti-
rabbit secondary antibody). Endothelium appears brown indicating positive staining.
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3.4.2 Measurement of a-MVD
Tissue sections from all group 1 and group 2 animals were prepared for analysis
using the above protocol. An independent assessor, not involved in the preparation
of the tissue, performed all vessel counts. I am grateful for the help of Dr J. Clark,
Surgical Resident, The St George Hospital, NSW Australia in this respect. All
counts were performed blinded to the details of the specimen. All results are
"y
expressed as vessels per unit area of 0.0625 mm .
3.4.2.1 Within-group analysis
Average MVD for group 1 animals for each of the locations examined is given in
Table 3.1. In all positions a-MVD was significantly higher deep to thepanniculus
when compared to the superficial plane (p<0.01). As expected however, within each
tissue plane vascularity was found to be uniform, with no significant difference in a-
MVD between positions 1 and 2 or in the axial pattern flap compared to the random
pattern extension (p>0.15). This being the case, the results for a-MVD in a given
plane were pooled to provide an average measurement for the flaps taken as a whole.
In this manner a-MVD for normal rat epigastric skin was found to be 8.6 C.I. (7.9,
9.3) vessels per unit area superficial to the panniculus carnosus whilst in the deep
plane it was!2.7 C.I. (11.6, 13.8) (p<0.01).
Table 3.1 - Average MVD for group 1 flaps (normal rat epigastric skin). Results are
per unit area of 0.0625 mm with 95% confidence intervals given in brackets. The
observed differences in mean values for level 'b' (below the panniculus) compared
to level 'a' (above the panniculus) were statistically significant at all locations
examined (p<0.01).
Average MVD (95% C.I.)
random pattern flap axial pattern flap
Position 1 (n=8)
level a 9.2 (7.8, 10.6) 8.9(7.9, 10.0)
level b 12.6(10.5, 14.7) 12.9(10.9, 14.9)
Position 2 (n=8)
level a 8.0(6.5, 9.5) 8.3 (6.9, 9.7)
level b 12.4(10.0, 14.7) 12.8(10.6, 14.9)
Position 1 represents sections taken at a position three quarters of the way along the
flap from caudal to cranial, marked at the time of elevation. Similarly, position 2
represents sections taken in the plane passing through the mid point of the flap (Fig.
3.2).
Level 'a' is above, and level 'b' below, the panniculus carnosus muscle.
Analysis of the data from group 2 animals (flap harvest at 1 week) found a similar
pattern (Table 3.2). Average MVD deep to thepanniculus was higher than in the
superficial plane in all locations examined. In all bar one location this difference
reached statistical significance (p<0.04). The exception was recorded for the axial
pattern flap at position 1 where p=0.13. Nevertheless, a-MVD at this location
remained consistent with the general pattern of increased vascularity deep to the
panniculus and may have reached statistical significance with further sampling. As
for group 1 flaps, analysing the data for each region as a whole (excluding the zone
of demarcation which represented a special and specific case), the vascularity within
each layer was found to be uniform with no significant difference in a-MVD between
positions 1 and 2 or in the axial pattern flap compared to the random pattern
extension (p>0.24). The data was therefore, pooled as before to give an a-MVD for
the whole flap of 10.0 C.I. (8.8, 11.1) vessels per unit area above the panniculus and
14.9 C.I. (13.2, 16.5) below it (p<0.01).
The highest a-MVD of all was recorded in the zone of demarcation in the plane deep
to the panniculus (22.2 C.I. (17.0, 27.5)) where it was significantly higher than at any
other location examined (p<0.01).
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Table 3.2 - Average MVD for group 2 flaps (rat epigastric island flap at one week).
Results are per unit grid area of 0.0625 mm2 with 95% confidence intervals given in
brackets. Highest values for a-MVD were recorded deep to the panniculus carnosus
within the zone of demarcation where they were significantly higher than at any
other location examined (p<0.01).
Average MVD (95% C.I.)
Zone ofdemarcation random pattern flap axial pattern flap
Position 1
level a 9.1 (6.5, 11.7) 9.8 (7.2, 12.4) 10.7(7.8, 13.6)
(n=8)
level b 23.4(15.1,31.8) 16.0(11.9, 20.2) 13.7(10.6, 16.8)
Position 2
level a 10.5 (7.7, 13.3) 10.1 (8.6, 11.6) 9.3 (7.6, 10.9)
(n=8)
level b 22.3 (17.3, 27.3) 14.7(11.4, 18.1) 15.3 (12.7, 17.9)
Position 1 & 2 and Levels 'a' & 'b' are as for Table 3.1
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3.4.2.2 Between-group analysis
Comparisons were made between the results for group 1 and group 2 flaps. Average
MVD was increased at all locations both above and below the panniculus in group 2
flaps when compared to the corresponding positions in group 1 flaps. This increase,
with one exception, did not reach statistical significance (p>0.06). The exception
was for the random pattern flap at position 2 above the panniculus where a-MVD
had risen from 8.0 to 10.1 vessels per unit area in group 2 flaps (p=0.02). We did not
consider this to be an important finding.
The data was further analysed by comparing the random and axial portions of each
flap taken as a whole i.e. combining the results for position 1 and position 2 for each
hemiflap. The change in a-MVD for the axial pattern flap was not significant on
either side of the panniculus carnosus (p>0.24) however, for the random pattern flap
the increase in a-MVD deep to the panniculus was significant (p=0.04) and tended to
significance in the superficial layer (p=0.06).
The most impressive rise in a-MVD was however, within the zone of demarcation
deep to the panniculus (Table 3.2). Since there is no zone of demarcation in group 1
flaps, comparisons were made instead with the results for the random pattern flap in
these animals. The difference in a-MVD above the panniculus did not reach
statistical significance (p>0.2) however, the observed rise in a-MVD below the
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position relative to panniculus
Figure 3.4 - Boxplot of a-MVD above and below the panniculus carnosus for the
random pattern flaps in both groups and the zone of demarcation in group 2 flaps.
Although no statistically significant change in vascularity is seen for the
measurements taken above the panniculus carnosus, a-MVD below it is increased in
both the random flap taken as a whole and at the zone of demarcation (zod) with the
increase being most marked in the latter. In both these locations the observed
increase in a-MVD was statistically significant (p=0.04 and p<0.01 respectively).
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Evidence of physiological angiogenesis within the experimental flaps at one week
was therefore most pronounced in the region deep to the panniculus carnosus within
the zone of demarcation and more apparent in the random compared to the axial
pattern flaps.
3.5 Discussion
Assessments of tissue vascularity may be made on standard Haematoxylin & Eosin
stained slides, with some authors reporting their preference for this technique over
the use of immunohistochemical stains (Rendell et al. 1998). In our experience
however, the use of immunostaining was of great help in the identification of small
blood vessels within our tissue blocks and as such, significantly improved our ability
to count them accurately and reliably. Published protocols for use in the
quantification of vascularity in human tumours, where the use of immunostains is
routine, supports this view (Weidner 1995). In our work, an additional consideration
was that the assessments were to be performed by a non pathologist, with limited
experience in this field, to whom the benefits of accurate staining proved a great
advantage.
In order to achieve consistent results however, time must be spent on the
optimisation of any given protocol, both in terms of the reagents used and also the
manoeuvres employed to enhance antigen staining whilst keeping confusing
background stain to a minimum. Although the technology has been designed
principally for use in human tissue, a degree of experimentation with standard
protocols will give very satisfactory results for animal preparations. More recently,
primary antibodies raised against specific animal antigens have become increasingly
available for research purposes and these are likely to further improve the quality of
results in the future (www.serotec.com).
The vascularity of abdominal rat skin in its normal state has not been previously
reported and represents a useful baseline with which to make comparisons. Average
MVD was found to be consistently higher in the plane deep to the panniculus
carnosus muscle relative to the superficial layer. Within each layer however, a-
MVD was uniform across the flap as might be expected for normal rat abdominal
skin. We were therefore encouraged that our technique for the collection of a-MVD
data was effective and capable of providing a useful assessment of flap vascularity.
At one week post elevation, the pattern was similar in that a-MVD remained highest
deep to the panniculus carnosus at all locations examined. Our results were similar
in this respect to those reported by Taub et al. (Taub PJ et al. 1998). who also
commented on the increased vascularity deep to the panniculus compared to the
superficial plane. In addition however, we found increases in a-MVD in the random
compared to the axial pattern flap and a marked increase in a-MVD deep to the
panniculus in the location immediately adjacent to the necrotic front, in the zone of
demarcation.
In attempting to explain these results it is helpful to consider the stimulus to
angiogenesis acting on the flap as being made up of two components, namely a low
local oxygen tension on the one hand and the requirements of tissue healing at the
interface between the flap and the abdominal wall on the other. Both of these
conditions are known to act as independent promoters of angiogenesis via the
activity of VEGF (Brown et al. 1992;Detmar et al. 1997).
Within the zone of demarcation, both of these stimuli will be active. On moving
away from the ischaemic front however, the hypoxic drive will diminish, leaving the
response to healing as the major promoter of angiogenesis. One might expect
therefore, a-MVD to increase in all positions deep to the panniculus with further
increases where tissue hypoxia is most marked, namely the random pattern flap and
in particular within the zone of demarcation where oxygen tension is at the lowest
level consistent with tissue viability.
The changes in a-MVD observed were, in general, in keeping with this view. The
greatest increase was recorded at the zone of demarcation deep to the panniculus
where it was significantly higher than at any other location. Smaller but definite
increases were also noted for the random pattern flap on both sides of the panniculus
although this fell just short of statistical significance in the superficial plane. The
axial pattern flap showed no significant change in a-MVD in either plane where I
would have expected to see a rise in the deep plane. Similarly the superficial plane
within the zone of demarcation showed no significant increase in a-MVD where one
may have been expected.
The pattern of changes in a-MVD observed was therefore, in general, consistent with
expectation. The inconsistencies highlighted are most readily explained by a lack of
sensitivity of the test and increased sampling in the zone of demarcation superficial
to the panniculus and in both planes of the axial pattern flap may have detected more
subtle changes in a-MVD.
Where experimental flaps raised in rats have been used to investigate therapeutic
angiogenesis to date, assessments of vascularity have tended to be subjective and
made by examining the plane deep to the panniculus carnosus (Kryger et al.
2000;Taub PJ et al. 1998;Zhang et al. 2003). My results demonstrate that
physiological angiogenesis is most apparent in this plane and that significant
increases in microvessel numbers are to be expected within the zone of demarcation.
When considering techniques most suited for the detection of stimulated
angiogenesis, these results support the use of objective vessel counts and suggest
they are best performed in the more stable vascular bed superficial to the panniculus
carnosus where induced changes in vascularity will be more easily detected against
the background of physiological angiogenesis.
3.6 Conclusions
1. Immunohistochemical staining of rat endothelium in formalin fixed tissue is
effective and helpful in the assessment of microvascular density in epigastric island
flaps.
2. Average microvascular density in the rat epigastric island flap at the time of
elevation is 8.6 vessels per unit area of 0.0625 mm2 in the superficial plane and 12.7
in the deep plane defined by the panniculus carnosus. Within each plane the
vascularity is uniform across the flap.
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3. Flaps analysed at one week demonstrate a significant increase in a-MVD in
the plane deep to the panniculus in the random pattern flap compared to normal rat
skin (p=0.04).
4. Highest a-MVD was recorded deep to the panniculus within the zone of
demarcation where it was significantly higher than at any other position within the
flap (p<0.01).
5. The optimal plane for the detection of induced angiogenesis in the rat
epigastric island flap model is likely to be superficial to the panniculus carnosus in
the random pattern flap where it is more easily distinguished from physiological
angiogenesis.




One of our primary aims in this project was to evaluate the use of raw plasmid DNA,
encoding the gene for VEFGB, as an agent for therapeutic angiogenesis. Amrad
Corporation Ltd (Burnley, Victoria, Australia) could supply a suitable plasmid
construct based on the mammalian expression plasmid pEF-BOS. Two plasmids
were made available, one containing the VEGFB insert, and one without for use as a
control. To proceed, we first required purified DNA stocks of both of these
plasmids.
4.1.2 pEF-BOS mammalian expression plasmid
Plasmids that have been optimised for protein production are referred to as
expression vectors. The pEF-BOS plasmid is one such expression vector designed
for use in mammalian cells (Fig 4.2) (Mizushima & Nagata 1990). Uetsuki et al. in
their work on the genetic structure of the polypeptide chain known as elongation
factor la (EF la), reported the discovery of a powerful promoter sequence isolated
from the human gene for EF- la in fibroblast cells (Uetsuki et al. 1989). Subsequent
experiments confirmed its great efficiency at inducing transcription in vitro. The
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construction of an expression plasmid, pEF-BOS, based on this promoter soon
followed (Mizushima & Nagata 1990). When tested against accepted standards,
Mizushima et al. showed the superiority of the new construct in achieving protein
production in a series of animal and human cell lines (Mizushima & Nagata 1990).
Similar success with this plasmid has been reported by others (Kinoshita et al. 1999).
pEFBOS S FLAG/MYC Vectors For
Secreted Expression
Figure 4.1 - Diagram of the mammalian expression plasmid pEF-BOS-FLAG
indicating the position of a number of important restriction sites.
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4.1.3 Purification of plasmid DNA
To be useful in the context of gene therapy, plasmid DNA must be pure. Extraction
from the host bacterial cell population must therefore be achieved with as little
contamination from other cellular components as possible. One highly successful
method of achieving this was set out by Birnboim and Doly and relies on the
existence of a narrow range of pH (12.0 - 12.5) within which linear DNA will
undergo irreversible denaturation but in which covalently closed circular DNA
remains intact (Birnboim & Doly 1979).
The published technique may be summarised as follows. The bacterial cell walls are
first lysed with sodium hydroxide and sodium dodecyl sulphate (SDS) in a closely
controlled manner. Chromosomal and plasmid DNA as well as proteins are
denatured by the alkaline conditions. The lysate is neutralised with acidic sodium
acetate. The high salt concentration causes SDS to precipitate, and the denatured
proteins, chromosomal DNA and cellular debris become trapped in salt-detergent
complexes. Plasmid DNA however, being smaller and covalently closed, renatures
correctly and remains in solution. The precipitated debris can then be removed by
centrifugation and the plasmid concentrated by ethanol precipitation (Birnboim
1983).
These principles have been incorporated into a number of commercially available
kits for the extraction and purification of plasmid DNA which are highly efficient
and offer excellent levels of plasmid yield and purity (Qiagen Pty Ltd 1997).
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4.1.4 DNA sequencing
The ability to sequence DNA molecules is fundamental to much of the work in
genetic engineering. Knowledge of the base sequence of a DNA region is essential if
cutting and joining procedures are to be conducted accurately. In addition,
sequencing allows confirmation that an intended genetic manipulation has indeed
taken place, and at the location expected.
Franca et al. have recently reviewed the various methods by which DNA molecules
may be sequenced (Franca, Carrilho, & Kist 2002). Of particular relevance to this
work is the chain-terminator method of Sanger which provides the foundation for
automated sequencing (Sanger, Nicklen, & Coulson 1977). The principles of this
technique will be considered briefly here.
The enzyme DNA polymerase, under normal circumstances will synthesize
complementary copies of a single-stranded DNA template from 2' deoxynucleoside
triphosphate substrates. If present however, it will also incorporate the analagous
2',3' dideoxynucleotide into the growing chain. This is significant since the latter
lacks a 3'- hydroxyl group on the pentose ring and as such will not allow further
chain elongation. The growing chain is therefore terminated at this point. If a
primer sequence is used to start a DNA polymerase reaction at a particular point in
four separate incubation mixes, each of which contain the full complement ofnormal
deoxynucleotide bases (radiolabeled), but in addition contain in turn, a single chain
terminating dideoxynucleoside base (A, G, C or T), then a population of partially
synthesised radioactive DNA molecules will result. These molecules will all have a
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common 5'- end (the primer sequence) but vary in length to a base specific 3'- end.
Denaturing the DNA and performing electrophoresis of the four samples side by side
allows the base sequence to be read directly form an autoradiograph (Fig. 4.3)
(Sanger, Nicklen, & Coulson 1977).
The replacement of radiolabels on the normal nucleotides with base specific
fluorescent tags on the chain terminating ones has allowed automation of the system
by the detection of each DNA band by its fluorescent colour as it electrophoreses
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Figure 4.2 - DNA sequencing with dideoxynucleoside triphosphates as chain
terminators after the method of Sanger. Asterisks indicate the presence of the
radioactive label '32P' and the prefix 'dd' indicates the presence of a
dideoxynucleoside. A, adenine; C, cytosine; G, guanine; T, thymidine (Taken from
Old & Primrose, Principles of Gene Manipulation, 1994).
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4.1.5 Aims
The aim of this work was to produce purified stocks of both pEF-BOS, and pEF-
BOS-VEGFB plasmids and to confirm the integrity of the VEGF-B insert in the
latter by sequencing the coding region.
4.2 Materials and Methods
4.2.1 Acknowledgments
Bacteriological culture work was performed with the aid of Dr S Tait, Department of
Molecular Biology, Centre for Thrombosis and Vascular Research, University of
New South Wales to whom I am very grateful. Amrad Corporation Operations
(Burnley, Vic, Australia) provided a map of the correct base sequence for the VEGF-














rrnw I -SYtc- gall
psrB I pcoR I • 1 pise I
ttccgctcctgatgaattcgactacaaggacgacgatgacaaggcccctgtctcccagcctgatgcccctggccaccaga
1 H ..... I ■ F—' 1 I I 1 h 160
aaggcgaggactacttaagctgatgttcctgctgctactgttccggggacagagggtcggactacggggaccggtggtct
I > I -)




Xma I Ect136 II
J pma 1 pcotCRI
ggaaagtggtgtcatggatagatgtgtatactcgcgctacctgccagccccgggaggtggtggtgcccttgactgtggag
1 —H I I I F- 1 1 1- 210
cctttcaccacagtacctatctacacatatgagcgcgatggacggtcggggccctccaccaccacgggaactgacacctc
rkvvswiovytratcqprevvvpltve
Bal I BstX I
jSacI psc I Pvu II pvu II pco47lll psg I
ctcatgggcaccgtggccaaacagctggtgcccagctgcgtgactgtgcagcgctgtggtggctgctgccctgacgatgg
—. ■ ■ I . H- 1 I 1 . I . . 1 1 F 320
gagtacccgtggcaccggtttgtcgaccacgggtcgacgcactgacacgtcgcgacaccaccgacgacgcgactgctacc
lmgtvakolvpscvtvqrcggccpodg
Bpm I ACC III BspHI Acc65l
pgl I jSsu I ppn2 I psaB I pee I | ppn I pvu II
cctggagtgtgtgcccactgggcagcaccaagtccggatgcagatcctcatgatccggtacccgagcagtcagctggggg




psm I psg 1
agatgtccctggaagaacacagccagtgtgaatgcagacctaaaaaaaaggacagtgctgtgaagccagatagccccagg









EeolCRI Sse83671 Avr II
j pac I pspM I j BspM I pcoR I pin I
CCTccgttgccaagggcggggcttagagctcaacccagacacctgcaggtgccggaagctgcgaaggtgaattccctagg
I I I ... I —I 1 1 F— 1 1 I 610
ggaggcaacggttcccgccccgaatctcgagttgggtctgtggacgtccacggccttcgacgcttccacttaagggatcc
lrcogrglelnpdtcrcrklrr
Figure 4.3 - Base and amino acid sequence for VEGFB provided by AMRAD
Corporation seen here preceded by the Flag tag detection sequence (A, adenine; C,
cytosine; G, guanine; T, thymidine)
4.2.2 Bacteriological reagents and equipment
Tryptone and yeast extract were from Difco (Becton Dickinson, MD, USA). Sodium
chloride and ampicillin were from Sigma-Aldrich (St. Louis, USA). Distilled water
was available in the laboratory. Isopropanol was from Lab Scan (Bangkok,
Thailand) and ethanol from Ajax Chemicals (NSW, Australia). Escherichia coli
transfected with the expression plasmids pEF-BOS and pEF-BOS-VEGFB were
supplied by Amrad operations, as two separate glycerol stocks. The shaking device
used was the B. Braun certomat and the centrifuge was the Beckman J2-21 model.
Glassware and reaction tubes were from stock held in the haematology research
laboratory at the Prince of Wales Hospital. Plasmid purification kit (QIAfilter
Plasmid Maxi Kit, product no. 12262) was from Qiagen (Clifton Hill, Vic,
Australia). The DNA spectrophotometer used was the Genequant from Pharmacia
(Australia office). All DNA sequencing was performed using the multichannel
sequencer at the University ofNew South Wales (Randwick, Australia).
4.2.3 Bacteriological solutions and media
Selective LB medium: Add 1 g tryptone, 1 g sodium chloride and 0.5 g yeast extract
to 100 ml distilled water in a suitable flask and stir to dissolve. Sterilise by
autoclaving for 15 minutes. Add 10 mg ampicillin and store at 4°C.
Dr S Tait supplied selective LB agar culture plates (ampicillin 100 pg/ml).
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4.2.4 Plasmid preparation
Both experimental plasmids (pEF-BOS and pEF-BOS-VEGFB) were prepared in the
same manner from glycerol stocks of E. coli transformants as described below.
4.2.4.1 Preparation ofbacterial colonies
Selective LB agar culture plates were streaked with bacteria from each glycerol stock
(pEF-BOS-VEGFB and pEF-BOS). The plates were incubated at 37°C for 16 hrs to
provide single colonies, sealed with parafilm, labelled and stored in a cold room at
4°C.
4.2.4.2 Inoculation ofminibroth
Two minibroths were started, one for each transformant. A single bacterial colony
was selected from each culture plate and used to inoculate 3 ml selective LB medium
in a 15 ml sterile plastic reaction tube. A heat sterilised wire loop was used to
transfer each colony to the culture medium in the standard way. The tops of the
tubes were covered but air was allowed to circulate. Each minibroth was incubated
for 8 hrs at 37°C with vigorous shaking (B. Braun certomat equipment set at 225
rev/min).
4.2.4.3 Dilution ofstarter culture
A 500 pi aliquot from each minibroth was used to inoculate 100 ml of selective LB
medium in a 1000 ml sterile glass container. A cotton wool bung was placed in the
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mouth of each flask and the culture returned to the shaker and incubated at 37°C for
16 hrs at 225 rev/min as before.
4.2.4.4 Bacterial cell harvest
Each of the 100 ml cultures was divided into 25 ml balanced aliquots and centrifuged
at 5000 rpm at 4°C for 10 min (Beckman J2-21 equipment). The supernatant was
discarded to leave well-circumscribed bacterial pellets adherent to the base of each
centrifuge tube.
4.2.4.5 Extraction ofpurifiedplasmid DNA
Plasmid DNA was extracted from the prepared bacterial pellets using the QIAfilter
maxi kit (Qiagen Pty Ltd) according to manufacturer's instructions. The technique
incorporates Qiagen modifications of the alkaline lysis technique ofBirnboim and
Doly (1979) outlined above. In summary, an anion-exchange resin, maintained at
appropriate low-salt and pH conditions, is used to bind plasmid DNA released from
host bacteria during alkaline lysis, avoiding the need for centrifugation. Impurities
are then removed by a medium-salt wash while the plasmid DNA is tightly bound to
the resin. Plasmid DNA is then eluted in a high-salt buffer before being concentrated
and desalted by isopropanol precipitation. The manufacturer's expected yield is
quoted as 500 pg plasmid DNA per QIAfilter cartridge used. Four cartridges were
used to prepare purified plasmid DNA for each of the experimental plasmids pEF-
BOS and pEF-BOS VEGFB. Following the final stage of air-drying each plasmid
DNA pellet was dissolved in 1ml lOmM TRIS buffer (pH 8.0) and stored at -20°C.
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4.2.4.6 Assessment ofyield
Final plasmid yield was assessed for each of the eight DNA solutions prepared. The
GeneQuant (Pharmacia) DNA spectrophotometer was used in accordance with the
manufacturer's instructions. The DNA samples were analysed at 1:100 dilution in
deionised water (5 pi in 495 pi). The same deionised water provided the reference.
4.2.5 Sequencing of purified pEF-BOS VEGFB
To verify the integrity of the VEGFB insert, the pEF-BOS-VEGFB plasmid was
subjected to sequencing in this region. Since all stock preparations of the pEF-BOS-
VEGFB plasmid had their origin in a single bacterial colony, confirmation of the
correct sequence in one preparation only was necessary.
Sequencing was carried out at the automated DNA analysis facility housed at
University ofNew South Wales, Sydney, Australia. The preparation ofappropriate
DNA samples was performed with the help and assistance ofDr Melissa Holmes,
Senior Research Scientist, Centre for Thrombosis and Vascular Research, University
ofNew South Wales.
The primer used corresponds to a sequence within the EF-1 alpha promoter, just
upstream of an IL-3 signal sequence and Flag tag (used for detection of expressed
protein) and the 5'- end of VEGFB. Sequencing used Perkin Elmer BigDye
chemistry with 3.2 pmole primer and 500ng plasmid and standard cycle-sequencing
conditions ie. 94°C for 1 min xl cycle, then 94°C for 10 sec, 50°C for 10 sec and
60°C for 4 min for 25 cycles. The samples were then precipitated with 1/10 vol 3M
sodium acetate + 2.5 vol ethanol, rinsed with 70% ethanol, the pellet dried and sent
for sequencing.
The first primer chosen resulted in inconsistencies in the sequence towards the 3-
end of the VEGFB coding region and so a second primer located further
downstream, within the 5'- end of the VEGFB insert, was used to review this area.
4.3 Results
The plasmid DNA yield and purity 1 achieved for each ofthe final DNA solutions
was in keeping with my expectations based on the kit manufacturers published
information (Table 4.1). Preparation number 3 of the VEGFB series was the poorest
quality sample. No difficulties were encountered during the preparation of this
material and no specific reasons for the poor result were identified.
DNA from pEF-BOS-VEGFB sample 2 was taken as representative of the pEF-BOS-
VEGFB plasmid preparations as a whole and subjected to sequencing. Sequencing
data for this plasmid are given in Figures 4.5 and 4.6. Comparison of this sequence
with that for the Flag tagged VEGFB gene sequence supplied by Amrad, showed
complete agreement between the two bar a single base discrepancy at position 394 in
our plasmid where a thymidine was recorded in place of the expected guanine base.
This was felt most likely to have resulted from a sequencing error rather than a true
base discrepancy
Table 4.1 - Plasmid yield and purity.
Plasmid Sample Yield Purity
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Figure 4.4b - Computer generated base and amino acid sequences from the first
pEF-BOS-VEGFB analysis. The Flag tag sequence seen highlighted in yellow
precedes the VEGFB coding sequence (standard abbreviations).
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Figure 4.5b - Computer generated base and amino acid sequences from the second
pEF-BOS-VEGFB analysis. Position 342 on the VEGFB reference map is indicated
together with the end of the VEGFB coding sequence (standard abbreviations).
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4.4 Discussion
The manufacturers expected yield for the plasmid extraction and purification
technique employed was 500pg per preparation and I was pleased to get close to this
figure for the majority of my stock solutions. The pEF-BOS-VEGFB sample 3
showed slightly different characteristics in comparison to the other samples. The
yield appeared much higher but with a higher level of impurities than were present in
the other preparations. Presumably this had resulted from technical errors at the time
of DNA extraction leading to the persistence of some chromosomal DNA fragments
in the final solution.
Although no literature is available on the specific influence of purity on the success
of gene transfer experiments clearly the aim is to use solutions of the highest purity
possible. In this respect I considered the plasmid DNA stocks in general to be of an
acceptable quality for use in subsequent gene transfer experiments with the exception
of sample 3 in the pEF-BOS-VEGFB group. The presence of significant quantities
of impurities in this sample I believed would make interpretation of results difficult
and I therefore decided to exclude this material from further experimental work.
The sequencing data was reassuring and confirmed the accurate inclusion of the full
VEGFB-Flag sequence in sample 2 of my pEF-BOS-VEGFB plasmid preparations
and that the orientation was correct. This sample was taken as representative of all
four preparations which we therefore considered as similarly containing an accurate
copy the VEGFB coding sequence also in the correct orientation.
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4.5 Conclusions
1. Purified stocks of the two experimental plasmids pEF-BOS and pEF-BOS-
VEGFB were produced according to expectations and in general an acceptable level
of quality was achieved.
2. An accurate copy of the coding sequence for the VEGFB gene was confirmed
as present within the purified pEF-BOS-VEFGB expression plasmids.
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Chapter 5 -Transfection experiments with bovine aortic
endothelial cells in vitro
5.1 Introduction
One of the primary aims of this project was to evaluate the pEF-BOS-VEGFB
plasmid as an agent for therapeutic angiogenesis in vivo. To approach this problem
effectively it was first necessary to investigate the properties of the plasmid in vitro.
Two features were of particular importance. Firstly, I wanted to identify the
optimum conditions for transferring plasmid DNA into endothelial cells and
secondly, to confirm that once this had taken place, the plasmid was indeed capable
of causing the production of VEGFB within the transfected cell.
Primarily cultured bovine aortic endothelial cells (BAECs) were readily available
locally and although rat endothelial cells were on offer in the DMSZ (German
Collection of Microoganisms and Cell Cultures) catalogue, their acquisition did not
appear to offer significant advantage.
To identify successful gene transfer amongst the BAEC population post transfection,
a detection system was also necessary. Since no monoclonal antibody was available
to detect the VEGFB protein directly, the FLAG detection system had been
incorporated into the design of the pEF-BOS-VEGFB expression plasmid. In this
system, the coding sequence for the marker octapeptide FLAG, is cloned into the
— 129
plasmid in a position adjacent to the main protein sequence. The fusion protein that
results now contains a FLAG epitope that is amenable to detection by
immunostaining with commercially available anti-FLAG antibodies. The addition of
this small polypeptide is considered to have no effect on the activity of the native
protein (www.sigmaaldrich.com).
The use of immunostaining techniques for the detection of successful transfectants is
however, a labour intensive process and necessitates fixing of the cells so preventing
sequential data collection without the setting up of multiple cultures. In the initial
work we therefore elected to use a reporter plasmid. These plasmids confer on their
host cell a more easily measurable phenotype and simplify the detection process
considerably (Naylor 1999). One such system codes for a green fluorescent protein
(GFP) first isolated from the jellyfish Aequorea Victoria (Prasher et al. 1992). When
viewed in the presence of long-wave ultraviolet light (e.g. from an appropriate
microscope), the green fluorescence of GFP is easily detected and signals both
successful gene transfer and, of particular importance to our work, successful protein
production in the host cell. The non invasive nature of this detection system also
makes possible the sequential monitoring of gene transfer and expression in a living
cell population (Tsien 1998).
To achieve expression however, a plasmid must first reach the interior of a cell, and
more specifically in the case of a mammalian cell, the nucleus (Goebel & Schiess
1975). In certain circumstances, DNA will pass spontaneously through a cell wall
however, the mechanisms by which this occurs are poorly understood and in general,
appear highly inefficient (Danko & Wolff 1994). For this reason, a variety of
techniques have been developed to facilitate the process (Schenborn 2000). One
highly effective method, termed lipofection, was described by Feigner et al. and
employs cationic liposomes as carriers for the raw DNA (Feigner et al. 1987a).
When in solution, complexes form between liposomes and DNA and these
complexes, having a net positive charge, allow associations to occur with the
negatively charged cell surface. Interaction between the liposomes and cell wall
membrane ultimately lead to the transfer of DNA into the cytoplasm, most likely by
endocytosis (Zuhorn & Hoekstra 2002). This technique is now a well established
method for gene transfer and more specifically, has been shown to be a highly
effective method for the transfection of endothelial cells (Teifel et al. 1997).
The success of this technique has lead to the development of commercially available
liposomal transfection agents such as DOTAP (N-[l-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methylsulfate) (http://biochem.boehringer-
mannheim.com). This agent has proved helpful in achieving gene transfer to a wide
variety of cell types, including endothelial cells, when tested in vitro. There is
limited published work concerning its use in vivo however, some reports of similar
success do exist (McLachlan et al. 1995;Uchida et al. 2002).
Optimal conditions for liposome-mediated transfection are known to vary between
recipient cell types, dependant principally on the nature and concentration of the
DNA construct being used and on the incubation time (Benhamou PY et al. 1997).
Optimisation is therefore necessary. My priority in this respect was to achieve
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maximum transfection efficiency whilst minimising incubation time (in view of the
planned in vivo experiments where incubation time would equate to ischaemic time
within the experimental flap). I therefore designed a series of experiments based on
the GFP reporter plasmid and the transfection agent DOTAP to assess transfection
efficiency for a variety of conditions in primary BAEC cultures before switching to
the pEF-BOS-VEGFB study plasmid.
5.2 Materials and Methods
5.2.1 Acknowledgements
Primary cultured bovine aortic endothelial cells (BAECs) were provided at passage
six by Dr L Juan, Cardiovascular Research Unit, University ofNew South Wales. I
am grateful for the instruction given to me in the techniques fundamental to cell
culture by Dr C Flicks, Department of Haematological Research, University ofNew
South Wales.
5.2.2 Cell culture reagents and equipment
All reagents were tissue culture grade. DMEM MultiCel powder (product ref: 50-
126-PA) and L-glutamine were from Trace Biosciences Pty Ltd (Noble Park,
Victoria, Australia). Sodium bicarbonate and penicillin G/streptomycin were from
Sigma-Aldrich (Castle Hill, NSW, Australia). Trypsin (0.25% in ImM EDTA),
phosphate buffer and fetal calf serum were from Gibco, Life Technologies (New
York, USA). Sterile water was from Baxter Healthcare (Deerfield, IL, USA). Ultra
filters (0.22pm, product ref: 4622) were from Gelman Sciences (Cheltenham,
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Victoria, Australia). Falcon sterile pipettes and 75 cm cell culture flasks were from
Becton Dickinson (Franklin Lakes, NJ, USA). Eppendorf tubes were from
Eppendorf (Hamburg, Germany). Cell cytometer with Neubauer improved rulings
was from Laboroptik (Friedrichsdorf, Germany). Eight-well chamber slides (product
ref: 177445) were from Lab-Tek (Nalge Nunc International, Naperville, USA). A
Westinghouse Pty (NSW, Australia) biological safety cabinet and Forma Scientific
(Marietta, Ohio, USA) incubator were used for all cell culture work.
5.2.3 Plasmids and transfection reagents
pEGFP-N2 was from Clontech (Mountain View, California, USA) supplied at a
stock concentration of 1 pg/pl DNA. pEF-BOS-VEGFB plasmid had previously
been prepared from E. coli glycerol stock and was available at a concentration of490
pg/ml (DNA ref #2). The transfection agent N-[l-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP) also at a stock concentration of 1 pg/pl
was from Sigma-Aldrich. Hepes buffer (1M stock) was from Fluka (St. Gallen,
Switzerland).
5.2.4 Immunohistochemical reagents and antibodies
General reagents and solutions used were as listed in Chapter 3. The M2 monoclonal
mouse anti-FLAG primary antibody was from Sigma (product ref: F3165) whilst the
biotinylated rabbit anti-mouse secondary antibody was from Dako (product ref: E
0354).
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5.2.5 Preparation of cell culture medium and reagents
DMEMwith 10% foetal calfserum: Add one preparation of DMEM powder to 900
ml sterile water and stir until dissolved. Add 2.4 g sodium bicarbonate and 1 ml
penicillin/streptomycin solution (working concentration 5 u/ml penicillin, 5 pg/ml
streptomycin) and adjust to pH 7.4 with 1M hydrochloric acid added dropwise.
Transfer to biological safety cabinet and add 100 ml heat inactivated (56 °C, 30 min)
foetal calf serum. Ultrafilter into sterile bottle and store at 4 °C. Replenish by
adding 1:100 dilution L-glutamine (200 mM) every 14 days.
Phosphate buffered saline: Dissolve 5 tablets phosphate buffer in 500 ml sterile
water. Ultrafilter into sterile bottle and store at 4 °C.
Hepes buffer: Use at 20 mM, pH 7.4. From 1M stock solution perform 1:50 dilution
in sterile water and adjust pH.
5.2.6 Subculturing of BAEC's (1:3 split)
All reagents should be warmed to 37 °C in a waterbath. Remove medium from cell
cultures and discard. Wash with one change of 5 ml PBS before adding 3 ml trypsin
solution. Incubate at room temperature for 5 min with agitation until cells separate,
neutralise trypsin with 3 ml media, transfer to 15 ml plastic reaction tube and
centrifuge at 1000 rpm (Beckman J2-21) for 5 min. Discard supernatant and
resuspend cell pellet in 3 ml medium, mixing gently to break up all cell clumps. A
cell count may be performed at this stage (see below). Pipette 15 ml fresh medium
•5
each into three sterile 75 cm" culture flasks and transfer one third of the final cell
suspension into each. Incubate at 37 °C, 5 % CO2 with the culture flask lid loosened
to allow gas exchange.
5.2.7 Estimation of cell concentration
A standard haemacytometer with Neubauer rulings was used in accordance with the
manufacturers instructions. Since large culture flasks were being used, a preliminary
dilution of 1:100 was carried out in fresh medium. Four grid counts were performed
under x40 magnification and cell concentration calculated using the formula:
•a
Cell concentration = mean cell count x dilution factor x 10 cells/mm
= mean cell count x 100 x 10 x 1000 cells/ml
= mean cell count x 106 cells/ml
5.2.8 Transfection of BAECs
All cell cultures were prepared in the same manner. Each well of an eight-well
chamber slide was inoculated with 1 x 104 BAECs in 0.2 ml medium the day prior to
transfection and returned to the incubator. The aim was to achieve a cell confluence
of 60% - 80% at the time of DNA transfer.
The transfection procedure was conducted in accordance with the manufacturers
instructions in all experiments using DOTAP i.e. DNA, at a concentration of 0.1
pg/ml in hepes buffer, was first combined with DOTAP in a sterile reaction tube and
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incubated for 15 mins at room temperature before gently mixing with an appropriate
volume of culture medium to achieve the desired final DNA concentration. 200 pi of
the resulting mixture was then transferred to the cell cultures in each well for the
planned incubation time. On completion the transfection mixture was removed and
replaced with fresh culture medium. The slide chamber lids were gently replaced




The influence of DOTAP concentration on transfection efficiency was investigated
for two concentrations ofDNA (2.5 pg/ml and 5 pg/ml), two incubation times (1 hr
and 3 hrs) and at two DNA:DOTAP ratios. The manufacturer's recommended
transfection conditions (2.5 pg/ml DNA, DOTAP:DNA 6:1, incubation time 3 hrs)
were incorporated as base line.
5.2.9.2 Experiment 2
In the light of the results from experiment 1, the influence of DNA concentration and
incubation time on transfection efficiency was further investigated with a fixed
DOTAP:DNA ratio of 6:1. DNA concentrations of 5 pg/ml, 10 pg/ml and 20 pg/ml
were each investigated with incubation times of 1 hr, 3 hrs and 12 hrs. Control
groups comprised one series of wells incubated with DOTAP only (60 pl/ml in
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DMEM representing the median DOTAP concentration used) as above and 2 wells
that underwent changes of medium only during the experimental period.
5.2.10 pEF-BOS-VEGFB plasmid
In three separate chamber slides, two wells each were inoculated with 4 x 104, 2 x
104 and 1 x 104 BAECs respectively. A transfection mixture of 10 pg/ml plasmid
DNA containing DOTAP at a ratio of 6:1 was incubated with the BAEC cultures for
3 hrs. To monitor the number of successful transfections , one slide per day was
fixed (10 % buffered formalin applied for 20 mins followed by two exchanges of
PBS) for a total of three days. Slides were then subjected to immunostaining using
the anti-FLAG primary antibody as described below. Prior to fixation, all wells were
examined daily.
5.2.11 Immunohistochemistry
The outer casing of the chamber slides were removed according to the manufacturers
instructions and the cells washed with PBS. Anti-FLAG monoclonal antibody was
diluted 1/100 in TRIS buffered saline as per the manufacturer and applied as an even
coat to each slide, ensuring all cells were covered, and incubated at room temperature
for 60 minutes. Two washes in PBS were performed before applying an even coat of
biotinylated rabbit anti-mouse secondary antibody at a dilution of 1/200 in TRIS
buffered saline. Incubation was for 30 mins at room temperature. Staining was
visualised using a streptavidin peroxidase label at a dilution of 1/150 applied evenly
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for 30 minutes followed by 2 washes with PBS and application of DAB reagent for 5
minutes. Slides were then washed in water, dried and coverslips applied.
5.3 Results
5.3.1 pEGFP-N2 plasmid
Examination of the BAEC culture wells was undertaken at 1, 24, 48 and 72 hrs post
transfection using a Leica inverted fluorescence microscope (Wild Leitz).
5.3.1.1 General observations
The following trends were noted when transfected cells were compared to media-
only controls:
1. All cultures, including DOTAP-only controls, displayed a change in cellular
morphology appearing more rounded from 1 hr and persisting to 72 hrs
2. There appeared to be a reduction in cytoplasmic volume
3. Evidence of cytotoxicity was apparent in all experimental wells at 1 hr
including the DOTAP-only control. This proved difficult to quantify
accurately however, the most affected were wells where DNA and DOTAP
concentration were highest and where incubation time was longest.
Approximately one quarter to one half of cells were lost at the time of
transfection under these conditions however, some recovery was apparent by
24 hrs. The most significant cell loss however, occurred when transfection
was conducted in the absence of medium. In this group over half of the cells
were lost at 24 hrs and all had died by 48 hrs.
5.3.1.2 Transfection efficiency
Cells expressing the EGFP-N2 gene were readily identified by the green fluorescence
of their cytoplasm when viewed in the presence of ultraviolet light (Figure 5.1). No
fluorescence was seen in the control wells (medium plus DOTAP, medium only) at
any time.
The mean number of successfully transfected cells per well (n=2) for each set of
transfection conditions is shown graphically for experiments 1 and 2 in Figures 5.2
and 5.3 respectively. Experiment 2 proved more successful than experiment 1
possibly reflecting the use of a new supply of DOTAP for this work. The most
successful transfer of pEGFP-N2 into the BAECs appeared to occur at a DNA
concentration of 10 pg/ml, with a DOTAP:DNA ratio of 6:1 and an incubation time
of 3 hrs.
In general, the highest numbers of GFP-producing cells were seen on the second post
transfection day for the time period studied. To investigate the relationship between
each variable and transfection success, this set of observations was subjected to
further analysis.
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Figure 5.1 -BAEC cultures following transfection with pEGFP-N2. (A) low and (B)
high magnification. The detection of the characteristic green fluorescence of GFP
confirms both successful gene transfer and active protein synthesis (Inverted
fluorescence microscope with ultra-violet illumination).
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Figure 5.3 - Bar charts showing the effect of further increases in DNA concentration
and incubation time on transfection efficiency using a DOTAP:DNA ratio of 6:1 in
all cases.
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5.3.1.3 DOTAP to DNA ratio
In all cases, the presence of DOTAP significantly improved transfection efficiency.
There appeared however, no advantage in increasing DOTAP:DNA ratio above 6:1
(Figure 5.4).
5.3.1.4 Duration of incubation
Increased transfection efficiency was noted with increased incubation time up to the
maximum of 12 hrs for DNA concentrations of 5 and 20 pg/ml. This did not appear
to hold for the 10 pg/ml concentration due to a very high reading for the 3 hour
incubation samples (Figure 5.5).
5.3.1.5 DNA concentration
No consistent relationship between DNA concentration and transfection efficiency
for a given incubation time was identified.
transfection conditions
Figure 5.4 - Line chart showing the effect of increasing DOTAP:DNA concentration
on transfection efficiency for two starting concentrations ofDNA.
Incubation time
Figure 5.5 - Line chart showing the effect of increased incubation time on
transfection efficiency for three starting concentrations of DNA.
144
5.3.2 pEF-BOS-VEGFB plasmid
Assessment of transfection efficiency was more difficult in this group reflecting a
less sensitive detection system. Cells staining positive for the FLAG antigen proved
more difficult to identify, and therefore quantify, with certainty than was the case for
GFP transfectants. The pEF-BOS-VEGFP plasmid appeared however, to behave
similarly to pEGFP-N2 in that the first signs of FLAG expression were noted at 24
hrs with a significant increase in the numbers of positive cells seen by 48 hrs
followed by a decline to 72 hrs post transfection (Figure 5.6). The numbers of
successful transfectants identified in general, appeared similar to the pEGFP-N2
plasmid.
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Figure 5.6 - Whole BAEC cell preparations stained for FLAG. (A) & (B) seen at 24
hrs and (C) & (D) at 48 hrs post transfection with 10 pg/ml pEF-BOS-VEGFB DNA,
DOTAP:DNA 6:1 with an incubation time of 3hrs. (E) & (F) represent a control
population of BAECs also stained for FLAG. Cells containing brown pigment are




Since first described, cationic liposomes have been employed to achieve successful
gene transfer to a wide variety of cells in vitro with, more recently, some authors
reporting encouraging results using this technology in vivo (Audouy & Hoekstra
2001). In this series of in vitro experiments I was similarly successful in achieving
GFP gene transfer to, and subsequent expression in, cultured BAECs. Also
recognised is the variability that exists in the susceptibility of any given cell to this
form of manipulation and like others, I found significant variation in the extent to
which gene transfer occurred dependant on conditions at the time of transfection
(Smyth 2003). Maximal transfection efficiency was achieved at a DNA
concentration of 10 pg/ml which is high relative to the manufacturers
recommendation of 1-2.5 pg/'ml however, is consistent with previously reported
protocols (Benhamou PY et al. 1997). The apparent cytotoxic effect of the
transfection mixture at higher DNA concentrations is perhaps one reason why further
increases in DNA concentration do not translate into improved transfection
efficiency. Other conditions proved optimal as suggested by the manufacturer.
In general, maximal gene expression was observed at 48 hrs post transfection, a
finding consistent with previous reports (Misteli & Spector 1997).
The pEF-BOS-VEGFB plasmid appeared equally as effective as pEGFP-N2 in
achieving successful transfection of BAECs in culture and this was encouraging.
In these experiments I have identified the optimum conditions for gene transfer to
BAECs in culture using the transfection agent DOTAP. I have also demonstrated the
ability of the pEF-BOS-VEGFB plasmid to transfer the VEGFB gene to mammalian
endothelial cells in vitro and to achieve expression of that gene as evidenced by
positive staining using the FLAG detection system. These results will prove useful
in attempting to achieve similar gene transfers in vivo.
5.5 Conclusions
1. The transfection agent DOTAP substantially improved transfection of
BAECs with pEFGP-N2 compared to DNA alone.
2. Optimal transfection was achieved with a DNA concentration of 10 pg/ml,
DOTAP:DNA ratio of 6:1 and an incubation time of 3 hrs.
3. pEF-BOS-VEGFB proved successful in achieving transfer and expression of
the VEGFB gene to mammalian endothelial cells in culture.




Strategies for the transfer of genetic material to the vascular tree in vivo have been
the subject of much research (George & Baker 2002). Success depends on many
factors however, two of the most important considerations are the choice of vector to
facilitate the transfer and the proposed method of administration (Nishikawa &
Hashida 2002).
In the search for a suitable vector, raw plasmid DNA in particular, has been a major
focus of attention. The low toxicity of DNA in solution makes for easy handling and
with few reported side effects, it contrasts markedly with the problems that must be
faced if for example, viral vectors are to be used (Young & Dean 2002).
Unfortunately however, transfection efficiency with raw plasmid DNA has proved
consistently low. Reissen el al. reported this to be in the order of 0.5% following
application of raw plasmid DNA to rabbit carotid arteries using an angioplasty
catheter (Riessen et al. 1993). As a result, many of the techniques known to improve
transfection efficiency in vitro, including the use of cationic liposomes, have been
applied, with varying degrees of success, in vivo (Smyth 2002). One additional
strategy has been to use very high concentrations of DNA, far in excess of the
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cytotoxic limit for cells in culture (Tsurumi et al. 1996). Using these methods
techniques for gene transfer using raw plasmid DNA have advanced however, low
overall efficiency remains a problem (Young & Dean 2002).
In the context of therapeutic angiogenesis however, this low efficiency is, to some
extent, balanced by the biological activity of VEGF which is known to remain active
even at picomolar concentrations (Ferrara N et al. 1991). This was demonstrated by
Takeshita et al. in the rabbit hind limb model of ischaemia. In these experiments
VEGFA was transferred to both iliac arteries in each rabbit, using the same technique
as Reissen. Notwithstanding the low transfection efficiency, a significantly greater
angiogenic response was detected in animals treated in this way when compared to
controls, leading the authors to conclude the production of VEGFA was at least
within the range of biological activity (Takeshita et al. 1996). There is some
evidence to suggest that the uptake of raw DNA by endothelial cells is enhanced in
the presence of ischaemia, making for a greater transfection efficiency in this model.
The exact mechanism by which this occurs however, remains a point of speculation
(Takeshita, Isshiki, & Sato 1996).
Equally important in the success of any given technique for gene transfer to the
vasculature is the route of administration. These may be considered in two groups,
intra- and extra-arterial. In the case of the later, the most popular method is that of
Wolff et al. and involves the direct intra-muscular injection of plasmid DNA (Wolff
et al. 1990). High levels of reporter gene expression have been achieved with this
technique although there appears considerable variability in results dependant not
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only on the plasmid construct but also the target muscle, species and even age of the
experimental animal (Danko etal. 1997). Nevertheless, expression of VEGFA
transferred to muscle in this way has resulted in an angiogenic response in animal
models when compared to controls (Tsurumi et al. 1996). Successful gene
expression has also been reported following subcutaneous administration of plasmid
DNA although the exact fate of the exogenous DNA in this technique is not clear
(Bohm etal. 1998).
Intra-arterial administration of plasmid DNA has proved similarly effective in animal
models and more recently has formed the basis of a number of clinical trials (Amant,
Berthou, & Walsh 1999). Where the size of the target vessel permits, Riessens
method is effective (Riessen et al. 1993). In this technique plasmid DNA is applied
to the surface of a balloon angioplasty catheter by means of a thin hydrogel coating.
Inflation of the balloon within the vessel lumen results in site-specific gene transfer
to the arterial wall (Takeshita et al. 1996). An alternative method described is the
direct intra-arterial injection of plasmid DNA which is also effective, although non
specific, with most successful transfections appearing to take place within the
supplied muscle groups (Zhang et al. 2001).
Our aim was to use this technology to influence the survival of ischaemic epigastric
flaps in rats and in this respect, there was little published work to guide us in the
planning of our experiments. The small size of the SIEA precluded the use of a
catheter-based technique for plasmid delivery. Intra-arterial administration however
was feasible. The ability to access the vascular network within the ischaemic half of
— 151
the flap, via the divided contralateral SIEA, coupled with an ability to control the
circulation through the flap by manipulating the pedicle on the ipsilateral side, served
as additional attractions of this method. In this manner we could effect a uniform
distribution of plasmid DNA throughout the vascular system in the ischaemic flap
and provide for the target incubation period of 3 hrs.
6.1.2 Aims
Having shown that pEF-BOS-VEGFB was effective in transfecting bovine
endothelial cells in vitro causing them to produce VEGFB, in these experiments I
planned to investigate the possibility that this plasmid could be used to stimulate
angiogenesis in vivo. In addition, transfection efficiency would be evaluated using
pEGFP-N2.
6.2 Materials and Methods
6.2.1 Animals
Fourteen male Sprague-Dawley rats weighing between 300 g and 400 g were used in
these experiments. The supply and care of the animals was as described in Chapter
2. Full ethical approval for this work was sought, and granted, form the Animal Care
and Ethics Committee of the University of New South Wales.
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6.2.2 Plasmids
pEF-BOS-VEGFB was from stock (preparation numbers 2 (490 pg/ml DNA) and 4
(440 pg/ml DNA) were used in this work {Chapter 4}) while pEGFP-N2 was from
Clontech (product ref: U57608).
6.2.3 Experimental groups
Three experimental groups comprised four rats each and a fourth group, 2 rats.
Transfection conditions were based on the most successful combinations identified in
vitro. In addition, a bolus dose of 100 pg, without the transfection agent, was also
investigated. DOTAP, when used, was always at the preferred ratio of 6:1,
DOTAP:DNA.
Group 1 (n=4)
The random pattern flap was infused with a transfection mixture comprising 10
pg/ml pEF-BOS-VEGFB with 60 pg/ml DOTAP in hepes buffer via the right SIEA.
Flap circulation was arrested for 3 hrs to allow incubation of the mixture with the
vessel wall.
Group 2 (n=4)
The random flap was infused with a transfection mixture comprising 20 pg/ml pEF-
BOS-VEGFB and 120 pg/ml DOTAP in hepes buffer. Incubation was for 3 hrs.
Group 3 (n=4)
The random flap was infused with 100 pg raw plasmid DNA (pEF-BOS-VEGFB) in
hepes buffer, no transfection agent was used in this group. Incubation was also for 3
hrs.
Group 4 (n=2)
Both right and left SIEAs were infused with pEGFP-N2 at a concentration of 10
pg/ml DNA and DOTAP at 60 pg/ml in hepes buffer. Incubation was for 3 hrs.
6.2.4 Transfection mixtures
From my angiogram work I knew that the volume of the arterial system of the flap
was approximately 200 pi and this would be the minimum volume of each
transfection mixture necessary per animal. Where practicable I prepared 400 pi to
allow for losses. Preparation of these mixtures was conducted in the Haematology
Research Laboratory, Prince of Wales Hospital, Sydney before transfer on ice, to the
operating facility at the Prince Henry Hospital.
6.2.4.1 Transfection mixture 1 (10 pg/ml DNA + DOTAP 60 pg/ml):
36 pi stock 4 DNA was pipetted into a sterile eppendorf reaction tube and reduced to
a working concentration of 0.1 pg/ml by the addition of 124 pi hepes buffer, pH 7.4.
In a separate reaction tube, 96 pi DOTAP was diluted to a working concentration of
0.3 pg/pl by adding 224 pi hepes buffer. The two solutions were combined and
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incubated at room temperature with gentle mixing for 15 mins. Hepes buffer was
added to a final volume of 1600 pi again with gentle mixing. 400pl of the final
solution was placed into each of 4 sterile eppendorf tubes for transport.
6.2.4.2 Transfection mixture 2 (20 pg/ml DNA + DOTAP 120 fig/ml):
Prepared in exactly the same manner using 72 pi stock 4 DNA made up to 320 pi
with hepes buffer and added to 640 pi of 0.3 pg/ml DOTAP. Incubation was for 15
mins and preparations for transport as above.
6.2.4.3 Transfection mixture 3 (100 pg DNA stat):
204 pi of stock 2 DNA would give the required dose. Administration of a volume to
this level of accuracy was not practicable therefore 210 pi was placed in each of four
sterile eppendorf tubes with the intention of using the full volume.
6.2.4.4 Transfection mixture 4 (10 pg/mlpEGFP-N2 + DOTAP 60 pg/ml):
This plasmid is supplied at a stock concentration of 1 pg/pl. 8 pi stock DNA was
diluted to a final volume of 80 pi in hepes buffer and gently mixed with 160 pi
DOTAP at 0.3 pg/ml, incubated for 15 mins and made up to a final volume of 800 pi
with hepes buffer. The final volume was divided between 4 sterile eppendorf tubes
in preparation for transport.
6.2.5 Surgical procedure
General anaesthesia was induced and maintained and the surgical field prepared and
draped as previously described (Chapter 2).
Groups 1 to 3 (n=4)
8 x 8cm epigastric island flaps were marked and raised preserving both left and right
superficial inferior epigastric pedicles in the first instance. On the left side the
femoral artery proximal to the origin of the left SIEA was dissected and controlled
with a rubber vascular sloop initially left slack. The right SIEA was then dissected
under the operating microscope and cannulated using a 24 gauge intravenous catheter
secured using a single 7/0 prolene ligature with the main vessel cauterised
proximally. A 0.5ml saline flush was performed to ensure freedom of flow before
tightening the sloop on the left SIEA, thus arresting the circulation in the whole flap.
400 pi of the appropriate transfection mixture was then introduced into the right
hemiflap via the right SIEA. The cannula was then removed and the right pedicle
divided completely. The flap was then stitched in position using 5/0 nylon suture
leaving the left groin open. Circulation to the flap was restored after a 3 hr
incubation period by removing the sloop from the left femoral artery. The left groin
wound was then similarly closed.
Group 4 (n=2)
Since this group would provide information on transfection efficiency only, no flap
was necessary. Both groins were opened and the femoral and superficial inferior
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epigastric arteries dissected. Proximal control of the femoral artery was achieved
with a rubber vascular sloop before introducing a 24 gauge intravenous cannula in a
retrograde manner distal to the origin of the SIEA. In this way it was possible to
infuse the SIEA system while avoiding injury to the artery itself. 200 pi of pEGFP-
N2 transfection mixture was introduced into both right and left SIEAs using this
technique. The distal femoral artery was ligated on each side following withdrawal
of the cannula and the transfection mixture incubated in contact with the vessel wall
for 3 hrs. The vascular sloops were then removed restoring circulation to the SEEA's
and the groin wounds closed as before.
Recovery and postoperative management and observation of these animals were as
previously described however, group 4 rats did not require a protective collar.
6.2.6 Data collection
Animals in groups 1-3 underwent data collection as previously described. They
were killed on the seventh postoperative day and templates drawn for the assessment
of flap survival, microangiography performed and tissue blocks prepared for
immunohistochemical staining prior to the quantification of a-MVD. Group 4
animals were killed on day 2 and both right and left SIEAs harvested over a length of
approximately 1 cm. Under the operating microscope each vessel was dilated and
opened along its length before placing luminal side uppermost on a microscope slide,
fixing and securing with a glass coverslip.
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6.3 Statistics
Results are expressed as means ± standard deviation and confidence intervals are
quoted at the 95% level. Comparisons between groups were made using the Mann
Whitney U test where p < 0.05 was taken to represent statistical significance.
6.4 Results
6.4.1 General observations
All surgical procedures were uncomplicated and each animal remained well during
the period of observation. Similarly, all flaps were in good condition at the time of
harvest. Two flaps from group 3 were noted to be mildly oedematous on the first
postoperative day however, this resolved in both cases by day 2. Evidence of




The mean flap survival was 81.5 ± 4.8 % in the pEF-BOS-VEGFB 10 pg/ml plus
DOTAP group, 83.3 ± 2.5 % in the 20 jug/ml plus DOTAP group and 81.8 ± 2.9 % in
the 100 pg stat group (Tables 6.1 to 6.3). There was no significant difference in flap
survival between any of the groups studied when compared to my control group of
standard flaps (p>0.67). The data is represented graphically in Fig. 6.1.
Table 6.1 - Flap survival at one week for rats receiving 10 pg/ml pEF-BOS-VEGFB
with DOTAP transfection agent into the right SIEA. W1 refers to the weight of a
template drawn from the whole flap while W2 is from the viable area only.
Animal
reference
Animal weight (g) Wl(g) W2(g) Flap survival (%)
PVgl 380 1.27 0.99 78
PVg2 360 1.28 0.98 77
PVg3 380 1.31 1.10 84





Table 6.2 - Flap survival at one week for rats receiving 20 tig/ml pEF-BOS-VEGFB
with DOTAP transfection agent into the right SIEA.
Animal
reference
Animal weight (g) Wl(g) W2(g) Flap survival (%)
PVg5 390 1.30 1.04 80
PVg6 350 1.21 1.00 83
PVg7 350 1.28 1.07 84





Table 6.3 - Flap survival at one week for rats receiving 100 pg stat pEF-BOS-
VEGFB (no transfection agent) into the right SIEA.
Animal
reference
Animal weight (g) Wl(g) W2(g) Flap survival (%>)
PVg9 340 1.57 1.35 86
PVglO 340 1.24 0.99 80
PVgll 330 1.35 1.09 81













Figure 6.1 - Boxplot of percentage flap survival against transfection conditions. No
difference between the groups is evident (p>0.67).
1= 11
10 mcgAnl 0NA*00TAP 100 meg DNAstat
20 mcaAnl ONAt-OOTAP control flap
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6.4.2.2 Microangiography
Mean HBPC/cm2 for each group are shown in Table 6.4. No significant difference in
mean HBPC was identified for any of the experimental groups when compared to the
control group of standard flaps (p>0.34) (Figure 6.2). Examples of microangiograms
obtained from each of the experimental groups are shown in Figure 6.3.
Table 6.4 - Mean HBPC/cm2 recorded for the random and axial portions of each
















random pattern 17.5 17.5 15.3 16.1
flap (14.2, 20.8) (13.7,21.3) (9.1,21.6) (13.1, 19.2)
axial pattern 15.0 16.0 17.0 16.9










I random pattern flap
B axial pattern flap
10 meg DNA + DOTAP 100 meg DNA only
20 meg DNA + DOTAP control
transfection conditions
Figure 6.2 - Highest angiographic branch point count/cm recorded for the axial and
random pattern flaps for each transfection group and controls. Differences between
experimental groups and controls did not reach statistical significance for either the
random or axial pattern flaps (p>0.34)
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Figure 6.3 - Examples of microangiograms obtained from group 1 animals {(A) and
(B)}, group 2 {(C) and (D )} and group 3 animals {(E) and (F)}. No statistically




Histological examination of the flaps in each group revealed a pattern similar to that
encountered in standard flaps, namely a-MVD was higher below compared to above
the panniculus carnosus at all sites sampled and the highest a-MVD was observed
deep to the panniculus within the zone of demarcation (Tables 6.5 to 6.7). When
compared to the control group of standard flaps however, no statistically significant
difference in a-MVD was noted in any of the positions examined (p >0.17). Figure
6.4 shows typical distributions of a-MVD for each group taking position 2 of the
random pattern flap as an example.
6.4.3 pEGFP-N2
There was no evidence of localising green fluorescence in any of the four femoral





Average MVD for rats receiving 10 p.g/ml pEF-BOS-VEGFB into the
■j
Results are per unit area of 0.0625 mm , 95% confidence intervals given
Average MVD (vessels per 0.0625 mm2) (95% C.I.)
Zone ofdemarcation random pattern flap axialpattern flap
Position 1 level a
11.3 (4.8, 17.7) 9.8 (5.2, 14.3) 8.8(6.0, 11.5)
(n=4)
level b 28.0 (21.0, 35.0) 17.5(11.3, 23.7) 16.8(11.0, 22.5)
Position 2
level a 11.3(5.1, 17.4) 8.5 (4.7, 12.3) 8.5 (4.3, 12.7)
(n=4)
level b 22.8(12.4, 33.1) 17.0(12.3,21.7) 18.0 (13.3, 22.7)
Position 1 represents sections taken at a position three quarters of the way along the
flap from caudal to cranial, marked at the time of elevation. Similarly, position 2
represents sections from the mid point (see Fig. 3.2)
Level 'a' is above, and level 'b' below, the panniculus carnosus muscle.
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Table 6.6 - Average MVD for rats receiving 20 jag/ml pEF-BOS-VEGFB into the
right SEEA. Results are per unit area of 0.0625 mm2, 95% confidence intervals given
in brackets.
Average MVD (vessels per 0.0625 mm2) (95% C.I.)
Zone ofdemarcation random pattern flap axial patternflap
Position 1
level a 11.0 (5.1, 17.0) 9.5 (5.7, 13.3) 8.8 (5.2, 12.3)
(n=4)
level b 19.5(15.7, 23.3) 14.0(11.1, 16.9) 15.0 (9.6, 20.4)
Position 2
level a 10.5(1.7, 19.3) 9.3 (4.0, 14.5) 8.0 (3.9, 12.1)
(n=4)
level b 21.5(8.9, 34.1) 17.5 (12.9, 22.1) 15.3 (8.7,21.8)
Position 1 & 2 and Levels 'a' & 'b' are as for Table 6.4
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Table 6.7 - Average MVD for rats receiving 100 jag pEF-BOS-VEGFB stat into the
right SIEA. Results are per unit area of 0.0625 mm2 with 95% confidence intervals
given in brackets.
Average MVD (vessels per 0.0625 mm2) (95% C.I.)
Zone ofdemarcation random pattern flap axialpattern flap
Position 1
level a 10.3 (7.0, 13.5) 8.3 (5.5, 11.0) 9.3 (5.1, 13.4)
(n=4)
level b 20.3 (12.0, 28.5) 16.0 (9.8, 22.2) 17.5(11.3, 23.7)
Position 2
level a 12.3 (7.3, 17.2) 10.5 (3.4, 17.6) 8.5 (6.5, 10.6)
(n=4)
level b 22.5 (12.4, 32.6) 16.5 (8.4, 24.6) 18.3(14.7,21.8)
Position 1 & 2 and Levels 'a' & 'b' are as for Table 6.4
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a* « 4 « «
10 mcg/tol DMA ♦ OOTA 100 meg DMA it at
20 mogAnJ ONA+ DOTA control flap
piasinid concentration
B* 4 4 4 6
10 mcgArrf ONA* DOTA 100 meg DNAstat
20 meg/ml DNA+ DOTA control flap
plasmid concentration
Figure 6.4 - Boxplots of a-MVD recorded for the random pattern flaps at position 2
(three quarters of the way along the flap) above (upper chart) and below (lower chart)
the panniculus carnosus muscle layer. These results are typical of the data set as a
whole. No significant difference in a-MVD was noted for any of the experimental
flaps in any of the locations examined when compared to the control group
Figure 6.5 - Full thickness arterial wall specimens taken from the SIEA's of group 4




In these experiments I failed to detect any evidence that pEF-BOS-VEGFB was
capable of inducing angiogenesis in the rat epigastric island flap when administered
intra-arterially in the manner described. In considering these results it is worth
reviewing the requirements for success. Firstly a suitable expression vector for
VEGF-B is required. I believe that pEF-BOS-VEGFB was such a vector. Having
purified the plasmid from E. coli stock, preliminary work had confirmed its ability to
induce expression of the VEGF-B gene in mammalian endothelial cells in culture.
Although I did not test expression in rat endothelial cells specifically, the success of
lipofection in achieving gene transfer in these cells has been previously reported by
others (Laulajainen et al. 1993). It seems likely therefore that the rat endothelial
cells would respond in a similar manner to BAECs.
One significant difference between the cell population in vivo compared to the in
vitro setting does however exist. Endothelial cells in vivo are known to be among the
longest lived in the body with only 0.01% in the process of cell division in adults at
any given time (Hobson & Denekamp 1984). This is significant since transfection is
known to occur most efficiently in the log growth phase in culture with much poorer
results in the lag or stationary phase (Rippe, Brenner, & Leffert 1990). Nevertheless,
skeletal muscle is also a predominantly stable cell population in vivo and yet very
high transfection efficiencies have been reported in this tissue following trans-arterial
infusion of plasmid DNA (Zhang et al. 2001). This suggests endothelial cells in
particular are less receptive to gene transfer by these methods. The lack of any
detectable reporter gene expression at 2 days post exposure supports the view that
transfection was significantly less efficient in vivo than was observed in vitro.
Although rat endothelial cells are likely to express the VEGFB gene in response to
pEF-BOS-VEGFB in a similar manner to bovine endothelial cells the timing of
expression may vaiy. I first detected the presence ofGFP in the BAEC cultures at 24
hrs rising to a peak at 48 hrs. Significant delay in expression of the reporter gene in
vivo would lead to a false negative result at the 48 hr assessment. It is certainly
possible that a cell population of the stability of endothelium may require a longer
time for gene expression to become apparent. I was unable to identify any specific in
vivo work looking at this issue however, Takeshita et al. working with an arterial
organ culture model, also reported good evidence of protein secretion by 24 hrs
following gene transfer (Takeshita et al. 1994a).
Takeshita et al. have also published work to suggest that maximal endothelial cell
proliferation in response to VEGF can be expected to occur between day 3 and 5
days following administration (Takeshita et al. 1995). Since flap demarcation is
clinically apparent by day three post-elevation, the lack of a survival advantage
would not necessarily translate to a failure of gene expression and in this model
therefore, flap survival represents the least sensitive indicator ofVEGFB production.
This being the case however, and accepting a possible delay in the anticipated timing
ofVEGFB production, I would still have expected to detect its activity in the flap by




HBPC/cm and histologically by an increase in a-MVD. Neither proved to be the
case.
The experience of Taub et al. in similar experiments with VEGF-A was significantly
different. Reviewing their experimental protocol one crucial difference was the
administration of their plasmid construct 4 days prior to rendering the experimental
flaps ischaemic. This may have helped in achieving the significant survival benefit
reported in their series however, interestingly they achieved these results with only a
veiy short incubation time of 10 mins. Immunoperoxidase staining for VEGF
appeared to confirm transgene expression in the periluminal region ofvessels in
transfected flaps however, they also reported no increase in absolute vessel numbers
within their flap specimens (Taub PJ et al. 1998). By definition therefore, any
observed improvement in flap survival cannot be attributed directly to induced
angiogenesis.
My results are most easily explained by a failure of the transfection process to
achieve the necessary efficiency such that any VEGF-B production failed to reach
biologically active levels.
6.6 Conclusions
1. pEF-BOS-VEGFB was unsuccessful as an agent for therapeutic angiogenesis
when administered intra-arterially to the rat epigastric island flap.
2. The most likely point of failure was at the level of gene transfer to the arterial
wall.
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Chapter 7 — Experiments with Chinese Hamster Ovary
cells genetically modified to produce VEGFB
7.1 Introduction
An alternative strategy for the targeted transfer of genetic material in vivo is to make
use of cultured cells as intermediaries (Plautz, Nabel, & Nabel 1991). In this way
gene transfer is performed in two stages with the initial transfection performed in
vitro with subsequent transplantation of the genetically altered cells undertaken as a
secondary procedure. This allows for greater control over the transfection conditions
and, by selecting only positive phenotypes for transplantation, has the potential to
greatly improve the efficiency with which functional gene transfer may be achieved.
This two-stage approach is often referred to as ex vivo gene therapy.
A significant problem however, in the development of this technology has been to
address the immune mediated rejection of the transplanted cells (Smythe, Hodgetts,
& Grounds 2000). Machens et al., working with a similar epigastric island flap
model in rats, performed their transfections in autologous cells to overcome the
problem (Machens et al. 1998). In this manner, fibroblasts carrying the gene for a
platelet derived growth factor, were shown to promote angiogenesis without
evidence of local inflammation. Their technique however requires the preliminary
harvest and expansion of fibroblast cultures specific to their population of
experimental animals. Another approach is to conceal the transplanted cells in such
a way that allows them to remain undetected by the host immune system. Rinsch et
al. employed this technique to influence the survival of random pattern dorsal skin
flaps in rats. In their technique microporous polymer membranes were used to
encapsulate myoblasts transfected with the genes for basic fibroblast growth factor
and vascular endothelial growth factor prior to injection under the distal ischaemic
region of the flaps. Improved flap survival was observed in these animals when
compared to controls (Rinsch et al. 2001b). Although potentially an attractive
option, such encapsulation relies on sufficient experience with the technique to
maintain cell viability during both the encapsulation and transplantation processes.
The further development and simplification of this technique may ultimately
however, provide a powerful tool for ex vivo gene transfer.
The cells made available to me for this work were Chinese Hamster Ovary (CHO)
cells genetically modified to secrete VEGFB (Amrad Corporation, Burnley, Victoria,
Australia). Although we anticipated that as foreign cells, they would be short-lived
in our rat model of flap ischaemia, we also knew that even a brief exposure to VEGF
can induce angiogenesis (Takeshita et al. 1994c). We reasoned therefore, that
prolonged survival of the cells may not be a requirement for a measurable angiogenic
response and may even be advantageous as a self limiting step in the system.
In addition to the gene for VEGFB, the genetically modified CHO cells also
contained a gene coding for resistance to the cytotoxic antibiotic puromycin,
allowing selection of the CHO-VEGFB phenotype in culture.
In considering my experimental approach I identified a number of important
variables. Firstly I needed to know how many cells were likely to be required to
deliver VEGFB to the tissues in a biologically active dose and secondly, I needed to
identify the best way in which to deliver these cells to the experimental flaps in vivo.
There was no work to guide us on the bioactivity of VEGFB specifically however,
Kryger et al. found a dose of 1 pg VEGFA delivered subdermally effective in
improving the survival of their experimental skin flaps also in rats (Kryger et al.
2000). Amrad quoted their average yield of VEGFB protein from a CHO cell
population of around 50 x 106 cells as approximately 12 pg VEGFB extracted from
the supernatant daily (Drinkwater 1998). Thus a yield of 1 pg VEGFB per day
would be expected from a cell population of approximately 4 x 106 cells. From my
initial cell culture work using 75 cm2 culture flasks I could expect a yield of
approximately 8 - 10 x 106 CHO-VEGFB cells per flask when harvested at a
confluence of 80%. This number appeared to be a suitable starting point.
The effect that method of delivery may have on the ability of VEGF to influence flap
survival was also investigated by Kryger and colleagues who reported success in a
variety of methods tested including direct injection into the flap, implying strategies
for delivery and site of administration may not be critical (Kryger et al. 2000). I
decided therefore, to deliver CHO-VEGFB cells as direct injections to the deep
surface of the experimental flaps following elevation, allowing careful placement of
each instillation and so minimising injury to the native vasculature. I was also
interested to know the significance, if any, that the site of injection had on
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angiogenic activity within the flaps. This arose out of concerns that CHO-VEGFB
cells injected into the ischaemic environment of the random pattern flap, would
likely suffer a disturbance of their own metabolism resulting in an unknown effect on
VEGFB protein production. In addition to injecting the random pattern flap I
therefore proposed to examine the effects of CHO-VEGFB when injected into the
axial pattern flap only where local oxygenation was presumed normal. To complete
the series I decided to include a final group where the whole flap was injected with
CHO-VEGFB cells at the same dose per unit area as planned for the first two groups.
Prior to any in vivo experiments it was necessary to confirm that the CHO-VEGFB
cells were indeed producing VEGFB as expected. Since no commercially available
VEGFB antibody existed at the time of this work, the VEGFB product had been
artificially tagged with the FLAG antigen at the time of initial gene transfer.
Immunohistochemical identification of this antigen is possible using the FLAG
detection system as previously described in Chapter 5.
The aim of this work therefore was firstly, to confirm CHO-VEGFB cells as a source
for VEGFB first in vitro and subsequently in vivo and secondly, to investigate their
ability to act as agents for therapeutic angiogenesis in the rat epigastric island flap
model of tissue ischaemia.
7.2 Materials and Methods
7.2.1 Acknowledgements
CHO cells stably transfected with VEGFB were supplied frozen, by Dr. C
Drinkwater, Senior Molecular Biologist, Amrad Operations while Dr S Tait, Centre
for Thrombosis and Vascular Research, The University ofNew South Wales,
provided standard CHO cells, without the VEGFB insert. To distinguish these two
cultures the former will be referred to as CHO-VEGFB and the latter, CHO-BLANK.
Immunohistochemical preparations were performed with the help ofMs P Marr,
Department ofAnatomical Pathology, The St George Hospital, Kogarah, New South
Wales, Australia.
7.2.2 Cell culture reagents and equipment
CHO cells, like BAECs, were cultured in DMEM with 10% foetal calf serum. The
cell culture reagents and methods used for sub-culturing were, in general, the same
for both cell lines and are listed in Chapter 5. There were however, some important
differences and these are described below.
In addition to the materials listed previously the selective agent puromycin (product
ref: P8833) was from Sigma-Aldrich, Castle Hill, NSW, Australia.
7.2.3 Preparation of cell culture medium and reagents
7.2.3.1 Puromycin aliquots:
Recommended working concentration is 25 pg/ml. Therefore require 375 pg
puromycin per 75 cm culture flask (15 ml medium). Stock puromycin prepared at
1.5 pg/pl and stored as 550 pi aliquots to provide sufficient agent for use in two
culture flasks with 50 pi wastage. Prepare aliquots from one 25 mg ampoule of
puromycin hydrochloride as follows: In the biological safety cabinet add 16.7 ml
sterile water to a 50 ml sterile reaction tube. Take 1 ml of this volume to the
puromycin ampoule and dissolve the powder by gentle pipetting before returning it
to the 50 ml tube. Draw into a 50 ml syringe and ultrafilter (0.2 pm pore size) into a
second sterile reaction tube. Pipette 550 pi aliquots into sterile 1 ml eppendorf tubes
and seal. Store at -20°C and thaw immediately before use.
7.2.3.2 DMEMwith 10% foetal calfserum:
Prepared as for BAEC culture however, the quantity of sodium bicarbonate used
should be 3.7 g/1 and the final solution adjusted to pH 7.2 with 1M hydrochloric acid.
7.2.4 CHO cell culture
7.2.4.1 Thawingfromfrozen:
Prepare a suitable culture flask containing fresh medium. Place cryotube containing
frozen cells directly into a waterbath at 37 °C, use forceps. Once thawed, transfer the
cell suspension dropwise to a sterile reaction tube containing 10 ml culture medium.
Centrifuge at 1000 rpm (Beckman J2-21) for 5 mins. Discard supernatant and
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suspend cell pellet in 4 ml fresh culture medium by gentle pipetting. Transfer to the
culture flask and incubate at 37 °C, 5 % CO2 with the lid loosened.
7.2.4.2 Passaging:
CHO cell cultures were split and sub-cultured in the same manner described for
BAECs with two important differences. Selective pressure was applied to the CHO-
VEGFB cultures by including puromycin (25 pg/ml) in the culture medium. 250 pi
of stock puromycin (1.5 pg/pl) was therefore added to each 75 cm culture flask
containing 15 ml fresh medium.
In addition, CHO cells propagated much more vigorously in culture than was the
case for BAECs, with the CHO-BLANK cells being especially prolific. Preliminary
work identified the cell doubling times as 22 hrs for CHO-VEGFB whilst CHO-
BLANK was significantly shorter at only 13 hrs. From this, an inoculation table was
drawn up quantifying the number of cells needed to achieve the target cell population
of 8 - 10 x 106 cells per culture flask (approximately 70 - 90% confluent) on a given
operating day (Table 7.1). Cell counts were performed using a standard
haemacytometer as previously described. CHO-VEGFB cell aliqots used for in vivo
experiments were transported to the operating theatre on ice in 2 ml fresh culture
medium.
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Table 7.1 - Inoculation schedule for CHO cells
operating day passage
inoculate per 75 cm culture flask (cells)
CHO-VEGFB CHO-BLANK
Mon Fri pm 1.5 x 106 4 x 103
Tue Fri pm 6x 105 9x 104
Wed Fri pm 4x 105 3x 104
Thu Mon am 9x 105 2.5 x 105
Fri Mon am 4x 105 8x 104
7.2.5 Immunohistochemical testing
Reagents, primary and secondary antibodies for immunohistochemical FLAG stains
were as previously described (Chapter 5). For in vivo stains, goat anti-rat
immunoglobulin was from Serotec (Centennial Campus, Raleigh, NC, USA, product
ref: STAR 71).
7.2.5.1 CHO-VEGFB cells in vitro
A single, 8-well chamber slide was used to prepare CHO-VEGFB and CHO-BLANK
2 .
cultures prior to immunostaining. Since the culture area of each well was 1 cm i.e.
1775th of the standard culture bottle area, an appropriate inoculation for each well was
calculated using the schedule in table 7.1 to allow expansion of the population for
between two and three days. Each of 4 wells were therefore inoculated with 1 x 104
CHO-VEGFB cells whilst the remaining 4 wells each received 3 x 103 CHO-
BLANK cells. The slide was fixed (10 % buffered formalin applied for 20 mins
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followed by two exchanges of PBS) when cell confluence had reached 70 - 80% and
transferred to the immunohistochemical laboratory for immediate FLAG staining.
The technique used was identical to that described in Chapter 5.
7.2.5.2 CHO-VEGFB cells in vivo
To assess the potential of the FLAG detection system to monitor VEGFB production
in vivo, 2 ml of an 8 - 10 x 106 CHO-VEGFB cell suspension was injected
subcutaneously into the midline ventral skin of 2 male Sprague-Dawley rats under
general anaesthetic. Biopsies of this area were performed immediately following
injection and then daily for the following 4 days. Each biopsy was fixed in formalin,
blocked and cut in preparation for immunostaining using the FLAG detection
system. Animals were monitored daily for signs of distress and surgical wounds
were checked for evidence of infection or dehiscence.
7.2.5.3 Immunohistochemical technique
Immunostaining was performed in essentially the same manner as previously
described for the localisation of von Willibrand factor on rat endothelium (Chapter
3). One significant problem however, arose from the fact that the primary anti-
FLAG antibody is supplied as mouse anti-FLAG making it necessary to use an anti-
mouse secondary antibody. This unfortunately led to a significant problem with
cross reactivity, with native rat IgG staining positive in addition to the target mouse
IgG. In an attempt to address this problem we used goat anti-rat immunoglobulin as
a blocking agent. Briefly, sections were dewaxed and taken to ethanol and
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endogenous peroxidase block applied. A protease digest was performed (5 min, 37
°C) and non-specific binding blocked with casein. Goat anti-rat immunoglobulin
was applied at this stage (diluted 1/50 in TRIS buffered saline) followed by mouse
anti-FLAG primary antibody (1/100 dilution). Incubation was for 10 mins and 60
mins at room temperature respectively. Biotinylated rabbit anti-mouse secondary
antibody and streptavidin detection system were used as already described.
7.2.6 CHO-VEGFB cells as agents for therapeutic angiogenesis
7.2.6.1 Animals
Sixteen male Sprague-Dawley rats weighing between 350 - 450g were used in this
work. All animals were supplied and cared for at the animal house facility, Prince
Henry Hospital, NSW, Australia. All cell cultures were grown at the Haematology
Research Unit, Prince of Wales Hospital, Randwick, harvested on the morning of
surgery when cell yield was estimated, and transported to the operating theatre on ice
in sealed sterile reaction tubes.
7.2.6.2 Experimental groups
Four experimental groups comprised four rats each. Cells were delivered to the
experimental animals as multiple instillations using a 22G hypodermic needle
mounted on a 5 ml syringe, attempting an even distribution to the area under test.
Injections to the flap were all performed from the deep surface avoiding damage to
the vascular network as far as was possible (Figure 7.1).
Groups 1 - 3 received 2 - 3 x 106 cells/cm2 to either the random pattern flap (group
1), the axial pattern flap (group 2) or the whole experimental flap (group 3). Group 4
animals received twice this dose to the axial pattern flap only.
7.2.6.3 Surgical procedure
All experimental epigastric island flaps were 8x8 cm, based on the left superficial
inferior epigastric vascular pedicle and raised under general anaesthesia as
previously described (Chapter 2). CHO-VEGFB cells suspended in 2 - 4 ml culture
medium were then injected into the test area of the flap as described above before
returning the flap to its bed and closing the skin with 4/0 prolene. The postoperative
care of the animals was provided as before.
7.2.6.4 Data collection
All animals underwent data retrieval in a similar manner to that described in Chapter
2. Daily flap observations were performed until the seventh postoperative day when
the animals were killed by CO2 overdose and microangiography performed through
the left SIEA. Measurement of flap survival was performed, as before, by
planimetry using a single, hand drawn template.
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Figure 7.1 - Technique for injection of CHO-VEGFB cells suspended in culture
medium into the rat epigastric island flap. (A) The flap has been raised on the left
superficial inferior epigastric neurovascular bundle and reflected over the animals
tail. Instillations begin in the vicinity of the pedicle with care taken to avoid injury to
the vascular network, and proceed outwards. (B) In this animal the whole flap has
been treated.
7.3 Statistics
The results from these experiments were compared with those obtained from
unmodified flaps presented in Chapter 2 and any differences subjected to statistical
analysis. Results for area flap survival were analysed using a one-way analysis of
variance (ANOVA) incorporating a post-hoc test while the Mann-Whitney U test
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was used to analyse angiographic data. Confidence intervals are reported at the 95%
level and p<0.05 was taken to represent statistical significance.
7.4 Results
7.4.1 Immunohistochemistry
Immunoperoxidase staining for the FLAG antigen in vitro was positive for CHO-
VEGFB cells confirming VEGFB production, whilst CLIO-BLANK cells stained
negative (Figure 7.2). Optimisation of the FLAG stain in vivo proved more difficult.
Serial biopsies identified the presence of CHO cells within rat abdominal skin for up
to 3 days however the FLAG stain proved unreliable for the detection of VEGFB
production (Figure 7.3).
Figure 7.2 - CHO cell monolayers immunostained for the FLAG antigen. In (A) a
number of CHO - VEGFB cells have stained positive indicating the presence of the
FLAG-VEGFB fusion protein whilst in (B) CHO cells without the FLAG-VEGFB
insert (CHO-BLANK) stain negative.
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Figure 7.3 - Flap section immediately following CHO-VEGFB transfer (A) H & E
(B) immunostain for the FLAG antigen. CHO cells are clearly seen in both sections
and although some cells in (B) appear to stain positive for the FLAG antigen, the
presence of background stain makes interpretation unreliable.
Figure 7.4 - Flap sections stained for the FLAG antigen at (A) 24 hrs and (B) 48 hrs
post CHO-VEGFB injection. Although CHO cells are clearly seen (containing the
large nuclei towards the centre of each image) all stain negative for FLAG.
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7.4.2 Flap survival
There were no intra-operative complications and all animals recovered from
anaesthesia without event. Mean operating time for completion of the surgery was
40 mins. Mild localised oedema was noted in two flaps receiving CHO-VEGFB into
their random halves, one each in the axially injected and whole injected groups and
two in the higher dose axially injected group. In all cases bar one, this had settled by
day two. The animal with prolonged oedema had received the higher concentration
of CHO-VEGFB cells to the axial flap only and flap oedema persisted until day 3.
All animals remained alive and well during the study period and no adverse reactions
were noted at the injection sites.
Mean flap survival for each experimental group is given in table 7.2. One group 5
flap showed complete survival (Figure 7.5). This was the first occasion for a flap to
show complete survival in any of the experimental work performed thus far. A
statistically significant difference was noted for percentage flap survival between the
five experimental groups, F(4, 19) = 5.87, p < 0.01. Post-hoc testing indicated that
the flaps receiving double quantities of CHO-VEGFB showed, on average, a 10.3%
higher mean flap survival than the control group (p=0.04). There was no significant
difference between any of the remaining groups when compared to controls (p>0.98).
The results are displayed graphically in Figure 7.6.
Table 7.2 - Mean flap survival expressed as a percentage of final flap area for each







Random flap 4 3.1 79.3 3.6
Axial flap 1 4 3.7 86.0 6.4
Whole flap 4 2.5 84.3 6.0
Axial flap 2 4 5.9 95.3 3.8
Control flaps (no
injection)
8 0 85.0 4.3
The control group was taken from the series presented in Chapter 2.
Figure 7.5 - (A) Complete survival of one of the experimental flaps receiving the
higher dose of CHO-VEGFB cells to the axial portion of the flap. (B) Angiographic








group 1 group 2
experimental group
group 3 group 4 control flaps
Figure 7.6 - Boxplot of flap survival against experimental group. The flaps
receiving the higher CHO-VEGFB dose to the axial portion (group 4) showed on
average a 10.3% increase in survival at seven days (p=0.04).
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7.4.3 Microangiography
All angiograms demonstrated an increase in vascular markings at the zone of
demarcation between viable and non-viable tissue within the random pattern flap as
seen previously (Chapter 2). Mean HBPC/cm2 for each experimental group is given
in Table 7.2. Mean HBPC/cm2 for the-axial-pattern region of group 4 angiograms
(20.8± 2.2) was higher than at any other position investigated within any of the
experimental groups and when compared to the control group, the difference just
reached statistical significance for this location (p=0.05). Differences in mean
HBPC/cm2 recorded from all other sites and in all experimental groups when
compared to the control group were not statistically significant (p>0.23). The results
are displayed graphically in Figure 7.7. Examples of angiograms from each of the
groups are given in Figure 7.8
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group 1 group 2 group 3 group 4 control
experimental group
Figure 7.7 - Boxplot of HBPC/cm2 recorded from the angiograms of each
experimental group and a control group of standard flaps. Mean HBPC/cm recorded
from the random pattern area of group 4 flaps was significantly higher than that
found in the control group (p=0.05).
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Figure 7.8 - Example angiograms from each experimental group. (A) Group 1
(CHO-VEGFB random flap), (B) group 2 (CHO-VEGFB axial flap), (C) group 3




These results were encouraging. CHO-VEGFB stained positive for FLAG in vitro
confirming the presence of the VEGFB-FLAG fusion protein. Interestingly
however, positive staining was not uniform within the CHO population. The use of
puromycin as a selective agent would prevent the survival of non-VEGFB containing
CHO cells since both genes, for VEGFB and puromycin resistance, were transferred
as a single coding sequence. The heterogeneity ofFLAG staining may therefore
either indicate a true variability in the expression of the FLAG-VEGFB sequence or
reflect a limitation in our ability to detect it using the FLAG system. Although no
data is available for VEGFB specifically, the half-lives of VEGF species in general
are known to be short (estimated by Ferrara et al. to be less than 6 mins) making any
variations in the rate of synthesis more apparent (Takeshita et al. 1994c).
The technique used to introduce the cells into the flap appeared effective with no
adverse events or reactions and their survival for three days was in keeping with our
expectations.
The apparent increased incidence of temporary flap oedema in the CHO injected
flaps compared with controls may have occurred as a consequence of the activity of
inflammatory mediators released in response to the presence of CHO cells
themselves, particularly since it was observed in all injected groups. It is worth
noting however, that temporary oedema is considered by some a constant feature of
VEGFA induced angiogenesis and although the situation for VEGFB is less clear,
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recent evidence suggests that increased vascular permeability accompanies
angiogenesis regardless of the stimulus (Bates et al. 2002;Dvorak et al. 1995a).
The improvement in mean flap survival noted for flaps receiving the higher dose of
CHO-VEGFB cells was especially encouraging although the numbers of animals in
each group were small. To achieve the complete survival of one of the experimental
flaps was something I had not encountered in any of my previous experiments and
gave us cause for optimism in the planning of further work. The lack of any
significant improvement in flap survival in any of the groups receiving the lower
dose of CHO-VEGFB cells confirmed the watershed for activity to be in excess of 3
x 105 cells/cm2.
Interpretation of the angiographic data however, proved more difficult. Although the
increase in mean HBPC/cm2 for group 4 flaps was consistent with the observed
increased area survival in this group we found it surprising that this increase was not
apparent at the site of CHO cell injection but rather on the contralateral side. Two
important physiological properties of VEGF and its receptors may help explain this
finding. Firstly the bioactivity of VEGF is potentiated by an upregulation of its KDR
receptors in the presence of local ischaemia (Brogi et al. 1996). Such ischaemic
conditions are expected within the random but not the axial pattern flap. Secondly,
VEGF is known to act on endothelial cells as a freely diffusible protein (Ferrara
1999).
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We postulated therefore, that VEGFB entering the blood stream within the axial
pattern flap would exert maximal effect on the ischaemic tissues of the random flap.
The effect of local ischaemia on the ability of VEGF to induce angiogenesis was
studied by Pu et al. (Pu et al. 1993a). Working with a rabbit model of hindlimb
ischaemia and delivering VEGF protein intramuscularly to both ischaemic and non
ischaemic muscles they found evidence of induced angiogenesis only in the former
when compared to controls. The bioactivity of exogenously administered VEGF
would appear therefore, to be significantly influenced by the prevailing levels of
tissue oxygenation. Our findings were consistent with this view.
My experience with the FLAG detection system for the identification of VEGFB-
FLAG fusion protein in vivo was, on the whole, disappointing. Cross reactivity and
background staining limited our ability to achieve clean stains when applied to fixed
tissue. Despite the various manoeuvres employed to improve the results, they
remained unreliable. As a result I could not reliably detect the presence of VEGFB
in my rat flap sections and was therefore unable to assess the duration of VEGFB
production by CHO-VEGFB cells following transfer using this technique.
The higher dose of CHO-VEGFB proved successful in improving mean flap survival
in our experimental model. Performed principally as a pilot however, there are
obvious weaknesses in the design of this study; the groups were small, there was no
randomisation and the controls used were from a previous series. To subject the
technique to a more critical analysis I proposed a randomised controlled trial using
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the higher dose of CHO-VEGFB cells and investigating all three sites of injection i.e.
axial pattern flap, random pattern flap and the whole flap.
7.6 Conclusions
1. Production of VEGFB by CHO-VEGFB was heterogeneous in vitro.
2. CHO-VEGFB cells survived within rat tissue for a maximum of 3 days
c <y
3. Given at a dose of approximately 5-6x10 cells/cm and administered to
the axial portion of the flap, CHO-VEGFB cells appeared to improve the survival of
experimental skin flaps compared to controls.
4. Increased area flap survival was associated with an increase in mean
angiographic HBPC/cm2 in the random portion of flaps injected with the higher dose
of CHO-VEGFB cells.
5. A randomised controlled trial would provide more substantive evidence of
the activity of CHO-VEGFB cells as agents for therapeutic angiogenesis.
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Chapter 8 - Randomised controlled trial to evaluate CHO-
VEGFB cells as agents for therapeutic angiogenesis
8.1 Introduction
8.1.1 Overview
To test the hypothesis that CHO-VEGFB cells could influence the survival of
ischaemic rat epigastric island flaps by the induction of angiogenesis I proposed to
conduct a randomised controlled trial. I decided to examine the effect of CHO-
VEGFB cells when administered subcutaneously to the same three regions of the flap
as the pilot study, i.e. random flap only, axial flap only and to the whole flap, using
the higher dose of approximately 6 x 105 cells/cm2. Control animals would receive
the same numbers of CHO-BLANK cells and flap survival, a-MVD and
angiographic data would be collected as previously described.
8.1.2 Power calculation
The pilot study data indicated that the injection of CHO-VEGFB cells into the axial
region of the epigastric island flap at a dose of 5.9 x 10 cells/cm , on average,
resulted in a 10.3% improvement in flap survival (p=0.04) (Chapter 7). To
determine an appropriate sample size for the proposed randomised trial, a power
calculation was performed using 10% as the difference between the experimental and
control group means that the trial was designed to detect.
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The equation can be written:
(ui - u2)2 = f(a, P)o2 (1/ni + l/n2)
where (ui - u2) is the difference between the means of two experimental groups Ui
and u2, f(a, P) is a constant for a given power (P) and significance level (a), a the
variance of the measurements and ni and n2 the two respective sample sizes (Bland
2000a). If each group contains equal numbers i.e. ni = n2 then:
n = 2f(a, P)a2 / (ui - u2)2
I chose a high value for P = 0.95 making it likely that my trial would detect this
difference should it exist, giving the value of f(a, P) at the 0.05 significance level as
13.0 taken from a published table (Bland 2000a). The standard deviation recorded
for the control flaps was 5.3. Therefore,
n = 2 x 13.0 x 5.32 / 102
n = 7.3
To allow for potential losses I decided to design the trial around a group size of 10
rats in each of the 6 groups making a total of 60 rats.
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8.1.3 Randomisation
Attempts were made to standardise the rats to be used in the trial in that they were all
male rats taken from the same breeding colony and only those weighing 350 - 450 g
were selected. To avoid any bias that may have resulted from an improvement in
technique over the course of the trial, the operative schedule was randomised using a
table of random numbers (Bland 2000b). Details of this schedule are given in
Appendix 4.
8.2 Materials and methods
8.2.1 Animals
Sixty male Sprague-Dawley rats were used weighing between 350-450 g. All
animals were supplied and cared for as before in the animal house, prince Henry
Hospital, NSW, Australia.
8.2.2 Preparation of CHO cell cultures
All CHO cells were cultured in the Department of Haematology Research, Prince of
Wales Hospital, Randwick, Sydney, Australia as set out in Chapter 7 following the
same subculturing schedule as used in the pilot study.
The cell culturing process was labour-intensive and on a scale that inevitably led to
some logistical problems in terms of accessing sufficient incubator space. As a
result, some departures from the planned schedule did occur, most frequently
involving the whole-flap injection group where insufficient capacity was available to
200
culture the required cells (four culture bottles required per animal). In this situation a
swap was done within the schedule to make the most use of the available capacity.
Cell counts were performed on a representative sample of flasks from each cell
culture batch where again, the large turnover made counts on every flask unrealistic.
The target cell population was 8 - 10 x 106 cells per culture flask at a confluence of
70 - 90%. Although in general the cell yield was very reliable, there were occasions
where cell counts outside the target range were used, usually higher, to keep up with
the operating schedule.
Cells were transported to the operating theatre on ice within sterile 15 ml reaction
tubes containing either 2 ml fresh culture medium (random and axial flap injection
groups) or 4ml (whole flap injection groups).
8.2.3 Surgical procedure
All experimental epigastric island flaps were 8x8 cm, based on the left superficial
inferior epigastric vascular pedicle and raised under general anaesthesia as
previously described. CHO-VEGFB or CHO-BLANK were delivered to the deep
surface of the flap in accordance with the operating schedule using the same
technique described for the pilot study (Chapter 7). All instruments, sutures,
syringes and pipettes were used sterile. Skin closure was with 4/0 prolene to the
inferior border of the flap and staples elsewhere. The animals were recovered and




All animals were examined daily for signs of flap oedema and for evidence of
demarcation between viable and non-viable tissue. All were killed by CO2 overdose
on the seventh postoperative day, the flaps photographed and further data collected
as follows:
8.2.4.2 Flap survival
Measured by planimetry using three consecutive hand drawn templates as previously
described (Chapter 2). A mean value for percentage flap survival based on the final
flap area was thus calculated for each flap and used in all subsequent analyses.
8.2.4.3 Angiography
Performed as described in Chapter 2 i.e. 0.2 ml barium contrast medium infused into
the flap following cannulation of the feeding artery (left SIEA). Imaging was
performed using mammography film with the previously noted equipment and
settings. An assessment of highest branch point density was performed for each
angiogram as before by a single examiner (CR) blinded to the nature of cells
injected.
8.2.4.4 Average microvascular density
Assessment of a-MVD followed the protocol described in Chapter 3. Each flap was
fixed in 10% buffered formalin, sectioned, blocked, cut and stained for von
Willebrand factor and all sections were examined by a single independent observer
(Dr. J Clark) blinded to the experimental group. In view of the large numbers of
sections to be analysed, five representative flaps only from each group were subject
to further analysis in this way. All results are expressed as previously described
namely, vessels counted per grid area of 0.0625 mm2.
8.3 Statistics
For parametric data, sample mean and standard deviation are quoted with confidence
intervals presented at the 95% level. Non-parametric data are summarised by the
median and inter-quartile range. Differences in results were subjected to statistical
analysis using a one-way analysis of variance (ANOVA) or the Mann - Whitney U




There were no intra- or immediate postoperative complications. Mean operating
time for the completion of each procedure was 38 mins (range 30 - 50 mins).
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There was no statistically significant difference in the time taken for flap
demarcation to become clinically apparent between any of the groups and the
incidence of temporary flap oedema was low (Table 8.1). In all cases the oedema
involved the whole flap, was noted on the first postoperative day and lasted only 24
hrs.






CHO-VEGFB random flap 10 2 2.9
CHO-BLANK random flap 10 0 2.8
CHO-VEGFB axial flap 10 1 3.1
CHO-BLANK axial flap 10 0 3.1
CHO-VEGFB whole flap 10 1 2.9
CHO-BLANK whole flap 10 1 2.9
Population 60 5 (8%) 3.0
* F(5, 54) = 0.45, p = 0.81.
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8.4.1.2 Complications
Postoperative complications are detailed in Table 8.2. Two rats required replacement
of their protective collars and a further two, repair of minor wound dehiscences.
Both procedures were performed under general anaesthetic.
Table 8.2 - Postoperative complications.
injection group n
wound



















Total 60 2 (3%) 2 (3%) 14(23%) 2 (3%)
The incidence of seroma (23%) was higher than previously experienced. Typically,
a small volume of fluid was encountered beneath the flap at the time of excision and
did not interfere with data collection. In 4 rats however, large seromas started to
collect between days 4 and 5 and by the time of excision (day 7), the flaps were
thickened and inflamed with exudates present on the deep surface. Specimens were
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submitted for microbiological analysis, which revealed a heavy bacterial growth in
two of the cases (enterobacter species) but no growth in the other two.
In two animals, flaps were damaged by autocannibalism despite the presence of a
protective head collar. Both animals were killed before completion of the trial
period.
8.4.2 Exclusions
A total of six animals were excluded from the trial. The condition of the four flaps
associated with large fluid collections made them unsuitable for data collection
(CHO-VEGFB axial: 1 flap; CHO-VEGFB whole: 1 flap; CHO-BLANK whole: 2
flaps) and they were excluded. Both autocannibalised flaps were also excluded.
Flap survival, microvascular density and angiographic data were therefore available
for analysis in 54 of the 60 flaps.
8.4.3 Flap survival
Mean CHO-cell dose administered to each flap was similar for each group (p > 0.06).
There was no statistically significant difference in percentage flap survival between
any of the experimental groups when compared to their respective controls (p > 0. 15)
(Table 8.3)
Table 8.3 - Median flap survival expressed as a percentage of final flap area and
mean cell infiltrate for each group.
Injection group n






9 5.5 80* 21.0
CHO-BLANK
random flap
10 7.1 78* 12.3
CHO-VEGFB
axial flap
9 6.3 79§ 26.7
CHO-BLANK
axial flap
10 5.4 81§ 9.0
CHO-VEGFB
whole flap
8 6.3 79f 14.0
CHO-BLANK
whole flap
8 6.6 82r 5.8
*p = 0.71; §p = 0.35; +P = 0.15.
8.4.4 Microangiography
Gross angiographic appearances were as previously noted i.e. increased vascular
markings were observed in the zone of demarcation between the viable and non¬
viable tissue when compared to other locations in the flap and this finding was
consistent across all experimental groups (Figures 8.1 to 8.3). In one angiogram, no
vascular markings were seen within the random pattern region of the flap as a result
of greater than expected flap necrosis suggestive of a pedicle injury at the time of
elevation. In all other flaps, angiographic data was available for collection from both
regions i.e. random and axial pattern.
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Figure 8.1 - Examples of epigastric island flaps and microangiograms at one-week
post CHO injection: (A) CHO-VEGFB and (B) CHO-BLANK injected into the
random portion of the flap. A vascular 'blush' at the zone of demarcation was
evident in the majority of flaps across all experimental groups.
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Figure 8.2 - Examples of epigastric island flaps and microangiograms at one-week
post CHO injection: (A) CHO-VEGFB and (B) CHO-BLANK injected into the axial
portion of the flap.
209
lit 811 ALT. 911 S|T WI SIT SjT XjT 0|T 16[lllllliilllililiililiiiiitiiiiiiiiltiutwtiuiiunLltnwutluuiuuUuumtuuLmuWuuti
VFC I1 C.HO-vEfcfQ WrtOLt.
08|t OZ.|T 0911 OSjT Ot> t OK;t OS|I 01'
' J,„.l
Vi-C - S? CHO - CkvHJA x-ittou
Figure 8.3 - Examples of epigastric island flaps and microangiograms at one-week
post CHO injection: (A) CHO-VEGFB and (B) CHO-BLANK injected into both the
random and axial portions of the flap (whole flap injected).
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Mean values for HBPC/cm2 for each flap region in each experimental group are
presented in Table 8.4 and the population data is displayed graphically in Figure 8.4.
Differences in mean HBPC/cm2 for each group were subjected to statistical analysis.
Whole flaps injected with CHO-BLANK cells were found to have a significantly
higher mean HBPC/cm2 when compared to whole flaps receiving CHO-VEGFB cells
(p = 0.02). This held for both the random and axial flap regions. This result was
unexpected and must be regarded as spurious. It may have arisen as a consequence
of the high exclusion rate, and therefore data loss, from this arm of the trial (four
animals excluded). Any variation in the technical quality of the remaining
angiograms would therefore be more likely to result in a skewing of the data.
Comparisons between the other experimental groups found no statistically significant
differences in mean HBPC/cm2 between CHO-VEGFB and CHO-BLANK injected
flaps in either of the regions examined (p > 0.06).
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Figure 8.4 - Boxplot of HBPC/cm2 for each experimental group. Diamonds
represent outliers. In the 'whole flap' injected group, the higher readings in the
CHO-BLANK compared to the CHO-VEGFB flaps was unexpected and likely to be
spurious.
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8.4.5 Average microvascular density
Average MVD for each of the groups followed the same pattern as seen previously
i.e. a-MVD was higher below the panniculus carnosus than above it (Tables 8.5 to
8.7). In the majority of cases, there was no statistically significant difference in a-
MVD at any location tested when compared with controls. In four locations
however, a significant difference was identified (p < 0.05) (Tables 8.5 and 8.7). In
three of these cases the CHO-BLANK injected flaps recorded the greater a-MVD. It
is unlikely therefore that the CHO-VEGFB cells were the cause of the higher a-MVD
in the final case and this result must again be regarded as spurious.
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In contrast to the positive findings of pilot study, these results were disappointing.
The survival advantage apparent for the axially injected flaps initially was not
reproduced in this trial. Similarly, there was no consistent evidence of induced
angiogenesis in either the histological or angiographic data. Some of the flaps
underwent more extensive necrosis than is usual, presumably as a result of vascular
injury sustained during the injection process. This resulted in some skewing of the
data however, even allowing for this, there was no significant difference in flap
survival between any of the CHO-VEGFB treated groups and their respective
controls.
The discordance in results for average flap survival between the pilot study and the
randomised controlled trial is difficult to explain. The CHO-VEGFB cells used in
the RCT were cultured from the same stock as those used in the pilot study,
administered in the same way and in comparable numbers. One possible explanation
was that expression of the VEGFB gene by the CHO-VEGFB cell population had
declined by the time of the second study compared to the first possibly as a
consequence of their increased age. The most likely explanation I believe however,
for the initial false positive was that it occurred by chance. The probability for this
being the case is 1 in 25 (p = 0.04).
The angiographic data suggestive of VEGFB activity in the pilot study was also not
reproduced in this trial. I found no evidence of increased HBPC/cm2 in any of the
CHO-VEGFB injected flaps in either the random or axial regions when compared to
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controls. The lack of reproducibility again suggests that the result of the pilot study
had been spurious in this respect and ultimately misleading.
The histological assessment of flap vascularity was in broad agreement with the
angiographic findings i.e. there was no convincing evidence of stimulated
angiogenesis over and above that which was apparent in the control flaps and which
represented the activity ofnative angiogenic pathways. The significant differences
that were noted followed no pattern and were most frequently associated with a
higher vascularity in the control flaps. They were therefore considered as erroneous.
The single animal that recorded a flap survival of 100% in the pilot study had a
significant impact both on the average flap survival for the CHO-VEGFB double
dose axially injected group but also on our belief that the technique had been
successful. This result shows that an island flap raised as I have described, can
survive completely purely by chance and in the absence of any effective therapeutic
intervention.
In reviewing these data however, I believe the experimental approach taken was
appropriate and maintain that the early successes were deserving of further
evaluation. I also believe the most significant factor in the failure of the CHO-
VEGFB cells to induce angiogenesis in our rat model was the low VEGFB yield as
demonstrated by our FLAG stain work in Chapter 7. This required the
transplantation of large quantities of cells that we knew to be immunogenic in their
host limiting still further the likely VEGFB yield in vivo.
8.6 Conclusions
1. CHO-VEGFB cells do not act as agents for therapeutic angiogenesis in the rat
epigastric island flap model of tissue ischaemia.
2. The most significant factors in the failure of the technique are likely to be the
generally low yield of VEGFB by the genetically modified CHO cells and the
activities of the host immune system in creating a hostile environment for the
transplanted cells, limiting YEGFB production still further.
3. The false positive results seen in the pilot study are difficult to explain
however, are most likely to have arisen by chance reflecting the small number of
animals in the test group.
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Chapter 9- Concluding remarks and future work
The aim of this project was to evaluate two separate agents, both incorporating the
gene for VEGF-B, for their ability to induce therapeutic angiogenesis in
experimental skin flaps raised in rats. In the course of this evaluation I found no
evidence to suggest that either agent had been successful in achieving this goal by
the methods examined. The most likely explanation for this failure, I believe, was an
inability to deliver sufficiently high quantities of cytokine to the tissues of the
experimental flaps such that the threshold for biological activity was never reached.
These results were disappointing and contrast with the success reported by a number
of other groups using similar strategies and based on a variety of angiogenic agents
including VEGF-A (Ishiguro et al. 1994;Machens et al. 2002;Padubidri & Browne
1996;Takeshita et al. 1994c;Taub et al. 1998).
Comparisons of technique and outcome are however, hampered by the diversity of
agents and experimental approaches that have been adopted by each individual
research group. Within the plastic surgery literature the two most commonly used
angiogenic agents have been VEGF-A and bFGF however, dosages, delivery
strategies, animal model used and data collection techniques vary widely between
authors (Lubiatowski et al. 2002;Rinsch et al. 2001b;Tucci et al. 2001;Zhang et al.
2003). In accounting for these different approaches, one contributory factor is likely
to be the relative difficulty in accessing the raw materials i.e. pure cytokine
preparations and cDNA constructs, used in the more successful experiments. In
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addition, the fact that to date, no vector has proved vastly superior to any other has
provided a stimulus for the development and use of more novel agents and delivery
strategies in the hope that existing results may be further improved.
This was the case in my project where I was offered the opportunity to be amongst
the first to study VEGF-B as an agent for therapeutic angiogenesis. At the time this
project was undertaken, details on the biology of VEGF-B were only just emerging
and there were certainly no reports of its use for therapeutic angiogenesis. The
activity of VEGF-B in this respect was therefore completely unknown. Published
data was however, encouraging and suggested that VEGF-B, like VEGF-A, was a
powerful mitogen for endothelial cells implicated in the control of both normal and
pathological angiogenesis (Olofsson et al. 1996). More recent work has since
confirmed its status as a potent stimulator of angiogenesis in a variety of
circumstances (Olofsson et al. 1999).
An obvious starting point for the investigation of VEGF-B as an agent for therapeutic
angiogenesis was to evaluate the purified VEGF-B protein itself in a similar manner
to that performed by Padubidri and Browne for VEGF-A (Padubidri A & Browne E
1996). We sourced our raw materials from the biotechnology company Amrad and
although they were prepared to offer us VEGF-B both as a plasmid construct and
contained within a culture of stably transfected CEIO cells, we were not given access
to the purified VEGF-B protein. This preliminary work was therefore not possible.
The successes reported by Isner and others in stimulating angiogenesis with plasmids
however, encouraged us to proceed in our attempts to apply this technology to plastic
surgery (Isner et al. 1996;Takeshita et al. 1996).
As more companies have become interested in this area of research the availability of
raw materials has similarly increased. Kryger at al. for example sourced the
recombinant human VEGF-A necessary for their work, as a purified protein
preparation directly from the biotechnology company Genentech* (Kryger et al.
2000). Plasmid constructs containing the cDNA for angiogenic cytokines produced
by the company may be obtained similarly. As the technology advances and as the
number of interested companies increases, both purified agents and plasmid
constructs are set to become increasingly easy to obtain. For now however, it
remains the case that little of what has been published has undergone the test of
independent reproducibility.
Not all experiments however, have met with success. Hayward et al. were amongst
the first to evaluate an angiogenic growth factor for its ability to influence the
survival of ischaemic skin flaps in rats. In a large study comprising 100
experimental flaps they reported no evidence of induced angiogenesis in flaps
injected subdermally with a relatively large dose (lOOpg) of basic fibroblast growth
factor (bFGF) when compared to control flaps receiving saline vehicle only. In the
discussion of their findings they comment on the large body of evidence confirming
*
Genentech will provide raw materials as part of their 'material transfer' service following
consideration and acceptance of a formal application.
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bFGF as a potent stimulator of new vessel growth in a variety of experimental
settings and raise the possibility that, as yet undefined, co-factors may be required for
the induction of angiogenesis in more complex models of tissue ischaemia such as
the rat epigastric island flap (Ftayward et al. 1991).
This theme has been developed more recently by Brindle et al. who make the point
that although relief of ischaemia is directly related to improved blood flow it does
not necessarily follow from an increased number of vascular channels observed
histologically since newly formed capillaries are known to be fragile and are often
not patent (Brindle, McCarthy, & Bell 1999). In this state they are therefore unlikely
to make a significant impact on blood flow. Furthermore, there is some experimental
evidence to suggest that new vessels produced by the action of VEGF collapse and
regress once this stimulus to growth is removed (Benjamin et al. 1999). An
important distinction may therefore need to be made between the ability of an agent,
or agents, to induce angiogenesis per se as against their potential to enhance the
vascularity of ischaemic tissue by the local production of functional blood vessels.
One agent known to promote the integrity and stability of newly formed blood
vessels is angiopoietin-1 and early experience in using this agent in combination with
VEGF appear to support its role as a 'survival factor' for the newly produced
capillaries (Suri et al. 1996). Asahara et al. (1998) using a corneal model of
angiogenesis reported a significant increase in the number of patent vessels using the
two agents together when compared with VEGF alone. Similarly Chae et al. (2000)
compared the efficacy of single versus combined agent delivery in the rabbit model
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of hind limb ischaemia and recorded angiographic evidence of increased collateral
vessel formation in the animals receiving angiopoiten-1 and VEGF when compared
to those receiving VEGF alone.
Although these results are encouraging and will certainly help direct future research
it is still too early to know the full impact they and others like them, may have on the
field as a whole. Undoubtedly as more experimental results become available, other
equally successful agents and combinations of agents will be identified. In the
interpretation of such results, one important aim will be the identification of critical
steps and agents in the process of therapeutic angiogenesis, which are fundamental to
success. This in turn will allow optimisation and simplification of the technique as
unnecessary steps are discarded.
Although such dual agent use may ultimately prove superior, the majority of
published reports to date have concentrated on single agent techniques for
therapeutic angiogenesis. Like us, other groups have explored a potential role for
VEGF-B in this respect. Although at the time of writing it remains the case that
purified VEGF-B protein has yet to be shown to induce angiogenesis in vivo in the
same way that has been shown for VEGF-A (Takeshita et al. 1994b;Takeshita et al.
1994c), I am aware of two reports where expression vectors encoding the gene for
VEGF-B have been used for this purpose, with mixed results. Silvestre et al. (2003)
working with a mouse model of hindlimb ischaemia, successfully induced
angiogenesis, as assessed angiographically, using a plasmid encoding for VEGF-B
administered as a single intramuscular injection.
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Rissanen et al. (2003) however, compared four species of VEGF (A, B, C and D) for
their ability to induce angiogenesis in rabbit hindlimb skeletal muscle following
adenovirus-assisted gene transfer. They recorded the strongest angiogenic response
following administration of the VEGF-D containing virus and found no evidence of
angiogenesis at all amongst animals receiving VEGF-B virus. It is possible
therefore, that the presence of local ischaemia is an important co-factor in the
induction of angiogenesis by VEGF-B in a way that is not shared by all VEGF
species (Elcin, Dixit, & Gitnick 2001). Silvestre's detection of VEGF-B induced
angiogenesis in mice however, supports my view that insufficient delivery of
cytokine to the tissues of the flap was the point of failure in my experiments rather
than the cytokine itself being ineffective in stimulating angiogenesis.
Perhaps the most significant addition to the literature in the field of therapeutic
angiogenesis however, has been the recent publication of the results of the VIVA
(Vascular endothelial growth factor in ischaemia) trial (Henry et al. 2003). This
work constitutes the first randomised, double-blind, placebo controlled trial using
recombinant human VEGF-A for therapeutic angiogenesis in patients with
myocardial ischaemia. Previous clinical trials had yielded some promising results
however, were often small in size and lacking in a control arm (Hendel et al.
2000;Henry et al. 2001;Schumacher et al. 1998). The VIVA trial was therefore
constructed to provide a rigorous examination of the efficacy of this technique using
the best available evidence as a starting point.
The study population comprised 178 patients with stable exertional angina,
unsuitable for standard revascularisation. Patients were randomised to two treatment
groups (low and high dose rhVEGF administered as an intracoronary infusion over
20 minutes and supplemented by three intravenous infusions on days 3, 6 and 9) or a
control group receiving placebo. The authors found no significant difference
between any of the trial groups in terms ofmyocardial perfusion or exercise
tolerance over the study period of 60 days. There was therefore no evidence that
VEGF-A had acted therapeutically to improve myocardial vascularity in this study.
These results again fell short of expectations and the authors site suboptimal
dosaging and route of administration as potential explanations for their findings. The
systemic administration of rhVEGF did however, appear safe with no evidence that
pathological angiogenic states (e.g. tumour growth, atherosclerosis, retinopathy)
were induced or accelerated in the treatment groups compared to controls, albeit over
a relatively short follow-up period of four months. The authors did point out the
need for longer follow-up data before a definitive assessment on safety can be made.
The potential for serious side effects however, cannot be ignored and Epstein
emphasises the importance of vigilance and long term data collection as dose
escalating trials are contemplated (Epstein et al. 2001). Bliznakov similarly draws
attention to the potential hazards ofproviding an angiogenic stimulus to untargeted
tissue where significant pathologies (e.g. rheumatioid arthritis, retinopathy, psoriasis)
may be initiated or aggrevated and in addition points to the extensive literature
linking angiogenesis with neoplasia (Bliznakov 2002). These are genuine concerns
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that must be acknowledged in the selection criteria and design of future clinical
trials.
There are, as yet, no reports of this technology being applied to plastic surgery within
the setting of a clinical trial.
In summary, although therapeutic angiogenesis holds much promise for the future
management of ischaemic conditions, including those relevant to plastic surgery,
results to date have lacked consistency making a reliable assessment of the
technology at this time difficult. It is anticipated however, that a better
understanding of the detailed biology of angiogenesis combined with the application
of increasingly sophisticated therapeutic techniques will lead to improvements in
both the consistency and reproducibility of results as the technology advances.
In completing this work I would like to make a number of recommendations for
future research based on my results and experience with this project. The CHO-
VEGFB cells were ultimately found to be inefficient in their ability to produce active
VEGF-B cytokine. To continue this work requires an improved cell culture capable
of producing significantly higher quantities of VEGF-B and preferably of Sprague-
Dawley rat origin. There is little published work to guide the choice of such a cell
however, Machens et al. report the successful use of fibroblasts for this purpose
while Rinsch and colleagues preferred myoblasts (Machens et al. 2002;Rinsch et al.
2001a). Sprague-Dawley fibroblasts can be bought directly from DSMZ and would
seem a reasonable starting point (www.dsmz.de). Transfection of these cells could
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be performed using pEF-BOS-VEGFB and DOTAP transfection agent in the manner
I described for BAEC's with clonal selection achieved using puromycin. The
immunohistochemical staining protocol that we developed for the identification of
FLAG tagged proteins would provide an assessment of the efficiency of VEGF-B
expression within the transfected cell cultures prior to any in vivo work.
To offer some protection against the host immune response Rinsch et al.
encapsulated their genetically modified cells in microporous polymer membrane
microspheres prior to implantation and this technique may have merit as a way to
extend the life of transplanted cells. The efficacy of the genetically modified
fibroblasts so produced as agents for therapeutic angiogenesis could then be
evaluated using the rat epigastric island flap model in a manner similar to that I
described for CHO-VEGFB cells.
Although the rat epigastric island flap model is appropriate for the testing of
genetically modified cells in this way, it may be less suited for use in gene transfer
experiments where the evidence suggests that skeletal muscle is a more receptive
target for transfection. Several authors have demonstrated reporter gene expression
in skeletal muscle following direct plasmid injection or intravascular infusion which
contrasts with the relative difficulty reported in achieving gene expression by
vascular endothelium and this was certainly my experience (Budker et al.
1998;Teifel et al. 1997;Wolff et al. 1990). The use of an animal model based on
skeletal muscle may therefore offer the greatest chance of success. Kryger et al.
(1999) describe a rat gracilis muscle flap model that has potential in this respect.
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In the first instance I would plan to use the reporter plasmid pEGFP-N2 initially to
confirm successful gene transfer and expression and then to optimise the transfection
conditions. The construction of a hybrid plasmid comprising the pEF-BOS backbone
and containing the GFP reporter gene would permit evaluation of the pEF-BOS
expression vector in vivo using the gracilis flap model. Fluorescence of muscle
biopsies taken sequentially beginning at 48 hrs would confirm successful gene
transfer and expression as well as providing data on the timing of gene expression.
Further optimisation of the system would allow identification of the most successful
conditions for gene transfer prior to investigating the angiogenic potential of the
pEF-BOS-VEGFB plasmid in this system. Microangiography and histological data
would be collected from both the injected and contralateral uninjected gracilis
muscles at one week. Data analysis would be similar to that described for the
epigastric island flap (i.e. highest angiographic branch point counts and average
microvascular density on histology). Evidence of enhanced vascularity in the
injected muscle compared to controls would confirm the pEF-BOS-VEGFB plasmid
as capable of inducing angiogenesis in vivo. On the basis of these results
experiments could then be designed to assess the rate at which new vessels are
formed by performing data collection at serial time intervals following gene transfer.
With respect to the use of therapeutic angiogenesis to influence the survival of
ischaemic flaps, I now believe that administration of the angiogenic agent
synchronous with flap elevation is unlikely to provide sufficient time for the
development of functional blood vessels within the flap, capable of preventing
ischaemic necrosis. I would favour instead the preoperative administration of these
agents. My in vitro transfection data using pEGFP-N2 and BAECs found maximal
gene expression 48 hrs post transfection. There is some evidence to suggest this may
occur slightly later in vivo at around day 7 (Takeshita, Isshiki, & Sato 1996).
Takeshita et al. (1995) studied the timecourse of increased cellular prolferation in
collateral arteries exposed to VEGF-A and found it to be maximal on day 5. The
optimal interval between administration of the angiogenic agent and flap elevation is
therefore likely to be 5 days for genetically modified cells where cytokine production
is continuous and between 7 and 12 days for plasmid based techniques allowing a lag
phase for gene expression to take place.
Although much has still to be learned before the considerable power that is
angiogenesis can be truly controlled for the benefit of patients, I remain optimistic
that with an increased understanding of the mechanisms involved, therapeutic
angiogenesis will one day become a reality.
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Appendices
Appendix 1 - Weight-area standard for exposed radiographic film
To calculate percentage flap survival from templates constructed from exposed
radiographic film requires that it be of constant weight: area ratio. To investigate
this, ten samples of exposed radiographic film were selected at random and cut to an
area measured at 8 x 8 cm. Each template obtained in this way was weighed and a
weight: area ratio calculated. The results compared and a mean value with 95%
confidence intervals calculated.
Results
The results are given in Table A1.1. Mean weight:area ratio was found to be 2.54 x
10"2 g/cm2 (95% C.I. 2.52 x 10"2, 2.55 x 10"2). The narrow overall range of the
results and confidence intervals suggest uniformity. We concluded that radiographic
film was a good choice of material for our purposes.
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Table Al.l - Weight: area ratios calculated for exposed radiographic film samples












Appendix 2— Estimate of right hemiflap survival area
Finseth & Cutting, in their original description of the rat epigastric island flap, chose
to express their data as an area survival for the right hemiflap only. To make the two
series more comparable requires the conversion of my data to this format. The
calculation may be performed in the following manner:
Mean starting template weight (8x8 cm) = 1.63 g
Mean right hemiflap template weight (8x4 cm) = 0.815 g
Allowing for flap contracture to 78.8 % of starting area at one week
Mean expected right hemiflap template weight (1 wk) = 0.788 x 0.815
0.642 g
Right hemiflap survival (RHS) is given by:
Expected hemiflap template weight - necrotic template weight
Weight-area standard
Using the data in Table 2.1, necrotic template weight = W1 - W2
Therefore,
RHS = 0,642 - (W1 - W2)
0.0254
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Mean survival of the randomly supplied right hemiflap in my series of group 2 flaps
was therefore, approximately 17 ± 2 cm . The purpose of this calculation was to
enable a board comparison with the results of Finseth and Cutting. The error
incurred by the assumption that flap contraction is uniform, which it is not, means
that this approximation is likely to be an overestimate of the true result.
Table A2.1 - Calculation of right hemiflap survival (RHS) for group 2 flaps from the
data given in Chapter 2.












Appendix 3 — Operating procedure used for the histological
preparation of rat skin
PURPOSE
To prepare rat ventral skin flaps for histological staining and examination. The flaps












All supplies and equipment are
available at the Anatomical
Pathology laboratory at The St.
George Hospital
PROCEDURE
This operating procedure has been designed for use in a pathology laboratory with
appropriate ' cut - up ' facilities.
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1. Complete St George pathology department request form using the following
identifiers:
Name: RESEARCH - POOLE
MRN: T 0008041
DOB: 05/06/98
Specimen: unique specimen identification number
2. Record unique specimen identification number on project record sheet
3. Remove flap from formalin and record total time in preservative on project
record sheet
4. Place flap on cutting board, leave holding pins in-situ
5. Perform gross pathological examination of tissue recording flap dimensions and
any striking features on project specimen sheet
6. Orientate specimen (generally the experimental half of the flap will be on the
right in-vivo)
7. Section specimen as marked (horizontal sections will be taken at a point 75% of
the way up from the base of the flap[ strip 1 ] and at the mid-point [ strip 2 ]) to
produce strips approximately 2-3mm wide
8. Store residual flap in formalin
9. Orientate specimen strips on cutting board
10. Further divide each strip into four blocks by sectioning at the midline and half
way to the edge of the flap on each side
11. For the medial specimens, mark the edges closest to the midline with black
ink
12. For the lateral specimens, mark the edges closest to the sides of the flap with
blue ink
13. Transfer marked specimes (2 specimens per cassette) to histology cassettes in
the follwing manner maintaining orientation and with the specimens nearest the
midline lowermost in the cassette:
75% strip[ strip 1 ]: random pattern blocks( RHS ) cassette 1
axial pattern blocks( LHS ) cassette 2
midpoint strip[ strip 2 ]: random pattern blocks( RHS ) cassette 3
axial pattern blocks( LHS ) cassette 4
14. Seal cassettes with metal lids provided
15. Transfer completed cassettes to formalin racks for paraffin embedding
16. Place completed pathology request form in file tray provided
17. Return project specimen sheet to file
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Appendix 4 — Randomisation details for CHO-VEGFB trial
The proposed trial comprised six experimental groups of 10 rats each giving a total
of 60 rats. To reduce bias, the experimental order was randomised using a table of
random sampling numbers according to the technique of random permutation. Each
individual rat was given a number form 1 - 60 as shown below:
Group 1 (CHO-VEGFB cells random flap) 1 - 10
Group 2 (CHO-BLANK cells random flap) 11 -20
Group 3 (CHO-VEGFB cells axial flap) 21 -30
Group 4 (CHO-BLANK cells axial flap) 31 -40
Group 5 (CHO-VEGFB cells whole flap) 41 -50
Group 6 (CHO-BLANK cells whole flap) 51 -60
The final position of each individual in the overall experimental order was generated
using the random number table and is given in Table A4.1 below (animal number is
given in black, experimental position is in red):
258
Table A4.1 - Randomisation table for CHO-VEGFB trial. Animal number is given
in black and trial number is in red.
1 14 11 11 21 58 31 50 41 35 51 18
2 9 12 16 22 30 32 34 42 2 52 24
3 24 13 3 23 47 33 20 43 37 53 49
4 13 14 48 24 52 34 10 44 7 54 54
5 21 15 29 25 41 35 18 45 5 55 29
6 49 16 4 26 15 36 42 46 39 56 30
7 1 17 26 27 31 37 25 47 36 57 28
8 45 18 51 28 57 38 43 48 46 58 21
9 19 19 32 29 55 39 22 49 53 59 40
10 17 20 6 30 56 40 59 50 38 60 58
The final operating schedule for the ventral flap CHO (VFC) trial is therefore given
in Table A4.2







VFC - 1 CFIO-VEGFB random pattern
flap










VFC-4 CHO-BLANK random pattern
flap




VFC-10 CHO-BLANK axial pattern
flap
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VFC - 15 CHO-VEGFB axial pattern
flap
VFC-40 CHO-BLANK whole flap
VFC - 16 CHO-BLANK random pattern
flap
VFC-41 CHO-VEGFB axial pattern
flap
VFC - 17 CHO-VEGFB random pattern
flap
VFC - 42 CHO-BLANK axial pattern
flap
VFC - 18 CHO-BLANK axial pattern
flap
VFC - 43 CHO-BLANK axial pattern
flap
VFC - 19 CHO-VEGFB random pattern
flap




VFC - 45 CHO-VEGFB random pattern
flap
VFC-21 CHO-VEGFB random pattern
flap
VFC - 46 CHO-VEGFB whole flap
VFC-22 CHO-BLANK axial pattern
flap




VFC-48 CHO-BLANK random pattern
flap
VFC-24 CHO-BLANK random pattern
flap
VFC - 49 CHO-VEGFB random pattern
flap
VFC-25 CHO-BLANK axial pattern
flap
VFC-50 CHO-BLANK axial pattern
flap
VFC-26 CHO-BLANK random pattern
flap








VFC-53 CHO-VEGFB whole flap
VFC-29 CHO-BLANK random pattern
flap
VFC-54 CHO-BLANK whole flap
VFC-30 CHO-VEGFB axial pattern
flap
VFC-55 CHO-VEGFB axial pattern
flap
VFC-31 CHO-VEGFB axial pattern
flap
VFC-56 CHO-VEGFB axial pattern
flap
VFC-32 CHO-BLANK random pattern
flap




VFC-58 CHO-VEGFB axial pattern
flap
VFC-34 CHO-BLANK axial pattern
flap




VFC-60 CHO-BLANK whole flap
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